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Chapter 1 
 
 
 
 
Introduction 
 
 
 
 
 
1.1  Peptides and proteins in the pharmaceutical area 
 
 
Biomolecules, like peptides and proteins, are crucial for a large variety of reactions in the 
human body, acting as hormones, enzymes, antibodies, and other active agents. Since the 
introduction of chemical and in particular biotechnological methods for the production of 
peptides and proteins, biomolecules also play an increasingly important role as 
pharmaceutical drugs for the medication of various diseases and diagnostic purposes. 
 
The preparation of peptides is accomplished by solid phase peptide synthesis [1, 2], in- 
vented by Merrifield in the early 1960s [3]. In this strategy, the amino acid sequence of 
the considered peptide is assembled successively starting at the resin bound C-terminal 
amino acid, while the side chains of the amino acids are disabled by protecting groups. 
However, incomplete coupling reactions may lead to undesired by-products (e.g. peptide 
fragments), which have to be characterized in detail and eliminated by different purifi- 
cation processes during the production of the drug. 
The solid phase synthesis strategy is restricted with respect to the length of the amino 
acid chain, i.e. the size of the peptide, and is thus not applicable to proteins. Beside the 
higher number of amino acids, the complexity of proteins is increased by the tertiary and 
the quaternary structure and often also by post translational modifications (PTMs). 
Among these PTMs glycosylations play an important role as about 50% of the endoge- 
nous [4] and one third of the therapeutic proteins [5] are glycosylated. The glycans are 
involved in crucial biochemical reactions but also increase the stability of the respec- tive 
protein [5–7]. Glycosylations additionally introduce a strong heterogeneity to the 
molecules as they often show complex type structures and great composition variations, 
thus leading to several different isoforms [6, 8, 9]. For this complexity, proteins used for 
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therapeutic purposes (biopharmaceuticals) are produced by recombinant technology, i.e. 
the proteins are expressed in cells [10]. 
 
Biopharmaceuticals often resemble endogenous proteins, including vaccines, cytokines (like 
interferon), therapeutic hormones (like erythropoietin, insulin and growth hor- mones), 
enzymes, and monoclonal antibodies. The application of biopharmaceuticals has 
revolutionized the modern medicine, improving the treatment of various diseases, like 
anemia, diabetes, cancer, and other [11].  The turnover of biopharmaceuticals in 
2010 amounted to 17% of the total amount of pharmaceutical drug sales, whereas the 
amount of biopharmaceuticals among new licensed drugs was about 30% in the same 
year [12]. However, regarding certain therapeutic areas, e.g. the immunology, biophar- 
maceuticals are the most important drugs showing increasing application over the past 
years (Fig. 1.1). 
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Figure 1.1 – Share of biopharamaceuticals in certain therapeutic areas in comparison to the total 
pharmaceutical market in Germany in the period of three years (2008 - 2010) [12] 
 
 
The patents of the innovator biopharmaceuticals have either expired or will expire in the 
next few years [13, 14], giving way to follow-on drugs, which may decrease the treatment 
costs in the medical sector. However, the so called biosimilars or follow-on biologics dif- 
fer considerably from generics [15]. Generics are exact copies of small molecule drugs, 
showing pharmaceutical equivalence, i.e. the active substance is identical, and compara- 
ble pharmacokinetics. By contrast, due to the expression in living cells, the production 
Introduction 3 
 
 
of exact copies of biopharmaceuticals is impossible. The composition of the expressed 
protein, especially regarding the PTMs, depends on several production parameters, in- 
cluding the cell line, the temperature, and the composition of the nutrition. Even if all 
adjustable parameters are kept strictly constant, variations between different products (e.g. 
batch to batch) occur due to the uniqueness of each living production cell. Consequently, 
the therapeutic equivalence of biosimilars to innovator drugs is not implicated, and 
possible differences in clinical efficacy, safety, and immunogenicity have to be considered 
[16–19]. Therefore, in contrast to the regulations on the release of generics extensive 
clinical studies have to be carried out prior to the approval of biosimilars, leading to 
increased development expenses and an increased development time [20, 21]. 
 
The key challenge for analytical strategies consists in the verification of the similarity of 
biosimilars to innovator biopharmaceuticals (confirmation of the structural and thera- 
peutic equivalence), but also in the determination of the respective differences. By this 
means, new biosimilars can be approved for further medication enhancement. In addition, 
cheaper-production “copies” sold in countries with less stringent regulatory control of 
licenses and patents can be identified. 
 
Apart from the need for the characterization of pharmaceutical drugs with respect to 
impurities and isoforms as described above, different common alterations of peptides and 
proteins, which may change the medical efficacy, have to be monitored in order to testify 
the quality of a product. Peptide and protein modifications may arise during production, 
purification, and (long-term) storage of the respective pharmaceutical drug. One of the 
most common modifications is represented by the deamidation, which is a spontaneous, 
non-enzymatic process under mild conditions, leading to a small change of the mass of 
the biomolecule (one dalton) and a change of the pI value, i.e. the charge of the protein 
[22–24]. 
 
 
 
1.2  Capillary electrophoresis-mass spectrometry 
 
 
The analytical strategies for peptides and proteins range from different types of elec- 
trophoresis, i.e. gel electrophoresis, isoelectric focussing, capillary electrophoresis (CE), 
etc., to different types of liquid chromatography, i.e. reversed phase high performance 
liquid chromatography (RP-HPLC), capillary electrochromatography, etc., applying op- 
tical and mass spectrometric detection methods [25–31]. Among these strategies ca- pillary 
electrophoresis-mass spectrometry (CE-MS) turned out to be a highly suitable technique 
for the detailed characterization of peptides and proteins [32–35]. CE shows a high 
separation efficiency and selectivity and a low sample and solvent consumption. In 
addition, there is no need for stationary phases or organic modifiers in the mobile 
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phase, which might lead to conformational changes or even degradation of proteins in 
particular. The MS detection provides high selectivity and sensitivity as well as the pos- 
sibility for identification and characterization by accurate mass determination and/or 
fragmentation experiments. 
These outstanding features, particularly the high overall selectivity of CE-MS may be 
used for e.g. the impurity profiling of synthetic products and pharmaceuticals, shown in 
detail for tetracosactide (TCS) in manuscript 1. 
 
 
1.2.1  Capillary electrophoresis 
 
 
The principle of CE is based on the migration of ions in an electric field, where ions are 
separated according to their charge to size ratio by voltage application [36–38]. The 
separation is influenced by different factors, including the electrophoretic mobility of the 
analytes and the electroosmotic flow (EOF). The EOF is a product of the interaction of 
background electrolyte ions with the inner capillary surface induced by the applied voltage. 
The electroosmotic mobility µEOF depends on the dielectric constant of the electrolyte 
solution ε, the zeta potential ζ  of the inner capillary wall, and the viscosity η of the 
background electrolyte (BGE): 
 
 
µEOF = 
ε ⋅ ζ (1.1) η 
The electrophoretic mobility of the analytes can be derived from the electric force af- 
fecting charged particles in an electric field and the frictional force due to Stokes’ law: 
 
 
µe = 6
 
q 
⋅ π ⋅ r 
 
(1.2) 
⋅ η 
 
with q being the charge of the ion, r the Stokes’s radius of the ion, and η the viscosity of 
the BGE. Common BGEs in CE with optical detection are composed of buffered salines, 
containing a relatively high content of sulphate, phosphate, or borate. However, only 
volatile electrolytes, like formic acid (FAc), acetic acid (HAc), and ammonium acetate, can 
be used when the detection is accomplished by electrospray ionization-mass spectrometry. 
 
Regarding the analysis of intact proteins by CE a special aspect has to be considered. 
Protein characteristics (e.g. hydrophobicity) may lead to their adsorption to the capillary 
wall, causing EOF alteration, irreproducible migration times, peak broadening and 
restricted separation efficiency [39, 40]. A common strategy for the prevention of protein 
adsorption implicates the application of permanent or physically adsorbed capillary 
coatings [27, 28, 34, 40, 41]. Dynamic coatings are not suitable for CE-MS analyses as non-
volatile coating agent additives in the BGE would lead to ion suppression 
ηrπ6
qµe   
η
ζεµEOF   
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during ionization. Coatings described in the literature for the separation of various intact 
proteins by CE-MS are prepared using neutral [42–48] or cationic [42, 43, 49–58] coating 
agents. Neutral coatings lead to a suppressed EOF, whereas cationic coatigs reverse the 
direction of the EOF, so that the cationic analytes migrate against the EOF. It should be 
noted that in CE-MS the polarity of the separation voltage has to be reversed, when 
cationic coatings are applied (EOF in MS direction!). 
In order to find a suitable coating for the separation of a given protein mixture, the 
resolution has to be considered. The resolution in CE is described by the following  
equation [37, 41]: 
 
U = 0.18 ⋅ ∆µe ⋅ D ⋅ ׀µ EOF + 
 
µe ׀ (1.3) 
 
with ∆µe being the mobility difference of two analytes, U the applied voltage, D the 
diffusion coefficient, µEOF the mobility of the EOF, and eμ the mean mobility of the two 
analytes. Hence, cathodic separations will show the highest resolution using neutral 
coated capillaries (µEOF ≈ 0). By contrast, the highest resolution in anodic separations 
(cationic coated capillaries) is achieved when the (absolute) mobility of the EOF is slightly 
higher than themobility of the analytes ( 0µµ eEOF  ). Thus, intact proteins, which in 
general show low electrophoretic mobilities, will be separated best using a cationic capillary 
coating, which induces only a low reversed EOF. Yet, a compromise has to be met, as an 
increase of the resolution always takes place at the expense of analysis time. 
The application of different neutral and cationic coatings with respect to an optimal 
separation of various intact proteins is discussed in detail in manuscript 2. 
The low concentration sensitivity of CE, which is induced by the small capillary vol- ume 
and the consequently low injection volumes, is irrelevant regarding the analysis of 
pharmaceuticals, pointing out the suitability of CE for the separation of peptides and 
proteins in the pharmaceutical area. 
 
 
1.2.2  Electrospray ionization 
 
 
The coupling of CE and MS is carried out by an electrospray ionization (ESI) source. ESI 
is a soft ionization producing pseudo molecule ions ([M+nH]n+ /[M-nH]n- ) at atmospheric 
pressure [59–61]. The number of charges carried by the ions depends on the distance of 
possible charge carriers in the molecule, and thus on the size of the analyte. Therefore, 
peptides and proteins appear as multiply charged ions in ESI-MS [62]. 
Atmospheric pressure ionization techniques revolutionized the coupling of liquid phase 
separations with MS detection. The great advantage is the removal of the separation 
eEOF
es
µµD
UΔ.R   
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solvent before the entrance of ions into the high vacuum of the mass spectrometer. In 
addition, non-volatile, polar and thermally labile substances can be analyzed. 
 
For the coupling of CE and MS special ESI interfaces have to be used [63], as the liquid 
flow provided by CE may vary strongly, which is inefficient with respect to a stable 
electrospray.  In addition, an electrical contact with respect to the separation voltage has to 
be provided. Figure 1.2 shows an example setup of a CE-ESI-MS instrumentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 – Schematic diagram of a CE-ESI-QTOF MS setup. The left upper corner shows an 
enlarged detail of the commercial sheath liquid interface. 
 
 
Here, the CE is coupled to a quadrupole time-of-flight mass spectrometer (QTOF MS) 
via a sheath liquid interface, which is the most common CE-MS interface [64]. The sheath 
liquid interface shows a triple tube design, thus a coaxial supporting liquid, i.e. the 
sheath liquid (SL), and a nebulizer gas are provided during analyses (see upper left corner 
of Fig.1.2). The SL serves for a stable electrospray but also provides the electrical contact 
for the CE separations. It typically consists of a water/organic solvent mixture with an 
addition of a small amount of a volatile acid (similar acid as used in the BGE), which 
supports the ionization of the analytes. The SL flow rate is in the range of a few 
microliters per minute. 
Generally, the coupling of CE and MS is straightforward when a system with a grounded 
sprayer is used. The sprayer represents both, the outlet electrode in the CE circuit and the 
counter electrode for the ESI voltage. The grounding of the sprayer causes both electrical 
circuits to operate independently. 
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1.2.3  Mass spectrometry 
 
 
The principle of MS is based on the separation of gas phase ions by electric fields [65– 
67]. The separation takes place according to m/z of the ions. The abbreviation m/z 
represents a dimensionless quantity obtained by dividing the mass of an analyte ion by the 
number of charges carried by the ion (in positive ESI-MS: [M+nH]n+ ions) [66, 68]. Units, 
like the unified atomic mass unit (u) or dalton (Da), are used only to indicate masses of 
atoms or molecules. In MS the masses of small molecules and peptides are often given as 
exact (monoisotopic) masses, which are calculated using the exact masses of the single 
isotopes of the elements. The respective measured (experimental) masses are denoted as 
accurate masses. By contrast, the masses of larger molecules, like proteins, are given as 
average masses, which are calculated taking the natural occurrence of the stable isotopes of 
the respective elements into account.  Exact masses of proteins are relevant when high 
resolving mass spectrometers are used. The resolving power (R) of a mass spectrometer 
is defined by the following equation [66]: 
 
m R = ∆m  (1.4) 
 
with m being the determined mass of the analyte and Δm the difference of two m/z values 
of two peaks considered to be separated. Conveniently, the full width at half maximum 
(FWHM) is used as Δm to determine R based on a single peak.  It should be noted that 
two peaks showing an m/z difference equal to FWHM are just not being separated. Thus, 
for isotopic resolution the value of R has to be considerably higher than the value of the 
molecular weight of the analyte in consideration, which in particular applies to intact 
proteins (e.g. an R of about 40,000 is needed to resolve the isotopes of a 30 kDa protein). 
Mass spectrometers showing medium and high resolving powers (R ≥ 10,000) and pro- 
viding the possibility for exact mass measurement can be used for the determination of 
the sum formula of unknown substances (small molecules). Furthermore pharmaceuticals 
can be characterized in detail by the identification of impurities, the differentiation of 
various isoforms, or the determination of modifications leading to minor changes of the 
molecular mass and charge, e.g. deamidation (manuscript 1 and 3). 
 
Among common mass spectrometers [66, 67], the time-of-flight mass spectrometer (TOF 
MS) represents a highly suitable technique for the analysis of peptides and intact proteins. 
The principle of a TOF MS is based on the acceleration of bunched ions by a strong 
electric field into a field free flight region and the subsequent detection of the cor- 
responding flight time [69]. In consideration of the conservation of energy (Eel  = Ekin ) 
Δ
m  
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the following equation applies to the determination of m/z based on the flight time t: 
 
 mi t = s ⋅ 2 ⋅ e ⋅ z (1.5) ⋅ U 
 
with s being the flight path, mi the mass of the ion, e the elementary charge, z the charge 
number, and U the acceleration voltage. Due to the feasibility of exact time measurement, 
TOF mass spectrometers enable the exact determination of m/z and hence the 
determination of accurate analyte masses. 
 
The routine application of TOF MS in combination with liquid phase separations was 
achieved by the introduction of orthogonal acceleration, which allows the coupling of 
continuous ion sources like ESI with pulsed techniques (TOF MS) without loss of re- 
solution and sensitivity [70]. The resolving power of TOF instruments depends on the 
length of the flight path, ranging from 10,000 for common bench-top TOF MS to 60,000 
for high-resolution TOF MS (with extended flight paths). 
With respect to the resolving power, TOF mass spectrometers are often compared to 
Fourier transform-ion cyclotron resonance (FT-ICR) [71–74] and orbitrap mass spec- 
trometers [75, 76]. Using these scanning type mass spectrometers, the m/z determination 
of ions is accomplished by determining the respective cyclotron frequency in a static 
magnetic field (FT-ICR) or the respective oscillation frequency along the inner electrode in 
a static electric field (orbitrap) and subsequent Fourier transformation (FT). Both 
techniques were shown to be able to resolve the isotopes of 40 kDa or even larger 
proteins [74, 77–79]. However, the resolving power of these FT-type mass spectrometers is 
inversely proportional to the acquisition time. Hence, the highest resolutions are achieved 
at high acquisition times (t > 1 s), being insufficient for the coupling of fast separation 
techniques like CE. By contrast, TOF mass spectrometers show a constant resolving 
power, even at fast data acquisition, and complete high resolution spectra can be obtained 
in less than 0.2 milliseconds. 
Regarding the analysis of intact proteins, TOF MS additionally show a higher suitability 
due to their outstanding wide mass range (principally unlimited). And in combination 
with isotopic resolution and appropriate separation (CE) the fast characterization of pro- 
tein modifications and overlapping isoforms on the intact protein level is accomplished 
easily (manuscript 3). 
 
Further performance enhancement is achieved by the combination of TOF mass spec- 
trometers with quadrupoles. Quadrupoles allow the selection of certain ions showing a 
defined m/z by quadrupolar fields induced by the simultaneous application of direct and 
alternating voltages [80]. QTOF hybrid mass spectrometers are composed of an analytical 
quadrupole, a gas filled quadrupole (collision cell), and a TOF MS [81]. Hence, ion 
fragmentation (MS/MS) can be carried out and the structural information gained may 
Uze2
mst i   
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be used for the identification of unknown substances including pharmaceutical impurities 
(manuscript 1). 
 
 
 
1.3  Statistical evaluation methods 
 
 
The application of statistical methods may be useful for the detailed evaluation of exten- 
sive multivariate data sets. Among these statistical methods, the Cluster Analysis (CA) and 
the Principal Component Analysis (PCA) represent highly efficient and common strategies 
for e.g. the determination of similarities among numerous samples based on various 
characteristics. 
 
Multivariate data sets can be explained as m data points in an n-dimensional coordinate 
system. In CA the distances between the different data points are used in order to assign the 
data set into groups of high similarity, i.e. clusters [82, 83]. Different types of CA are 
known, among which the Hierarchical Clustering represents a highly illustrative method 
[84]. Therewith, clusters are formed successively, starting with either small clusters building 
up ever larger clusters (Agglomerative Hierarchical Clustering) or large clusters dividing 
into smaller ones (Divisive Hierarchical Clustering). The results of the Hierarchical Cluster 
Analysis are displayed in a dendrogram. 
 
The PCA is a multivariate statistical method for the determination of hidden structures 
in extensive data sets [85–87]. The aim of PCA is to reduce the dimensions of the n- 
dimensional multivariate coordinate system without great loss of information in order to be 
able to display the multivariate data set in a two-dimensional coordinate system (score 
plot). The abscissa and the ordinate of this “new” coordinate systems are represented by the 
Principal Components, which can be determined mathematically by the solution of the so 
called eigenvalue problem. In this context, the major variance of the data set is explained 
by the first Principal Component (PC) whereas the second-biggest variance is explained 
by the second PC and so on. By this means, possible hidden structures present in the 
multivariate data set are visualized by clustering in the “new” coordinate system (score 
plot). 
 
Multivariate statistics shows a wide application range in different areas of analytical 
chemistry. In particular, statistical evaluation is crucial when glycoproteins, which show a 
high complexity due to numerous isoforms present in each sample, are involved. As an 
example, the PCA was used for the differentiation of bladder cancer patients from healthy 
people based on the differences in the isoform distribution of α-1-acid glycoprotein [53]. 
A similar approach can be used for the comparison of biopharmaceuticals and biosimilars 
using PCA and CA (manuscript 4). 
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1.4  Aims and scopes 
 
 
The aim of this work was the improved and detailed characterization of peptide and protein 
pharmaceuticals by the application of highly efficient analytical and statistical methods. 
Capillary electrophoresis-mass spectrometry was used for the identification of impurities 
and the detection of various isoforms of a glycoprotein and protein modi- fications leading 
to small mass changes. Principal Component Analysis was used as a supporting procedure 
in method validation and, being accompanied by cluster analysis, for the differentiation of 
biopharmaceuticals and biosimilars based on the various isoforms. 
In detail, the following issues emerged: 
 
 
1. Capillary electrophoretic separation 
In combination with ESI-MS detection CE represents a powerful and selective analysis 
technique, being the method of choice for the separation of pharmaceutically 
relevant peptides and proteins. The aim was an appropriate separation of TCS and 
its detected impurities on the one hand and the various isoforms of EPO as well as 
protein modifications on the other. With respect to intact proteins, the determination 
of a fast and widely applicable method was of high interest, being addressed by the 
optimization of several CE-MS parameters for the analysis of different model 
proteins and EPO and the validation of the optimized method. An appropriate 
separation is significant with respect to the facilitation of the identification of 
unknown substances (impurities, modifications) and the characterization of various 
isoforms by TOF MS. 
 
2. Application of mass spectrometry 
In combination with the electrophoretic separation QTOF MS was meant to be 
applied for the identification of unknown impurities of TCS and various EPO 
glycoforms present in different samples as well as the verification of the presence of 
protein modifications based on accurate masses and/or MS/MS experiments. 
According to the requirements (isotopic resolution), a common bench-top and a high 
resolution instrument had to be used, respectively. 
 
3. Application of multivariate statistics 
Based on the information gained by CE-QTOF MS evaluation methods applying 
multivariate statistics were developed i) as a supportive strategy with respect to 
method validation, and ii) for the comprehensive comparison of different marketed 
and pre-production EPO preparations using differences in the relative abundances 
of selected glycoforms. 
  
 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
Manuscripts 
 
 
 
 
 
Manuscript 1:  
A. Taichrib, G.K.E. Scriba, C. Neusu¨ß: 
Identification and Characterization of Impurities of Tetracosactide by Capillary Elec- 
trophoresis and Liquid Chromatography coupled to Time-of-Flight Mass Spectrometry. 
Analytical and Bioanalytical Chemistry (2011), 401, 1365-1375. 
 
 
Manuscript 2: 
A. Taichrib, M. Pioch, C. Neusu¨ß: 
Towards a Standard Method for the Analysis of Small Intact Proteins by CE-ESI-TOF 
MS. 
Electrophoresis (2011), submitted. 
 
 
Manuscript 3: 
A. Taichrib, M. Pelzing, C. Pellegrino, M. Rossi, C. Neusu¨ß: 
High resolution TOF MS coupled to CE for the analysis of isotopically resolved intact 
proteins. 
Journal of Proteomics (2011), 74, 958-966. 
 
 
Manuscript 4: 
A. Taichrib, M. Pioch, C. Neusu¨ß: 
Multivariate Statistics for the Differentiation of Erythropoietin Preparations based on 
Intact Glycoforms determined by CE-MS. 
Analytical and Bioanalytical Chemistry (2011), submitted. 
 
 
 
 
 
 
 
11 
Manuscripts 12 
 
 
Manuscript 1 
 
 
 
 
Identification and Characterization of Impurities of Tetracosactide by 
Capillary Electrophoresis and Liquid Chromatography coupled to 
Time-of-Flight Mass Spectrometry 
 
A. Taichrib, G.K.E. Scriba, C. Neusu¨ß 
 
Analytical and Bioanalytical Chemistry (2011), 401, 1365-1375. 
 
 
 
 
 
 
 
 
 
The manuscript describes the application of accurate mass and fragment ion spectra for 
the identification of the impurities of a chemically synthesized peptide pharmaceutical. A 
comparison of the separation of the impurities by capillary electrophoresis and liquid 
chromatography was carried out and the different separations are discussed. The relative 
amounts of the various impurities in different tetracosactide samples were determined. 
 
 
 
 
 
 
 
 
 
Candidate’s work: 
Implementation of the CE-TOF MS, the HPLC-TOF MS, and the fragmentation ex- 
periments, adaption of the HPLC method for the improved peptide separation, data 
processing and interpretation, manuscript preparation. 
Manuscripts 13 
 
 
 
 
 
 
Anal Bioanal Chem (2011) 401:1365–1375 
DOI 10.1007/s00216-011-5183-0 
 
ORIGINAL PAPER 
 
 
 
Identification and characterization of impurities 
of tetracosactide by capillary electrophoresis and liquid 
chromatography coupled to time-of-flight mass spectrometry 
 
Angelina Taichrib ⋅ Gerhard K. E. Scriba ⋅  
Christian Neusüß 
 
 
 
Received: 2 May 2011 / Revised: 9 June 2011 / Accepted: 13 June 2011 / Published online: 6 July 2011 
# Springer-Verlag 2011 
 
Abstract Tetracosactide is a synthetic peptide analogue of the 
human adrenocorticotropic hormone that stimulates the 
production of cortisol in the adrenal cortex. The medical use 
of the compound is primarily the diagnosis of the adrenal 
cortex function. In order to characterize impurities of the 
drug, tetracosactide samples were analysed by both liquid 
chromatography and capillary electrophoresis cou- pled to a 
quadrupole time-of-flight mass spectrometer. The 
identification of the impurities was carried out based on 
accurate mass determination and fragment ion spectra. The 
presence of several peptides of lower and higher masses than 
tetracosactide could be shown, including N- and C- terminally 
truncated peptides as well as peptides which still contained  
protecting  groups  or additional  amino acids. Furthermore, a 
semi-quantitative estimation of the relative amounts of the 
impurities in different samples as well as a commercial 
preparation revealed that the number and the type of the 
impurities varied between the  samples. Comparing the 
selectivity of liquid chromatography and capillary 
electrophoresis regarding the separation of tetra- cosactide 
impurities, it can be stated that capillary electro- phoresis 
showed a higher suitability for the separation of 
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tetracosactide fragments (smaller peptides) while the larger 
peptides, i.e. those  wearing  protecting  groups,  were 
separated more efficiently by liquid chromatography. 
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Introduction 
 
The synthetic peptide hormone tetracosactide  (SYSME 
HFRWGKPVGKKRRPVKVYP, TCS) is an analogue of the 
human adrenocorticotropic hormone (ACTH) produced by 
the pituitary gland. TCS contains the first 24 amino acids of 
ACTH which is composed of 39 amino acid residues. Like 
ACTH, TCS stimulates the production of steroid hormones  in 
the adrenal cortex,  primarily  the production of 
glucocorticosteroids such as cortisol and, to a  minor 
extent, mineralocorticosteroids and  adrogenic steroids [1–4]. 
The medical use of TCS is primarily the diagnosis of adrenal 
cortex dysfunction [5–8]. Besides its medical purpose, the 
hormone was considered to be a performance-enhancing 
substance [9]. Although this has been questioned [10, 11], 
TCS and analogous substances are still on the list of 
prohibited substances of the World Anti-Doping Agency 
[12]. Thus, the analysis of TCS is of great importance in the 
pharmaceutical area as well as in doping control. 
For the determination in doping control, TCS needs to be 
analysed in body fluids, i.e. plasma and urine. Due to the 
short half-life [13] and consequently low concentrations in 
plasma and urine samples, analytical  methods combine 
immunoaffinity  purification  followed by reversed-phase 
high-performance liquid chromatography–mass spectrome- 
try (RP-HPLC/MS) [14–16]. In pharmaceutical analysis, 
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for quality  control  as, for example,  described  in the 
monograph of the  European  Pharmacopoeia  [17], the 
samples are analysed by RP-HPLC using gradient elution 
with ammonium sulphate and acetic acid containing mobile 
phases and UV detection. The European Pharmacopoeia lists 
two specified impurities, i.e. tetracosactide sulphoxide and a 
compound with unknown structure. Further peaks can be 
found in the chromatogram supplied by the European 
Directorate for the Quality of Medicines [18]. Thus, the purity 
of TCS is not well described by the present analytical 
methods. In order to further characterize impurities of TCS, 
HPLC as well as capillary electrophoresis (CE) coupled to a 
quadrupole time-of-flight mass spectrometer (QTOF MS) 
were applied. QTOF mass spectrometers enable the fast 
determination of the accurate masses of considered analytes 
and, in addition, fragmentation experiments of selected 
precursor ions can be performed. Furthermore, TCS from 
two different suppliers as well as a pharmaceutical TCS 
formulation have been analysed. 
 
 
Materials and methods 
 
Chemicals 
 
Methanol,  2-propanol  (ROTISOLV® ≥ 99.95%,  LC/MS 
grade, ammonium acetate (≥97%, p.a., ACS), and formic acid 
(ROTIPURAN® ≥ 98%, p.a., ACS) were purchased from Carl 
Roth GmbH & Co. KG (Karlsruhe, Germany) and used  
without  further  purification. NaOH p.a. was purchased from 
Merck (Darmstadt, Germany). Ultra pure water of an 
electrical resistivity > 18 MΩcm was supplied by an 
ELGASTAT® UHQ PS water purification system (Elga Ltd., 
High Wycombe, England) and used for the preparation of all 
samples, rinsing solutions  and back- ground electrolytes 
(BGEs). 
Tetracosactide, the 16D-Lys-TCS diastereomer, and the 
TCS sulphoxide were supplied by the Federal Institute for 
Drugs and Medical Devices (BfArM, Bonn, Germany). 
Another sample  of TCS  was purchased  from Bachem 
(Bachem  Distribution  Services GmbH, Weil  am Rhein, 
Germany),  the commercial  preparation  SYNACTHEN® 
(sigma-tau  Arzneimittel  GmbH,  Düsseldorf,  Germany) 
was purchased  in a local pharmacy.  All samples were 
prepared at a concentration of 1.0 or 0.5 mg/mL in ultra 
pure water. 
 
Capillary electrophoresis 
 
CE experiments were performed on an Agilent HP 3DCE 
equipped with ChemStation software (version B.04.02) for 
instrument control (Agilent Technologies, Waldbronn, Ger- 
many). An 80-cm fused-silica separation capillary with an 
ID of 50 μm from Polymicro Technologies (AZ, USA) was 
used. New capillaries were conditioned by flushing with 
methanol (5 min), water (5 min), 1 M NaOH (20 min), water 
(5 min) and the BGE (5 min). When not in use, the 
capillaries were stored air-dried. The BGE for TCS analyses 
consisted of 0.5 M aqueous formic acid. Samples were 
injected hydrodynamically (100 mbar for 6 s). Prior to the 
injection, the capillary was flushed with the BGE for 2 min. 
The analyses were carried out applying a constant separa- 
tion voltage of +15 kV. 
 
High-performance liquid chromatography 
 
HPLC separations were performed on a Dionex UltiMate 
3000 liquid  chromatography  system  (Dionex Softron 
GmbH, Germering, Germany) controlled by HyStar soft- 
ware, version 3.2 (Bruker Daltonik, Bremen, Germany). The  
analyses were performed  on an Agilent  Poroshell 
300SB-C18 column  (75 × 2.1 mm, particle  size 5 μm; Agilent 
Technologies, Waldbronn, Germany). The mobile phase 
consisted of 0.1% formic acid in water (A) and methanol (B). 
The flow rate was set to 0.2 mL/min and gradient elution  was 
performed  applying  the following steps: 100% A for 1 
min, ramp to 100% B in 20 min, keep constant at 100% B 
for 10 min, return to 100% A in 
0.5 min, equilibration  for at least 3 min.  During the analysis, 
the column was kept at 40 °C and the sample tray at 15 °C. 
The injection volume was 2 μL. 
 
Electrospray mass spectrometry 
 
The CE/MS coupling was carried out via  electrospray 
ionisation (ESI) using a commercial CE-ESI-MS interface 
(Agilent Technologies, Waldbronn, Germany) which has a 
triple tube design. Thus, a co-axial sheath liquid (SL) flow 
is provided during analyses. In all CE/MS experiments, the 
SL consisted of water and 2-propanol (50:50). The SL was 
supplied by a syringe pump (Cole-Parmer®, Illinois, 
USA) equipped  with a 5 mL  syringe (5MDF-LL-GT, SGE 
Analytical Science Pty Ltd, Melbourne, Australia) at a flow 
rate of 4 μL/min.  The outer coating at the capillary  tip  was  
burned  off  a  few  millimeters  and cleaned using 2-
propanol. 
The HPLC/MS coupling was carried out by a conven- 
tional ESI sprayer (Agilent  Technologies,  Waldbronn, 
Germany). 
A micrOTOFQ quadrupole time-of-flight mass spec- 
trometer  controlled  by  micrOTOF  control  software 
(Bruker Daltonik GmbH, Bremen, Germany) was used. The  
ESI  sprayer  was  grounded  while  the  transfer capillary 
was kept at a constant voltage of −4,500 V (positive ion 
polarity mode). For CE/MS analyses, the drying gas 
(nitrogen) flow rate was set to 4 L/min, the 
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drying temperature  to 170 °C, and the  nebulizer  gas 
(nitrogen) to 0.2 bar. For HPLC/MS analyses, the drying 
gas flow rate was set to 10 L/min, the drying temperature 
to 200 °C, and the nebulizer gas to  1 bar. The ion optics 
were optimized to the highest possible intensity in the mass 
range m/z 400–3,000 by direct infusion of a 100-fold 
dilution of ES Tuning Mix (Agilent Technologies, Wald- 
bronn, Germany). The same solution and flow rate were 
also used for the mass calibration of the TOF MS which 
was performed at least once a day. MS/MS experiments 
were performed using the multiple reaction monitoring 
(MRM) mode of the Bruker micrOTOFQ where selected 
precursor ions are isolated within a given width (usually 
4 m/z) and fragmented in the collision cell (filled with argon) 
by collision induced dissociation at a collision energy of 18 
eV. For fragmentation experiments, the mass range was 
extended to m/z 50–3,000. 
Data  processing  was  carried  out  by  the  Bruker 
Compass  DataAnalysis  software  (Version  4.0  SP  2, 
Bruker Daltonik GmbH, Bremen, Germany). The exact 
masses,  isotopic  patterns,  and  the  respective  charge 
distributions of the theoretical peptides used for ion trace 
extraction were calculated using the ‘IsotopePattern’ tool of 
the Bruker software. 
 
 
Results and discussion 
 
According to the European Pharmacopoeia, the analysis of 
TCS is carried out by RP-HPLC with UV detection [17]. 
Only  two  specified  impurities  are mentioned  in the 
monograph but further peaks can be seen in the sample 
chromatogram [18]. Thus, further characterization of TCS 
by HPLC/MS  and  CE/MS  was performed  in order to 
identify additional minor components of the drug. 
Due to the relatively high salt content of 0.5% (w/v) 
ammonium sulphate in the mobile phases specified by the 
European Pharmacopoeia, the standard RP-HPLC method 
had to be adapted for MS coupling. The first approach 
consisted in the substitution of ammonium sulphate in the 
mobile phase by ammonium acetate. Several experiments 
were carried out applying the stationary phase recommen- 
ded by the European Pharmacopoeia and different elution 
modes, i.e. isocratic at different water/organic solvent ratios 
as well as gradient elution using ammonium acetate/acetic 
acid mobile phase. However, no separation of TCS and its 
impurities comparable to the reference chromatogram was 
obtained (results not shown). The second approach con- sisted 
in the substitution of both the stationary phase and the 
mobile phase. The application of a Poroshell 300SB- C18 
column originally recommended for the separation of 
proteins in combination with a 0.1% aqueous formic acid– 
methanol gradient resulted in a reasonable separation of 
TCS and impurities (see base peak chromatogram in the upper 
left corner of Fig. 1). 
The separation efficiency of RP-HPLC was compared to 
the separation efficiency of CE as a highly suitable 
separation technique for peptides [19]. Furthermore, CE and 
HPLC are complementary techniques. CE separation of TCS 
and impurities was achieved in a fused-silica capillary using 
0.5 M formic acid as BGE and a separation voltage of 15 
kV. Shorter capillaries as well as BGEs of lower ionic 
strength and higher separation voltages lead to lower 
resolution. 
Figure 1 shows the base peak chromatogram (BPC; top 
left) and the base peak electropherogram (BPE; top right) of 
a TCS  sample analysis by RP-HPLC/MS  and CE/MS, 
respectively. As our aim was not the quantitation of TCS 
itself but the characterization of impurities, the concentra- 
tion of the samples was relatively high (0.5 mg/mL for HPLC 
and 1 mg/mL for CE analysis) resulting in a very broad 
peak of TCS in both HPLC and CE analysis and near 
saturation of the respective detector signal of the QTOF MS. 
For the identification of all other peaks present in the BPC 
and the BPE,  the respective mass spectra were investigated. 
All peaks were due to peptides with either higher or lower 
mass than TCS. A peak with the same charge distribution and 
mass as TCS (marked with the 
asterisk  in Fig. 1) was supposed  to be the  16D-lysine 
diastereomer of TCS. This was verified by spiking with the 
synthetic diastereomer (data now shown). The separation 
efficiency with respect to TCS and its diastereomer is clearly 
higher in CE than in RP-HPLC (compare BPC and BPE in 
Fig. 1). Another impurity identified by exact mass and by 
spiking with the reference substance was TCS 
sulphoxide originating from the oxidation of 4M. In this 
case, the separation behaviour was opposite. In RP-HPLC, 
the sulphoxide is separated from TCS as indicated by the 
arrow in the BPC in Fig. 1 while co-migration of the 
compounds is observed in CE. 
The following approach for the identification of TCS- 
derived peptides was based on the amino acid sequence of 
the parent peptide. Starting with the complete sequence of 
24 amino acids, the masses of peptides lacking subsequent 
amino acids were calculated starting at the C-terminus, i.e. 
1-23 TCS, 1-22 TCS, etc. The presence of the particular 
peptides in the sample was verified by ion trace extraction, 
i.e. by accurate mass. The process was performed for all 
possible peptides above m/z 400. The same procedure was 
carried out for N-terminally shortened peptides. According 
to the extracted ion chromatograms (EIC) and extracted ion 
electropherograms (EIE) all of the  theoretical peptides down 
to a size of seven amino acids shortened from the N-
terminus and eight amino acids shortened from the C- 
terminus, respectively,  could  be detected  in  the TCS 
sample. A complete list of all truncated peptides found in 
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Fig.  1 TCS sample analysis by RP-HPLC/MS (left) and CE/MS 
(right): BPC, BPE and ion traces of selected peptides smaller 
than TCS (fragments 1–15 TCS, 1–14 TCS, 1–13 TCS, 1–12 TCS, 
1–11 
TCS, 1–10 TCS, 1–9 TCS and 1–8 TCS). EICs and EIEs were created 
by extraction of the masses of the three main isotopes of the 
most abundant  charge state of the respective  peptide (listed in the 
figure). The extraction  width was adapted in order to exclude 
 
contaminants or isotopes of other ions showing the same 
nominal mass. The letters indicate the missing amino acid from 
one peptide to the following starting with the peptide 
SYSMEHFRWGKPVGK. The asterisk indicates the 16D-Lys-TCS 
diastereomer, the arrow indicates TCS sulphoxide. X denotes peaks 
arising from background substances or isotopes of co-migrating 
peptides lying within the specified extraction width 
 
 
TCS is summarized in Table 1. Some peptides (2-24 TCS, 
1-22 TCS, 1-20 TCS, 1-19 TCS, and 1-11 TCS) could only 
be detected by CE/MS but not by HPLC/MS analysis, as 
indicated by the missing retention time in Table 1. The 
truncated peptides can be explained by incomplete reactions 
during solid-phase peptide synthesis of TCS. Regarding the 
chemical synthesis of peptides in general, different impu- 
rities may arise [20, 21]. In the solid-phase strategy [22] 
peptides  are assembled  successively  starting  at the C- 
terminal amino acid bound to the resin. Hence, peptides 
truncated at the  N-terminus  may arise by incomplete 
coupling reactions. Peptides lacking amino acids at the C- 
terminus may be due to incomplete coupling of the first 
amino acid to the resin in the initial step. 
Besides the base peak traces, Fig. 1 shows the EICs and 
EIEs of selected C-terminally truncated peptides, i.e. the 
16
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Table 1 List of identified impurities in TCS, their corresponding 
e  xact masses, and the respective retention and migration times  
Peptide MW [Da] HPLC CE 
RT [min] MT [min] 
 
TCS 2,931.5806 9.4 12.9 
D-Lys-TCS  2,931.5806 10.1 12.6 
1–23 TCS 2,834.5279 9.3 12.7 
a
 
CE/MS analysis, but needed to be decreased when the mass 
of contaminants or isotopes of other ions showing the same 
nominal mass interfered with the m/z values in 
consideration. 
A detailed evaluation of the retention and migration times 
of the truncated  peptides  showed  that peptides missing a 
basic amino acid, i.e. K or R, and herewith 
missing  a charge  carrier,  migrated  considerably  more 
1–22 TCS 2,671.4645 – 12.4 slowly in CE/MS analysis than their respective ‘ancestor ’ 
1–21 TCS 2,572.3961 9.1 12.1 
a
 peptide (compare EIE 1→EIE 2 and EIE 5→EIE 6 in 
1–20 TCS 2,444.3012 – 12.6 Fig. 1). Vice versa, peptides missing an acidic or neutral 
1–19 TCS 2,345.2328 –a 12.3 
1–18 TCS 2,248.1800 9.0 12.2 
1–17 TCS 2,092.0789 9.2 12.7 
1–16 TCS 1,935.9778 9.3 13.4 
1–15 TCS 1,807.8828 9.8 14.5 
1–14 TCS 1,679.7878 10.6 15.9 
1–13 TCS 1,622.7664 10.8 15.7 
1–12 TCS 1,523.6980 10.2 15.3 
1–11 TCS 1,426.6452 –a 15.1 
1–10 TCS 1,298.5502 10.5 17.2 
1–9 TCS 1,241.5288 10.9 17.0 
1–8 TCS 1,055.4495 8.2 16.2 
2–24 TCS 2,844.5486 –a 12.6 
3–24 TCS 2,681.4853 9.3 12.5 
4–24 TCS 2,594.4533 9.2 12.3 
5–24 TCS 2,463.4128 8.9 12.1 
6–24 TCS 2,334.3702 8.9 11.9 
7–24 TCS 2,197.3113 9.0 12.4 
8–24 TCS 2,050.2429 8.1 12.1 
9–24 TCS 1,894.1417 8.1 12.7 
10–24 TCS 1,708.0624 6.8 12.1 
11–24 TCS 1,651.0410 6.7 12.0 
12–24 TCS 1,522.9460 6.9 12.6 
13–24 TCS 1,425.8932 7.0 12.4 
14–24 TCS 1,326.8248 6.6 11.9 
15–24 TCS 1,269.8034 6.3 11.8 
16–24 TCS 1,141.7084 6.7 12.5 
17–24 TCS 1,013.6134 7.1 13.6 
18–24 TCS 857.5123 7.4 15.3 
TCS + YSM 3,312.7165 11.1 13.4 
TCS + SYSM 3,399.7485 11.0 13.6 
Ac-TCS 2,973.5912 10.6 13.8 
tBu-TCS 2,987.6432  11.4 13.0 
tBoc-TCS 3,031.6331 12.0 13.7 
10–24 TCS + G 1,765.0839 7.4 13.5 
TCS sulphoxide 2,947.5756 9.2 13.0 
amino acid migrated faster than the longer peptide due to 
their smaller size. A similar behaviour was observed for 
the retention times of the TCS fragment peptides in HPLC/ 
MS analyses, even though not as strictly as in CE/MS 
(compare Fig. 1). While the migration time is influenced 
more strongly by charge, the retention time shows a higher 
dependence on hydrophobicity of the analytes. Figure 2 
illustrates  the observed  retention  and  migration  time 
behaviour of the truncated peptides. The retention and 
migration  times  are plotted  against  the corresponding 
amino acid sequence of the N- and C-terminally shortened 
peptides  starting  with TCS.  The  retention  time plot 
contains five gaps of peptides that could not be detected 
in HPLC/MS analysis. However, it is clearly visible that the 
observed migration behaviour in CE and retention behaviour 
in HPLC is consistent within the whole set of peptides.  
The migration behaviour of peptides as a function of their 
structural and chemical characteristics has been  studied  in 
detail  and  even migration  time prediction models in CE 
have been developed [19, 23– 
28]. Similar studies carried out for the retention behaviour of 
peptides in RP-HPLC indicated the influence of the peptide 
sequence and the hydrophobicity of the analytes in addition 
to other parameters like the stationary and mobile phases 
[29–33]. However, to the best of our knowledge, the 
example given here illustrates for the first time the situation  
for  structurally related  peptides  based  on a synthetic 
peptide and its impurities caused by incomplete peptide 
synthesis. 
The  comparison of the EIEs of the identified TCS- derived 
peptides with the BPE revealed that almost all previously 
unknown peaks could be explained by incom- plete solid-
phase synthesis. However, a similar comparison in RP-
HPLC/MS analysis revealed that only the unknown peaks 
of low abundance originated from N- or C-terminally 
truncated  TCS  peptides.  The high  abundant  impurities 
   showing  a stronger  retention  than TCS  could  not be 
a Not detected by HPLC/MS analysis 
 
fragments 1-15 TCS, 1-14 TCS, 1-13 TCS, 1-12 TCS, 1-11 
TCS, 1-10 TCS, 1-9 TCS and 1-8 TCS. The extraction width 
was set to ±0.02 m/z in LC/MS analysis and to ±0.01 m/z in 
explained in this manner. For the identification of these main 
impurities in HPLC/MS, the mass differences of the 
respective peptides and TCS were considered first. Without 
exception, all of these impurities appeared to be peptides 
with a higher mass than TCS, showing mass differences of 
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Fig. 2 Migration and retention times of TCS and truncated peptides (N- and C-terminal). The letters represent the missing amino acid from one 
peptide to the following peptide 
 
 
42, 56, 100, 381 and 468 Da. Thus, peptides with additional 
amino acids compared to TCS were considered. The mass 
differences were matched with short amino acid sequences 
already present in the sequence of TCS. A correlation was 
found for the two mass differences 381 and 468 Da, which 
matched  the amino acid  sequences  YSM and SYSM, 
respectively. In  addition  to exact mass correlation,  the 
sequence of the assumed peptides was verified by frag- 
mentation experiments. The other found mass differences did 
not match any amino acid or amino acid sequence. Hence,  
the presence of protecting groups  used  during peptide 
synthesis [20, 21] had  to be considered.  The cleavage of the 
protecting groups is the final step in the solid-phase 
synthesis and may be incomplete leading to by- products. 
Acetyl (Ac), tert-butyl (tBu) and tert-butylox- ycarbonyl 
(tBoc), match the mass differences of 42, 56 and 
100 Da, respectively. In solid-phase peptide  synthesis 
applying the Fmoc-strategy, tBu is used for side chain 
protection of the amino acids D, E, S, T and Y, while tBoc is 
used for side chain protection of W and K. As several of 
these amino acids are present in TCS, incomplete depro- 
tection  reactions  may  result  in these  side  products. 
Verification of the impurities was carried out by MS/MS 
experiments. As an example, Fig. 3a shows the fragment 
ion  spectrum  of the putative  tBu-TCS  obtained  at a 
collision energy of 18 eV after isolation of the fivefold 
charged precursor ion m/z 598.6. In agreement with the 
literature [14, 16, 34], the fragment ion spectrum not only 
showed mainly multiply charged y-fragments, but also a Y 
immonium ion and an a-fragment at m/z 223, which can be 
used as transition ion for TCS determination by MRM [14] 
(the fragment ion denomination is according to Roepstorff 
and Fohlman [35]). The assignment of the fragment ions was 
carried out based on exact masses. As indicated by the 
annotations in Fig.  3a,  several  y-fragments  and  the 
respective  y-fragments  containing  a tBu moiety  were 
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Fig. 3 A MS/MS spectrum of the fivefold charged precursor ion m/z 
598.6 (RT 11.5 min) at a collision energy of 18 eV. B Detail of 
the corresponding charge deconvoluted MS/MS spectrum. Charge 
decon- volution was performed using deconvolution function for 
peptides/ 
 
small molecules of DataAnalysis software. Distances between peaks 
were correlated with amino acid masses using the annotation function 
of DataAnalysis software. The mass precision for the respective amino 
acid is given in daltons 
 
 
present in the fragment ion spectrum of the putative tBu- 
TCS. This is due to the non-selective fragmentation in the 
argon-filled collision cell, leading to several fragments of 
different  size  and  type.  The  distances  between  two 
neighbouring m/z values  of  singly  charged  ions were 
matched with certain amino acids present in the sequence 
of TCS. Analogous distance matching was carried out in the 
corresponding  charge  deconvoluted  mass spectrum (Fig. 
3b). Based on consecutively linked amino acids the sequence 
of a peptide can be determined. By this means, sequence 
fragments of the non-deprotected peptide as well as the 
tBu-fragment itself were found to be present in the charge 
deconvoluted MS/MS spectrum shown in Fig. 3b. Both the 
accurate masses of the y-fragments in the MS/MS 
spectrum and the distances matching the exact masses of the 
corresponding amino acids wearing the tBu protecting 
group (E and S)  in the charge  deconvoluted  MS/MS 
spectrum verify the presence of tBu-TCS in the consid- 
ered sample. Analogous verification was carried out for 
tBoc-TCS  and Ac-TCS  (data not shown).  The acetyl group 
is not considered a protecting group in solid-phase peptide 
synthesis. However, TCS is commercially used as the 
acetate salt so that  Ac-TCS can be explained  by reaction of 
acetic acid with TCS. The European Pharma- copoeia 
specifies an acetic acid content between 8.0% and 13.0% 
[17]. 
Figure  4 shows the BPC/BPE and the corresponding 
extracted  ion traces  of the  peptides  containing  either 
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Fig. 4 BPC (left), BPE (right) and ion traces of identified peptides 
with higher masses than TCS due to additional amino acids or 
protecting groups. EICs and EIEs were created by extraction of 
the exact masses of the three main isotopes of the most abundant 
charge state of the respective peptide in a ±0.02 extraction width: m/z 
 
663.7511; 663.9518; 664.1525 for TCS +  YSM, m/z 681.1575; 
681.3582; 681.5589 for TCS + SYSM, m/z  595.7255; 595.9261; 
596.1268 for TCS + Ac, m/z 598.5359; 598.7365; 598.9372 for TCS + 
tBu, m/z 607.5345; 607.7352; 607.9358 for TCS + tBoc. The asterisk 
indicates the 16    -Lys-TCS diastereomer 
 
 
additional amino acids or remaining protecting groups. The 
analytes exhibited different hydrophobicities but only small 
differences in the charge density (charge-to-size-ratio) so that 
the peptides with additional amino acids or protecting 
groups are better separated by HPLC than by CE. The ion 
traces of tBu-TCS and tBoc-TCS in HPLC analysis show 
several  peaks, which is due to the attachment  of  the 
protecting groups to different amino acids in the sequence 
of TCS. The exact site of the remaining protecting groups 
was not determined in the present study. A complete list of 
the impurities identified in TCS can be found in Table S1 in 
the Electronic Supplementary Material. Similar impurities 
(e.g. peptides  with additional amino acids or residual 
protecting  groups  and diastereomers)  have  also been 
described for other synthetic peptides by Sanz-Nebot et al. 
[36–39] and Litowski [40]. 
Three batches of TCS supplied by the BfArM, a sample 
from a commercial supplier as well as a pharmaceutical 
preparation of TCS were investigated by RP-HPLC/MS and 
CE/MS. In principle, the same impurities were detected in 
the different samples although they seemed to be present in 
varying amounts. Subsequently, a semi-quantitative estima- 
tion of the relative amounts of the impurities in TCS by 
HPLC and CE was carried out using the peak areas of the 
extracted ion traces. Each peak was scaled relatively to the 
peak area of TCS. Thus, the resulting  values do not represent 
a true content of the respective related peptides but the data 
can rather be used to compare the relative amounts of the 
impurities within the different samples. The data of the 
different samples are listed in Table 2. Repeat 
determinations revealed a mean deviation of 7–10%. Due to 
their low abundances, the relative amounts of the TCS- 
derived fragments are reported as a sum only. A detailed list 
of all impurities found in batch one can be seen in Table S1 
in the Electronic Supplementary Material. The amounts of 
the tBu and tBoc peptides do not represent a single peptide 
but rather the sum of several compounds with the same mass 
as discussed above. 
The  relative  contents  determined  by  the  semi- 
quantitative approach differ for RP-HPLC/MS and CE/MS 
which may be explained by quenching effects due to co- 
elution or co-migration as for example shown above for the 
TCS sulphoxide. The relative amounts of the impurities in 
the different batches provided by the BfArM show small 
differences, but a similar order of magnitude. The three main 
impurities are the peptides containing the residual 
protecting groups  tBu or tBoc and the  16D-lysine-TCS 
diastereomer. Similar results were found for the pharma- 
ceutical preparation  SYNACTHEN®. Only the peptide 
containing an Ac group and the 10–24 TCS fragment with 
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Table 2 Comparison of the relative amounts of impurities in different TCS batches, a pharmaceutical preparation and a sample from a commercial 
supplier 
 
Batch 1 Batch 2 Batch 3 SYNACTHEN® Commercial supplier 
 
Peptide Massa  [Da] Area%  
  LC CE  LC CE  LC CE  LC CEb  LC CE
TCS 2931.5806 100 100 100 100 100 100 100 100  100 100
16 D-Lys-TCS 2931.5806 5.02 6.00 3.37 4.58 3.39 5.29 3.46 0.95 – 0.62
TCS + YSM 3312.7165 0.76 0.75 0.96 0.84 1.00 1.45 0.62 0.26 – –
TCS + SYSM 3399.7485 1.14 1.10 1.52 1.31 1.45 2.23 1.04 0.35 – –
Ac-TCS 2973.5912 1.56 1.82 1.08 1.28 1.76 3.13 0.54 0.25 – –
tBu-TCS 2987.6432 14.59 20.51 14.82 19.16 14.24 26.13 11.02 6.36 0.29 –
tBoc-TCS 3031.6331 2.93 5.20 2.89 4.18 2.84 6.94 1.87 0.79 0.01 –
10–24 TCS + G 1765.0839 0.38 0.69 0.46 0.87 0.38 0.71 0.02 0.02 <0.01 –
TCS sulphoxide 2947.5756 0.83 5.72 1.48 2.88 0.80 4.33 1.58 10.28 5.06 6.60
Σ TCS fragments  3.60 8.84  4.38 8.79  3.20 9.03  6.03 3.90  0.26 0.56
Due to the low abundance, the N- and C-terminally truncated fragments are reported as sum. The area% value represents the corresponding area of 
the different peaks scaled to the area of the TCS peak 
a Calculated neutral monoisotopic mass 
b Different response probably due to lower sample concentration (for further explanation see text) 
 
 
an additional G appear to have a notably lower abundance. 
The relative amounts of the impurities in SYNACTHEN® 
calculated for HPLC and CE differ considerably. This may 
be due to the lower sample concentration of only 250 μg/ 
mL. In contrast to HPLC, this could not be compensated in 
CE by an increase of the injection volume. However, the 
detailed impurity profiling as the aim of this study required 
a high concentration of the  samples,  so that the TCS detector 
signal was out of the linear range (estimated by dilution 
experiments). Consequently, the lower concentra- tion of the 
solution of the pharmaceutical product may have led to a 
different response of the main substance and to uncertainties 
in the semi-quantitative estimation. Neverthe- less, both 
techniques may be used to estimate the major impurities. For 
a ‘real’ quantitation of the minor compo- nents of TCS, 
peptide standards have to be employed in the respective 
methods. In the batches provided by the BfArM as well as 
the pharmaceutical product, the tBu containing peptide was 
the major impurity. In contrast, the sample obtained from 
another supplier appeared to contain fewer impurities with 
TCS sulphoxide  as the most prominent impurity. 
In the literature, the percent completion of each step in 
solid-phase peptide synthesis is stated at 99–99.5% [20, 21, 
41]. Hence, the purity of a 24-amino acid peptide will be 
about 80% unless it is further purified. Interestingly, based 
on the peak areas of the EICs and EIEs an estimated overall 
purity of 70–80% of TCS was found in this study. 
Conclusions 
 
In combination with efficient separation by RP-HPLC and 
CE, a quadrupole time-of-flight mass spectrometer enabled 
the identification of a total of 41 impurities of TCS  by  
means  of  accurate  mass  determination  and 
fragmentation. The impurities covered peptides truncated 
at the N- or C-terminus down to eight remaining amino 
acids as well as peptides with additional amino acids and 
peptides with residual protecting groups, such as 
tBu and tBoc. Furthermore, TCS sulphoxide and the 16D- 
Lys-TCS diastereomer as well as acetylated TCS were 
detected. The latter may arise from reaction between TCS 
and acetate as the counter ion of the drug substance. 
Regarding the separation efficiency of the impurities, CE 
displayed  higher  separation  efficiency  for truncated 
peptides, whereas  the impurities  of higher  molecular mass, 
particularly the peptides with remaining protecting groups 
were better separated by RP-HPLC. According to the peak 
areas of  the extracted ion traces, the main impurities of 
TCS were peptides with residual protecting groups. A 
semi-quantitative estimation revealed a TCS purity of 
about 80%. The commercial preparation SYN- ACTHEN® 
showed a similar impurity pattern and also similar amounts 
of the impurities. In conclusion,  RP- HPLC/MS as well as 
CE/MS as orthogonal techniques should be performed for 
complete impurity profiling of TCS. 
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TCS 2931.5806 9.4 12.9 36003554 100 1455716 100 37836034 100.0 2607264 100.0 EIC (587.3234; 587.5240; 587.7247)±0.05 +All MS
D-TCS 2931.5816 10.1 12.6 1808149 5.0 195385 13.4 2271344 6.0 486296 18.7 EIC (587.3234; 587.5240; 587.7247)±0.05 +All MS
1-23 TCS 2834.5279 9.3 12.7 27542 0.1 2808 0.2 76869 0.2 23228 0.9 EIC (473.4286; 473.5957; 473.7630)±0.02 +All MS
1-22 TCS 2671.4645 12.4 7378 0.0 1944 0.1 EIC (446.5214; 446.4185; 446.5858)±0.02 +All MS
1-21 TCS 2572.3961 9.1 12.1 13816 0.0 1579 0.1 23993 0.1 6140 0.2 EIC (515.4865; 515.6871; 515.8878)±0.02 +All MS
1-20 TCS 2444.3012 12.6 4566 0.0 1036 0.0 EIC (612.0826; 612.3333; 612.5842)±0.02 +All MS
1-19 TCS 2345.2328 12.3 9165 0.0 2124 0.1 EIC (470.0538; 470.2544; 470.4551)±0.02 +All MS
1-18 TCS 2248.1800 9.0 12.2 9156 0.0 1823 0.1 8772 0.0 2600 0.1 EIC (563.0523; 563.3030; 563.5539)±0.02 +All MS
1-17 TCS 2092.0789 9.2 12.7 27109 0.1 7450 0.5 64893 0.2 19420 0.7 EIC (524.0270; 524.2777; 524.5286)±0.02 +All MS
1-16 TCS 1935.9778 9.3 13.4 6606 0.0 3635 0.2 80667 0.2 13348 0.5 EIC (485.0017; 485.2525; 485.5033)±0.02 +All MS
1-15 TCS 1807.8828 9.8 14.5 7565 0.0 1429 0.1 50290 0.1 10016 0.4 EIC (452.9780; 453.2288; 453.4796)±0.02 +All MS
1-14 TCS 1679.7878 10.6 15.9 183938 0.5 41489 2.9 418086 1.1 84196 3.2 EIC (560.9366; 561.2710; 561.6053)±0.02 +All MS
1-13 TCS 1622.7664 10.8 15.7 11241 0.0 2790 0.2 21492 0.1 4316 0.2 EIC (541.9294; 542.2638; 542.5982)±0.02 +All MS
1-12 TCS 1523.6980 10.2 15.3 8655 0.0 1774 0.1 6507 0.0 2220 0.1 EIC (508.9066; 509.2410; 509.5754)±0.01 +All MS
1-11 TCS 1426.6452 15.1 33798 0.1 6580 0.3 EIC (476.5557; 476.8901; 477.2245)±0.02 +All MS
1-10 TCS 1298.5502 10.5 17.2 6760 0.0 1962 0.1 9188 0.0 2064 0.1 EIC (650.2824; 650.7840; 651.2856)±0.02 +All MS
1-9 TCS 1241.5288 10.9 17.0 2754 0.0 1053 0.1 5801 0.0 936 0.0 EIC (621.7717; 622.2733; 622.7748)±0.02 +All MS
1-8 TCS 1055.4495 8.2 16.2 9583 0.0 2789 0.2 14412 0.0 2568 0.1 EIC (528.7320; 529.2336; 529.7352)±0.02 +All MS
2-24 TCS 2844.5486 12.6 30658 0.1 6408 0.2 EIC (475.0987; 475.2658; 475.4331)±0.02 +All MS
3-24 TCS 2681.4853 9.3 12.5 185374 0.5 34886 2.4 671661 1.8 77444 3.0 EIC (537.3043; 537.5049; 537.7056)±0.02 +All MS
4-24 TCS 2594.4533 9.2 12.3 11922 0.0 3269 0.2 43714 0.1 9564 0.4 EIC (433.4162; 433.5833; 433.7505)±0.02 +All MS
5-24 TCS 2463.4128 8.9 12.1 23539 0.1 3396 0.2 41809 0.1 8792 0.3 EIC (493.6898; 493.8904; 494.0911)±0.02 +All MS
6-24 TCS 2334.3702 8.9 11.9 38009 0.1 5195 0.4 32518 0.1 6204 0.2 EIC (467.8813; 468.0819; 468.2826)±0.02 +All MS
7-24 TCS 2197.3113 9.0 12.4 76609 0.2 7969 0.5 148803 0.4 27796 1.1 EIC (440.4695; 440.6701; 440.8708)±0.02 +All MS
8-24 TCS 2050.2429 8.1 12.1 129181 0.4 3655 0.3 105517 0.3 19204 0.7 EIC (411.0558; 411.2564; 411.4571)±0.02 +All MS
9-24 TCS 1894.1417 8.1 12.7 35361 0.1 2391 0.2 90222 0.2 22176 0.9 EIC (474.5427; 474.7935; 475.0443)±0.02 +All MS
10-24 TCS 1708.0624 6.8 12.1 101217 0.3 7557 0.5 348699 0.9 68840 2.6 EIC (428.0229; 428.2737; 428.5245)±0.02 +All MS
11-24 TCS 1651.0410 6.7 12.0 94878 0.3 11350 0.8 290443 0.8 53640 2.1 EIC (413.7675; 414.0183; 414.2691)±0.02 +All MS
12-24 TCS 1522.9460 6.9 12.6 142441 0.4 13274 0.9 135632 0.4 23448 0.9 EIC (508.6559; 508.9903; 509.3248)±0.02 +All MS
13-24 TCS 1425.8932 7.0 12.4 9510 0.0 1078 0.1 15156 0.0 2824 0.1 EIC (476.3050; 476.6394; 476.9739)±0.02 +All MS
14-24 TCS 1326.8248 6.6 11.9 4482 0.0 740 0.1 15944 0.0 3408 0.1 EIC (443.2822; 443.6166; 443.9511)±0.02 +All MS
15-24 TCS 1269.8034 6.3 11.8 88543 0.2 5962 0.4 311720 0.8 58844 2.3 EIC (424.2751; 424.6095; 424.9439)±0.02 +All MS
16-24 TCS 1141.7084 6.7 12.5 2656 0.0 606 0.0 8141 0.0 1872 0.1 EIC (571.8615; 572.3631; 572.8648)±0.02 +All MS
17-24 TCS 1013.6134 7.1 13.6 7905 0.0 1470 0.1 7439 0.0 1172 0.0 EIC (507.8140; 508.3156; 508.8173)±0.02 +All MS
18-24 TCS 857.5123 7.4 15.3 25057 0.1 4966 0.3 47536 0.1 5540 0.2 EIC (429.7634; 430.2650; 430.7667)±0.02 +All MS
TCS + YSM 3312.7165 11.1 13.4 272538 0.8 28017 1.9 283037 0.7 49952 1.9 EIC (663.7511; 663.9518; 664.1525)±0.02 +All MS
TCS + SYSM 3399.7485 11.0 13.6 408871 1.1 57072 3.9 416044 1.1 80608 3.1 EIC (681.1575; 681.3582; 681.5589)±0.02 +All MS
Ac TCS 2973.5912 10.6 13.8 560983 1.6 46911 3.2 688959 1.8 67540 2.6 EIC (595.7255; 595.9261; 596.1268)±0.02 +All MS
tBu TCS 2987.6432 11.4 13.0 5252583 14.6 184412 12.7 7761100 20.5 602668 23.1 EIC (598.5359; 598.7365; 598.9372)±0.02 +All MS
tBoc TCS 3031.6331 12.0 13.7 1056342 2.9 76402 5.2 1966442 5.2 218332 8.4 EIC (607.5345; 607.7352; 607.9358)±0.02 +All MS
10-24 TCS + G 1765.0839 7.4 13.5 136015 0.4 9919 0.7 259563 0.7 34928 1.3 EIC (442.2782; 442.5290; 442.7799)±0.02 +All MS
TCS ox. 2947.5756 9.2 13.0 297840 0.8 38326 2.6 2164593 5.7 154808 5.9 EIC (590.5224; 590.7230; 590.9237)±0.02 +All MS
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Table S1: Detailed list of identified impurities in the TCS sample, batch 1 provided by the BfArM. 
 
 
Peptide MW [Da] 
RT 
[min] 
MT 
[min] Area LC   Area% LC   Int. LC  Int.% LC   Area CE   Area% CE   Int. CE  Int.% CE Chromatrogram 
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The manuscript describes an approach for the determination of a CE-MS method which is 
widely applicable to a large variety of intact proteins. Different parameters were varied in 
order to find the optimal conditions for the analysis of intact proteins.  The method was 
validated to a large extent and Principal Component Analysis was carried out in order to 
examine the reliability of this method. 
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Abstract 
 
CE-MS more and more gains in importance as an analytical technique for the identification 
and characterization of intact proteins in the biopharmaceutical area. Thus, a CE-MS method 
was optimized and validated systematically with respect to the general application in intact 
protein analysis. The optimization was accomplished by variation of different CE-MS 
parameters, like capillary coating, BGE, SL, and nebulizer gas pressure, while monitoring 
both the resolution and the intensity. Achievable separation is discussed quantitatively in the 
context of the coating and the resulting EOF, protein mobilities, and the suction effect of the 
sprayer. The observed precisions of the optimized method regarding the migration times (mean 
RSD = 1.4%) and peak areas (mean RSD = 12.3%) and an extensive principal component 
analysis  revealed that the presented method is reliable and useful for the quantitation of intact 
proteins and protein isoforms. The applicability of this method to various proteins showing 
different  characteristics (pI value, molecular weight, hydrophobicity, etc.) is discussed. The 
presented method will contribute to the improved characterization of a large variety of intact 
proteins in the biomedical and pharmaceutical area. 
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1 Introduction 
 
Proteins, in terms of e.g. biomarkers, hormones or antibodies, play an increasingly important 
role in the pharmaceutical, biomedical and clinical area. Thus, the analysis of proteins is of 
high relevance regarding impurity profiling, stability testing, quality control and diagnostic. 
Analytical approaches include different forms of electrophoresis and liquid chromatography 
(LC) with optical or, even more important, mass spectrometric detection. Mass spectrometry 
(MS) combines high selectivity and sensitivity with the possibility of identification and 
characterization (by exact mass measurement and/or fragmentation). In combination with LC 
or CE it represents a highly suitable technique for the analysis of proteins [1-8]. Common 
analytical strategies include the enzymatic cleavage of the proteins followed by the analysis of 
the corresponding peptide mixture by CE-MS or LC-MS (bottom-up). However, due to lower 
effort on sample preparation and lower sample complexity there is a trend towards the direct 
analysis of the intact proteins, regarding both proteomics (top-down strategy) and other 
biomedical and pharmaceutical applications [9-15]. Generally, CE is more suitable for the 
analysis, particularly the characterization of intact proteins due to its considerably higher 
separation efficiency, which is crucial for the separation of e.g. protein isoforms. In addition, 
there is no need for stationary phases or organic modifiers in the mobile phase which might 
lead to conformational changes or even degradation of the proteins. 
Nevertheless, the adsorption of the proteins to the negatively charged capillary wall causes 
their analysis to be challenging [16, 17]. Most approaches to solve this problem deal with the 
application of highly acidic or highly alkaline BGEs and/or the coating of the capillary wall 
using different materials [6, 17-20]. Extreme pH values of the BGE ensure the electrostatic 
repulsion of the proteins and the capillary wall, leading to appropriate separations of certain 
proteins using bare fused silica capillaries [21-25]. However, due to additional hydrophobic 
interactions outweighing the electrostatic interactions, protein adsorptions cannot be avoided 
in most cases. Thus, the combination of capillary coatings with acidic [26-45] and alkaline 
BGEs [39, 46-48], mostly based on acetic or formic acid and ammonium acetate/formate, 
respectively, turned out to be highly suitable for the analysis of intact proteins by CE-MS. 
Therefore, only permanent or physically adsorbed coatings can be applied because coating 
agent additives in the BGE (needed for a dynamic coating) would cause ion suppression in 
electrospray ionization (ESI). The majority of coating agents applied in CE-MS analysis of 
intact proteins is represented by positively charged materials [26-38, 40, 41], leading to a 
reversed EOF, and neutral materials [28, 38, 41-45], suppressing the EOF considerably. 
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Cationic coating agents are also used for the preparation of bi- or multiple-layer coated 
capillaries [39, 46-48]. 
The aim of this contribution is to present an optimized and validated CE-MS method for the 
characterization of a large variety of proteins with a focus on small ones (i.e. MW < 33 kDa). 
In order to find the best conditions, several parameters, including the capillary coating, the 
BGE, the sheath liquid (SL), and the nebulizer gas pressure, were tested on different settings 
and compositions for the analysis of two model samples, i.e. a mixture of 8 standard proteins 
and EPO. The proteins show a wide range of pI values (4.4 – 11.3) and considerable differences 
in the molecular weights (12 – 33 kDa) and hydrophobicities. In addition, strong heterogeneity 
is covered by EPO, which exhibits numerous naturally occurring glycoforms with low 
mobilities (at acidic pH) and minor mobility differences, thus being challenging with respect to 
the separation and characterization by CE-MS. Apart from the optimization the method was 
validated to a large extent and a principal component analysis (PCA) was carried out in order 
to reveal the analysis parameters that might influence the EPO quantitation by changing the 
isoform distribution. 
 
2 Materials and methods 
 
 
2.1 Chemicals 
 
Methanol,  acetonitrile,  2-propanol  (all  ROTISOLV®  ≥ 99.95%,  LC-MS  grade),  NH3 
(ROTIPURAN®  30%,  p.a.,  ACS),  ammonium  acetate  (≥ 97%,  p.a.),  formic  acid 
(ROTIPURAN® ≥ 98%, p.a., ACS) and acetic acid (ROTIPURAN® 100%, p.a.) were purchased 
from Carl Roth GmbH & Co. KG (Karlsruhe, Germany) and used without further 
purification. NaOH p.a. and HCl (37%, p.a.) were purchased from Merck (Darmstadt, Germany). 
Ultrapure water of an electrical resistivity > 18 MΩcm was supplied by an ELGASTAT® UHQ 
PS (Elga Ltd., High Wycombe, England) water purification system and used for the 
preparation of all samples, rinsing solutions and background electrolytes. Lysozyme (from 
chicken egg white, purity not specified), β-lactoglobulin A (from bovine milk, ≥ 90%), 
myoglobin (from horse skeletal muscle, 95 – 100%), cytochrome c (from horse heart, ≥ 95%), 
trypsin inhibitor (from soybean, purity not specified), carbonic anhydrase (from human 
erythrocytes, purity not specified), and RNase A and B (from bovine pancreas, 
≥ 80%) were purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany). Stock 
solutions (3 µg/µL) were prepared by dissolving the solid material in water. The analyzed 
protein sample was a mixture of the single stock solutions, containing 63 µg/mL of lysozyme 
Manuscripts 30 
 
 
 
 
and β-lactoglobulin A, 125 µg/mL of ribonuclease (RNase) A and B, 188 µg/mL of myoglobin 
and cytochrome c, and 375 µg/mL of trypsin inhibitor and carbonic anhydrase. EPO beta 
(NeoRecormon®, Hoffmann-La Roche Ltd, Basel, Switzerland) was provided as an injection 
solution containing 10,000 international units of EPO. The syringe content (0.6 mL) was 
purified by ultra filtration through a cut off 10,000 membrane (Microcon® YM-10; Millipore 
Corporation, USA). Thereafter EPO was lyophilized by a vacuum centrifuge (SpeedVac, Thermo 
Scientific, Waltham, USA) and re-dissolved in 20 µL of water for 
measurement leading to a final concentration of ≈ 4 µg/µL (10,000 IU ≙ 83 µg EPO). 
 
 
2.2 Capillary electrophoresis 
 
CE experiments were performed on a HP 3DCE (Agilent Technologies, Waldbronn, Germany) 
using capillaries with an ID of 50 µm and a length of approximately 60 cm. Prior to usage 
new bare fused silica capillaries (Polymicro Technologies, AZ, USA) were conditioned by 
flushing (1000 mbar) with methanol (5 min), water (5 min), 1 mol/L NaOH (20 min), and 
water (5 min), followed by the coating procedure (3 mol/L HCl (5 min), water (5 min), 
coating solution (5 min) water (2 min) and BGE (2 min)), which was used for re-coating as 
well (every 5 to 10 runs). During the re-coating procedure the capillary was removed from the 
interface in order to avoid contamination of the ESI source and the MS. In this way no signals 
were observed in the mass spectra which could be assigned to the LN coating material. The 
coating solutions used were UltraTrol™ low normal (LN) and UltraTrol™ high reversed (HR) 
(both derivatized polyacrylamide, Target Discovery, Palo Alto, CA, USA) and 0.1 mg/mL N,N-
dimethylacrylamide-ethylpyrrolidine metacrylate copolymer in water (hereafter termed 
“copolymer” – lab prepared and kindly provided by A. Cifuentes, Spain [49]). Permanently 
coated capillaries (Guarant™ from Alcor BioSeparations, Palo Alto, CA, USA, and 
polyacrylamide (PAA) coated capillaries from WICOM, Heppenheim, Germany) were 
conditioned only with water. The trimethoxysilylpropyl(polyethylenimine)  coating (PEI, Gelest 
Inc., Morrisville, PA, USA) was prepared according to the US Patent 6,923,895 B2, 
applying one layer. 
EOF measurements (fused silica, LN and HR) were carried out using 1 mol/L HAc as BGE 
and caffeine as the neutral marker (CE-UV experiments). The EOF of the HR coated capillary 
was determined straightforwardly applying -30 kV (12 repetitive measurements). The EOF 
determination of the uncoated and the LN coated capillary was accomplished by performing 
two different experiments, i.e. the simultaneous application of +30 kV and 20 mbar as well as 
the simultaneous application of -30 kV and 20 mbar (6 repeats each). The difference of the 
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caffeine velocity determined for these two experiments was then used to calculate the EOF 
 
mobilities of the bare fused silica and the LN coated capillary. 
 
Various background electrolytes (BGE) were tested for the method optimization; for the 
validation experiments the BGE was composed of 0.5 mol/L acetic acid (HAc), pH 2.5, in the 
case of model proteins and 1 mol/L HAc, pH 2.4, was used for EPO validation experiments. 
Samples were injected hydrodynamically (50 or 100 mbar for 24 or 12 sec. respectively). 
Prior to injection the capillary was rinsed (1000 mbar) with BGE for 2 min. A constant 
voltage of 30 kV was applied during separations, resulting in typical currents of 11 – 15 µA. 
The experiments were carried out at room temperature (ca. 25 °C) without capillary cooling. 
When not in use, the coated capillaries were stored in water. PEI coated capillaries were 
stored in methanol. 
 
2.3 Electrospray mass spectrometry 
 
The CE-MS coupling was carried out via electrospray ionisation (ESI) using a commercial 
CE-ESI-MS interface (Agilent Technologies, Waldbronn, Germany) which has a triple-tube- 
design. A co-axial sheath liquid (SL) flow, typically composed of water and 2-propanol (1:1 
v/v) with an addition of 1% HAc, was provided during analyses. It was supplied by a syringe 
pump (Cole-Parmer®, Illinois, USA) equipped with a 5 mL syringe (5MDF-LL-GT, SGE 
Analytical Science Pty Ltd, Melbourne, Australia) at different flow rates (typically 3 µL/min). 
Prior to conditioning the outer polyimide coating at the capillary tip was burned off a few mm 
and the tip was cleaned with 2-propanol. 
A micrOTOFQ quadrupole time-of-flight mass spectrometer controlled by micrOTOFcontrol 
software (Bruker Daltonik GmbH, Bremen, Germany) was used. The ESI sprayer was grounded 
while the transfer capillary was kept at a constant voltage of -4500 V (positive ion polarity 
mode). The dry gas (nitrogen) flow rate was set to 4 L/min, the dry temperature to 
170 °C, and the nebulizer gas (nitrogen) pressure to 0.2 bar (varied for optimization). The ion 
optics were optimized to the highest possible intensity in the mass range of m/z 700 – 3000 by 
direct infusion of a 100-fold dilution of ES Tuning Mix (Agilent Technologies, Waldbronn, 
Germany) at 4 µL/min. The same solution and flow rate were used for the mass calibration of 
the QTOF MS which was performed at least once a day. 
Data processing was carried out by the Bruker Compass DataAnalysis software (Version 4.0 
 
SP 2, Bruker Daltonik GmbH, Bremen, Germany). The exact masses and charge distributions 
of  the  theoretical  proteins  used  for  ion  trace  extraction  were  calculated  using  the 
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„IsotopePattern‟   tool  of  the  Bruker  software.  Maximum  Entropy  was  used  for  the 
deconvolution of the mass spectra. 
 
2.4 Principal component analysis 
 
The principal component analysis was carried out using The Unscrambler® 7.51 (CAMO 
Software AS, Oslo, Norway). The data matrix was composed of 8 variables and 81 samples 
(experiments with different parameters or characteristics). The chosen variables were EPO 
isoforms showing differences in the glycosylation, which covered the EPO sialic acid (SA) 
distribution as well as the distribution of isoforms caused by the number of hexose N- 
acetylhexosamine (HexHexNAc) units: Hex22HexNAc19Fuc3SA10, Hex22HexNAc19Fuc3SA11, 
Hex21HexNAc18Fuc3SA12, the mono-acetylated isoform of Hex22HexNAc19Fuc3SA12, 
Hex23HexNAc20Fuc3SA12, Hex24HexNAc21Fuc3SA12, Hex22HexNAc19Fuc3SA13, and 
Hex22HexNAc19Fuc3SA14. The considered peak areas were scaled to the peak area of the most 
abundant isoform Hex22HexNAc19Fuc3SA12, which was not considered as a variable itself. 
 
3 Results and discussion 
 
 
3.1 Resolution in the context of EOF 
 
A CE-MS method was investigated with respect to its general applicability to intact proteins. 
Thereby, the capillary coating plays a crucial role, as both protein adsorption and ion suppression 
by non-volatile BGE additives have to be prevented. In comparison to bare fused silica 
capillaries different coatings were tested for the separation of the 8 model proteins and EPO 
using an acidic BGE: commercially available UltraTrol™ LN and HR, which are both 
derivatized polyacrylamides, underivatized PAA (as permanent coating), Guarant™, which is 
composed of thermally immobilized galactomannans guaran and locust bean gum (US Patent 
7,799,195), “copolymer”, and PEI. The application of bare fused silica capillaries in combination 
with an acidic BGE resulted in a strong tailing of most of the model proteins (except for 
myoglobin and cytochrome c) and severe quenching was observed due to the really poor 
separation (results not shown). By contrast, good separations were obtained using any of the 
three neutral coatings (LN (A), PAA (B) and Guarant™ (C)), shown in Figure 1. Even some 
isoforms and impurities of the model proteins could be separated; however, no further 
characterization was performed here. The separation of the 8 model proteins on a PEI coated 
capillary (Fig. 1D), which caused a high reversed EOF, was considerably faster, however, a 
considerable loss of resolution was observed. Both other cationic coatings, i.e. UltraTrol™ 
HR and copolymer, led to extended migration times and considerable peak 
µ
Δ0
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broadening regarding the analysis of the model proteins (not shown). In contrast, HR and 
copolymer were well suited for the separation of EPO. Figure 2 shows the base peak 
electropherograms (dotted lines) and the extracted ion electropherograms (solid lines) of 8 
EPO isoforms corresponding to EPO separations carried out on an LN (A) and an HR (B) 
coated capillary, respectively. The isoforms cover the SA distribution of EPO as well as the 
distribution caused by the number of HexHexNAc units (listed in Table 1). In agreement to 
the separations of the model proteins, the cationic coating led to a faster separation, but a 
lower resolution, though only slight differences were observed here. The separation quality 
described above can be confirmed by the electrophoretic mobilities of the proteins and the 
EOF, which was already discussed in detail for various analytes [20] and shown for EPO to 
some extent [28]. In the following, this discussion is extended to other proteins and a more 
detailed insight is given. The resolution in CE can be described by the following equation [20, 
50]: 
 
 
R  .18  µe 
U 
 
D   µEOF e 
 
(1) 
 
where ∆µe  is the mobility difference of two analytes, U the applied voltage, D the diffusion 
 
coefficient, µEOF the mobility of the EOF and µe 
 
the mean mobility of the two analytes. The 
 
resolution will be maximal when the sum of µEOF and µe is minimal (absolute value), with 
 
the disadvantage of an extended analysis time. Despite the EOF, the influence of the nebulizer, 
which causes liquid suction (acting in EOF direction) [51], should be taken into account for 
the calculations. 
 
3.2 Effect of the nebulizer 
 
In order to investigate the influence of the nebulizer, subsequent separations of the model 
proteins were carried out at a nebulizer pressure of 0.1, 0.2 and 0.4 bar, respectively, using an 
LN coated capillary. A considerable decrease of the migration times was determined when the 
nebulizer pressure was increased, resulting in a linear relationship for the apparent protein 
mobilities as a function of the nebulizer pressure (not shown). However, for the determination 
of the effective protein mobilities the extrapolation of the trend lines to a nebulizer pressure of 
zero is questionable as the minimum nebulizer gas pressure showing no suction is unknown. 
Hence, additional experiments were carried out in order to determine properly the effect of the 
nebulizer. Caffeine was analyzed using a bare fused silica capillary and 1 mol/L HAc as BGE 
applying 20 mbar and -30 kV (+30 kV) in combination with a second vial (UV detection) or 
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the ESI sprayer at Nebulizer pressure of 0.2 bar (MS detection), respectively (10 repetitive 
runs each). The difference of the velocity of caffeine was then used to determine the effect of 
the nebulizer in terms of an imaginary mobility, amounting to 7.5·10-9 ±0.1 m2V-1s-1. Within 
the measurement uncertainty, this result corresponds to the difference of the apparent protein 
mobilities at a nebulizer gas pressure of 0.1 and 0.2 bar, indicating that a Nebulizer pressure 
of 0.1 bar has (hardly) any suction effect. It should be noted that the effect of the nebulizer 
depends on the ESI-sprayer used (i.e. the position of the inner metal needle relative to the 
outer nebulizer tube) and has to be determined separately. 
Despite the observed nebulizer suction effect, all experiments were carried out at a nebulizer 
gas pressure of 0.2 bar, as the reduction of the pressure to 0.1 bar led to a considerable loss of 
analyte intensity. The effective electrophoretic mobilities of the model proteins and the selected 
EPO isoforms were then calculated by the subtraction of the observed nebulizer 
effect (7.5·10-9 m2V-1s-1) and the electroosmotic mobility of an LN coated capillary (1.3·10-9 
m2V-1s-1) from the respective apparent mobilities of the proteins and isoforms separated in an 
 
LN coated capillary (Tab.1). 
 
 
3.3 Capillary coating 
 
As mentioned above, the resolution in CE depends, among others, on the EOF mobility. The 
EOF mobilities corresponding to the coatings under consideration are given in Table 2, both 
experimental and manufacturer specified (if available). The EOF in the permanent PAA coated 
capillary was estimated to be similar to the EOF of the LN coating, as similar apparent protein 
mobilities were obtained. At pH 2.4 (1 mol/L HAc) the neutral coated capillaries (LN, 
PAA, Guarant™) showed an EOF of ca. 1·10-9  m2V-1s-1, thus having considerably less 
influence on the protein separation as compared to an apparent EOF of 7.5·10-9  m2V-1s-1 
caused by the nebulizer (see discussion above). By the way, neutral coated capillaries can thus 
also be used for anion separation applying reversed polarity. The PEI coated capillary showed 
an EOF mobility that was about three times higher than the mobilities of the model proteins 
(absolute value), leading to a considerably worse resolution during separation (as can be seen 
in Figure 1D). The EOF mobilities of the HR and copolymer coated capillaries are -2.6·10-8 
m2V-1s-1 (pH 2.4) and -1.5·10-8 m2V-1s-1 (pH 3) [49], respectively. In combination with the 
nebulizer suction effect, the mobilities of the EOF and the model proteins would be nearly 
equal, causing the separation to be very slow (not shown). However, both cationic coatings 
are well suited for the separation of the EPO isoforms, which show considerably lower 
mobilities (Table 1). In summary, the coating, which is used to prevent protein adsorption to 
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the capillary wall, can be used to optimize the separation: Slow migrating proteins (acidic pI) 
are separated best on a neutrally coated capillary. By this means, proteins and protein isoforms 
(here EPO glycoforms) with small mobility differences down to 0.02·10-8 m2V-1s-1 can be 
separated. A reversed EOF gives best separations when being slightly stronger than the 
mobilities of the proteins (absolute value, e.g. < -1.5·10-8 m2V-1s-1 to give a better separation 
of EPO isoforms than the neutral coating). 
Despite the good separation efficiency of neutral coated capillaries, it should be noted that 
reversed CE systems (induced by cationic capillary coatings) show a higher coating stability 
[38] and a higher stability regarding current breakages due to the presence of a considerable 
EOF. Furthermore, the suitability of neutral coatings for the analysis of intact proteins depends 
on the protein characteristics and the composition of the formulation when analyzing 
pharmaceuticals. Certain proteins, like fetuin (as also observed by Huhn et al. [20]), and 
certain formulation additives (observed for single EPO preparations), that are present in the 
sample even after purification, may adsorb to the neutral capillary surface and in this way 
cause a reversed EOF. As a consequence, the capillary is useless for further experiments. 
Nevertheless, UltraTrol™ LN, which gave good separation and relatively low analysis times, 
turned out to be appropriate for many proteins. In addition, the preparation of the coating was 
cheap and simple. Thus, it was chosen for the optimization of the different CE-MS parameters 
for protein analysis using the mixture of 8 model proteins and EPO. 
A preliminary coating stability study revealed a continuous increase of the migration times of 
the model proteins separated on new LN coated capillaries (10 consecutive runs). In order to 
improve the coating stability, the coating procedure had to be adapted. A simple 5 min rinse 
with 3 mol/L HCl prior to the coating solution [52] resulted in stable protein migration times 
over several consecutive runs (not shown here). In this way, recoating with respect to the 
analysis of the model proteins and EPO was required every 10 runs only. 
 
3.4 Background electrolyte 
 
Besides the capillary coating, the composition of the BGE showed the strongest influence on 
the separation of the model proteins. In comparison to HAc based BGEs (pH < 2.9), a BGE 
composed of 0.2 mol/L formic acid (pH 2.2) was observed to result in slightly higher protein 
intensities, but a considerably worse resolution (co-migration of two protein couples). The 
performance difference is attributed to the different anion of the BGE changing the solvation 
properties. The pH value was not considered as a reason here, as it is similar to the pH value 
of 2 mol/L HAc, which in comparison led to higher resolutions of the model proteins. Due to 
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this poor performance formic acid based BGEs were not further investigated with respect to 
the analysis of intact proteins. Ammonia containing BGEs (5 – 15 mmol/L) led to worse 
separations as well and in addition, ion suppression was observed for several proteins. 
Subsequently, the HAc based BGE was optimized for protein separations by variation of the 
concentration. A concentration of 0.1 mol/L (pH 2.9) or lower led to a change in the migration 
order of the model proteins due to lower acidity. The increase of the HAc concentration from 
0.5 mol/L (pH 2.5), which showed the best resolution, to 2 mol/L (pH 2.2) led to a slightly 
increase of the migration times and a decrease in the resolution. It should be noted here that a 
considerable increase of the HAc concentration in the BGE (c >> 1 mol/L) leads to severe 
changes of the properties of the BGE, with HAc being the solvent rather than a supporting 
additive. Separations of EPO using 0.5, 1, and 2 mol/L HAc as BGE, respectively, revealed 
that the concentration of 0.5 mol/L was not suitable for EPO analyses. Due to insufficient 
acidity,  low  abundant  isoforms  were  disproportionately  disadvantaged  regarding  the 
ionization. In addition, high abundant isoforms showed a considerably lower resolution, leading 
to severe signal quenching. By contrast 1 and 2 mol/L HAc gave similar and good 
separations for the various isoforms and no ion suppression was observed. 
 
3.5 Sheath liquid 
 
The investigation of the SL was carried out for the model proteins regarding the composition 
and the flow rate. In CE-MS analyses the SL typically consists of a mixture of water and an 
organic solvent. The addition of a small amount of acid may enhance the ionization of the 
analytes. A similar acid as present in the BGE should be used in order to avoid moving ionic 
boundaries [53], which may restrict the separation. 2-Propanol, acetonitrile and methanol in 
combination with different ratios of water were tested for the separation of the model proteins. 
Methanol showed a similar performance as 2-propanol regarding the separation efficiency and 
electrospray stability, but led to about 3 times lower protein intensities (comparison was 
carried out with equal water/organic solvent ratios). A strong electrospray instability was 
observed applying acetonitrile in the SL. This effect is probably due to the aprotic property of 
ACN [54, 55]. A test of different 2-propanol/water ratios revealed optimal protein analysis 
conditions at a ratio of 1:1 (v/v). An addition of HAc (similar acid as used in the BGE) to the 
SL was found to be crucial for spray stability and best results were achieved for a HAc 
amount of 1 – 3%. The optimal SL flow rate was in the range of 2 – 4 µL/min. An increase of 
the flow rate (up to 7 µL/min) led to a constant decrease in peak intensities, slightly higher 
migration times and peak shape worsening, indicating quenching or dilution effects. Lower 
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flow rates than 2 µL/min resulted in considerably worse overall performance regarding the 
resolution, intensity and protein peak shapes due to insufficient analyte ionization. 
 
3.6 Overall optimization 
 
Apart from the qualitative evaluation of the parameters described above, two analysis 
characteristics, i.e. the resolution and the intensity in terms of the S/N, were evaluated in 
detail for the model proteins based on the whole optimization data set of 47 different 
experiments and the corresponding repeats. The resolution of all neighbouring peak couples in 
each measurement was calculated and the smallest as well as the highest S/N of the eight 
peaks in each experiment were determined. Plotting the number of peak couples showing a 
resolution of greater than 1.5 against the lowest S/N revealed the optimal parameters for the 
analysis of this set of intact proteins by CE-MS, i.e. LN coating, a BGE composed of 0.5 
mol/L HAc, a SL consisting of 2-propanol/water 1:1 (v/v) + 1% HAc, a SL flow rate of 3 
µL/min and a nebulizer pressure of 0.2 bar. Using these parameters at least 4 to 6 peak 
couples showed a resolution of 1.5 or higher (5 – 7 proteins were baseline separated) and the 
highest intensities (without exception) were achieved. Still, the interactions between the 
parameters, as a conventional design of experiment would have taken into account, were not 
investigated and slightly different parameters might be preferable for the separation of individual 
proteins (compare EPO). 
 
3.7 Validation 
 
The optimized method was validated to a large extent, determining the intra- and inter-day 
precisions of the migration times and the peak areas, the LODs and LOQs of the model 
proteins (Tab. 3) and EPO (Table 4), as well as the linearity and the sensitivity. In addition, 
the robustness of the method is shown somehow. Still, the validation shown here is incomplete 
with respect to e.g. trueness and test for matrix effects, which are irrelevant for the analysis of 
standard proteins (reference material) but need to be determined with respect to real sample 
applications (pharmaceutical formulations, body fluids, etc.) [56]. 
Regarding the migration times (MTs) similar results were obtained for the intra- and inter-day 
precisions, being in the range of 0.3 – 2.4% in the case of model proteins (Tab. 3) and 1.4 – 
1.9% in the case of the 8 selected EPO isoforms (Tab. 4). These results are in good agreement 
to other CE-MS analyses [30, 33, 35, 46] and similar to the precisions found for model 
proteins by LC-MS [15]. The observed MT precisions represent the improvement of the system 
by the introduction of an HCl rinsing step during the coating (and re-coating) procedure 
(described above). 
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Regarding the peak areas, RSDs of 9.0 – 23.8% (on average 12.4%) were found for the model 
proteins and 6.7 – 18.0% (on average 11.4%) for EPO isoforms, respectively, being similar 
for intra- and inter-day experiments as well. These results are in the range of collected 
quantitation data on small molecule analyses [57] indicating similar precisions for the analysis 
of intact proteins. With respect to the model proteins the influence of the number of charge 
states being considered for the ion trace extraction (3 vs. all detected) on the peak area 
precisions was investigated. For the peak area RSDs of most of the proteins it was immaterial 
whether 3 (most abundant) or all detectable charge states were used for ion trace extraction. 
Only slight  deviations  in either direction were found (on average ± 5.7%). However, regarding 
the peak area RSDs of β-lactoglobulin A (intra-day and inter-day) an improvement of ca. 35% 
was achieved when all detectable charge states were integrated in the extracted ion 
electropherogram. The discrepancy is due to strong ESI dependent fluctuations of the 
abundances of the individual charge states of β-lactoglobulin A, which were not observed for 
the  other  proteins.  The  RSDs  displayed  in  Tab.  3  are  based  on  extracted  ion 
electropherograms using all detectable charge states, whereas the RSDs for the EPO isoforms 
(Tab. 4) are based on a single (most abundant) charge state. 
LODs were calculated based on the ion traces created by the m/z extraction of the 3 most 
abundant charge states in the case of the model proteins, whereas the ion traces of the EPO 
isoforms were created by the m/z extraction of a single (most abundant) charge state. The 
LODs were based on S/N=3. Regarding the model proteins, LODs of 0.06 – 0.81 µg/mL were 
observed (Tab. 3), with the results for lysozyme and RNase B being better than those obtained 
by Haselberg et al. using a sheath-less ESI-MS interface [33], although an exact comparison 
cannot be performed (different MS and CE instruments, capillary dimensions, injection volume, 
etc.). For EPO LODs of 0.08 – 0.24 µg/µL were found. These LODs represent the LOD of 
the overall EPO concentration calculated based on a single isoform. Due to the presence of 
nearly 100 glycoforms in one EPO sample, the real LOD of each single isoform would 
amount to only a small fraction of the LOD calculated for the whole glycoprotein. The 
corresponding LOQs (S/N = 10) were in the range of 0.20 – 2.5 µg/mL and 0.28 – 0.79 µg/µL 
for the model proteins and EPO, respectively (Tab. 3 and 4). The injection volume of 36 nL 
corresponded to ca. 3% of the capillary volume, taking the applicability of this method to real 
samples (high salt content) into account. However, the injection volume can be increased up 
to 10% of the capillary volume, when low conductivity samples are analyzed. Thus, lower 
LODs (and LOQs) can be determined using field amplified sample stacking. Lower LODs can 
also be obtained by the extraction of the m/z values of more charge states determined. 
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Furthermore, the LOD strongly depends on the instrument‟ s condition, e.g. detector. Linearity 
was shown for model protein concentrations of 0.20 – 375 µg/mL, covering at least two 
orders of magnitude (mean R2  = 0.95, Tab. 3). Certainly, higher concentrations can be analyzed 
likewise, which however are not required in most cases. With respect to EPO, a smaller 
linear range was observed (0.08 – 4 µg/µL, mean R2  = 0.98, Tab. 4) as no higher 
concentration of EPO was available. 
The robustness, as part of the validation, was not tested for all parameters explicitly. However, 
results from the optimization of the method indicate that the method is robust with respect to 
the SL composition and flow rate, the BGE composition (compare discussion below), the 
nebulizer pressure, the injection volume, the separation voltage, the temperature etc. Minor 
modifications of these parameters might slightly influence the peak height and precision, 
however the method remains applicable. 
 
3.8 PCA as a supporting strategy in method validation 
 
A PCA was carried out on various EPO measurements in order to clarify whether certain 
experimental characteristics show an influence on the observed EPO isoform distribution and 
ratios  which in turn would affect the detection of low abundant glycoforms and the quantitation 
of EPO. As described in section 2.4, the PCA was based on 8 variables observed in 81 
experiments which differed in the HAc concentration (BGE), the EOF direction, the 
operator, the intensity, the resolution, and the mass spectrometer itself (Tab. 5). In each case 
the data set was divided into two or three groups (e.g. reversed vs. normal EOF, low vs. high 
intensity, etc.) in order to find clustering by PCA. As mentioned above, 0.5 mol/L HAc as 
BGE showed considerable influence on the different glycoforms, having a bias on the ionization 
and detection of isoforms with larger glycan moieties. This relation caused significant clustering  
in the PCA (not shown). Apart from differences in the overall distribution of the data points, all 
other experimental characteristics monitored didn‟ t show any significance applying the 
PCA. A representative example for the performed PCAs is given in the score plot in Figure 3. 
The dataset was divided into two groups representing EPO measurements carried out in the 
normal and the reversed CE mode (neutral and cationic coated capillaries), respectively. The 
distribution of the data points is random, ruling out possible clustering (i.e. influence). In 
summary, based on the PCA, the optimized and validated method was found to be highly 
reliable, as most parameters, including the use of other coatings, different operators, different 
instruments, and overall EPO concentration, do not affect the relative quantitation of EPO 
based on different single isoforms. In contrast, the 
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pH of the BGE is somehow critical, though the method is still robust regarding typical random 
errors in BGE preparation as the concentration of the weak acid HAc causes only small 
changes in the pH. 
 
4 Concluding remarks 
 
Different CE-MS method parameters were investigated systematically with the objective of a 
reliable standard method for the analysis of a large variety of intact proteins. Best results 
regarding resolution and intensity were found for neutral coatings, a BGE composed of 0.5 
mol/L  and 1 mol/L HAc for model protein and EPO analyses, respectively, an SL composition 
of 2-propanol/water (1:1 v/v) with an addition of 1% HAc, an SL flow rate of 2 – 
4 µL/min, and a nebulizer gas pressure of 0.2 bar. Most of the optimized parameters, like the 
SL composition and flow rate and the nebulizer pressure, were found to be widely applicable 
to various intact proteins showing different pI values and molecular weights, including model 
proteins, EPO, AGP, fetuin, and growth hormone. By contrast, the BGE and in particular the 
coating may have to be adapted when analyzing certain complex proteins or pharmaceutical 
preparations. Generally, a neutral coating leads to better separations of proteins showing low 
mobilities (acidic pKa, e.g. EPO) as no coating with a small reversed EOF is available 
(commercially). Even for most proteins analyzed here, the neutral coating lead to better 
separations. 
The optimized method was validated to a large extent, being one of the first validated methods 
for intact protein analysis by CE-MS. The validation results, particularly the precisions of the 
migration times, were in the range typically observed in CE-MS and LC-MS. Therewith it is 
possible to quantify intact proteins with an accuracy similar to small molecules (mean 
precision 12.3%). Therefore, extracted ion electropherograms based on major charge states 
are sufficient for most proteins. However, in some cases all charge states should be taken 
into account. Still, the validation has to be completed regarding real sample matrix 
applications, as e.g. trueness or matrix effects were not investigated here [56]. 
The convincing results on the model proteins and EPO, covering a wide range of properties 
and pI values, may provide an idea of a standard method for the analysis of intact proteins by 
CE-MS,  contributing  to  the  improved  characterization  of  intact  proteins  in  the 
biopharmaceutical area. Limitations of this method may be revealed regarding the analysis of 
certain proteins showing numerous challenging properties, e.g. self aggregation, limited 
solubility and pH stability, strong adsorption to the acrylamide-based coating, and other. It 
also has to be kept in mind that acidic systems exhibit drawbacks with respect to applications 
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where native protein folding has to be maintained, as conformational changes are rather likely 
at extreme pH values. Nevertheless, based on the mass of the proteins, which is not affected 
by conformational changes, the characterization of the proteins with respect to e.g. post 
translational modifications is possible. Hence, the provided method represents a good starting 
point for any intact protein analysis by CE-MS. 
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Figure captions 
 
Figure 1: Separation of model proteins using different capillary coatings. A. LN, B. permanent 
PAA, C. Guarant™, C. PEI coating. The ion traces were created by extraction of the m/z 
values of the 3 most abundant charge states of each protein: m/z 1431.4, 1590.4, 
1789.1 for lysozyme (1), m/z 1148.7, 1225.2, 1312.6 for β-lactoglobulin A (2), m/z 883.7, 
 
951.7, 1030.8 for cytochrome c (3), m/z 1244.8, 1369.2, 1521.1 for RNase A (4), m/z 1060.4, 
 
1131.1, 1211.8 for myoglobin (5), m/z 1242.6, 1355.5, 1490.9 for RNase B (6), m/z 1817.1, 
 
1998.8, 2220.8 for trypsin inhibitor (7), and m/z 1200.1, 1252.3, 1309.3 for carbonic anhydrase 
(8). Further conditions see text. 
 
 
Figure 2: Separation of EPO on a LN (A) and a HR (B) coated capillary. Further conditions 
see text. The dotted lines represent the base peak electropherograms, while the solid lines 
show the ion traces of the EPO glycoforms  Hex22HexNAc19Fuc3SA10 (1), 
Hex22HexNAc19Fuc3SA11 (2), Hex21HexNAc18Fuc3SA12 (3), Hex22HexNAc19Fuc3SA12 (4), 
Hex23HexNAc20Fuc3SA12  (5), Hex24HexNAc21Fuc3SA12  (6), Hex22HexNAc19Fuc3SA13  (7) and 
Hex22HexNAc19Fuc3SA14 (8). Ion traces were created by extraction of the m/z value of 
the most abundant charge state ([M+15H]15+) of each isoform (1935.3, 1954.7, 1949.8, 
 
1974.1, 1998.5, 2022.9, 1993.6, 2013.0) 
 
 
 
Figure 3: Score plot of a PCA carried out on various EPO measurements. The data set was 
divided into measurements carried out using a neutral coated capillary (low normal EOF, 
represented by the solid triangles) and measurements carried out on different cationic coated 
capillaries (reversed EOF, represented by the circles). 
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Table 1: Mean electrophoretic mobilities of model proteins and EPO isoforms separated on an LN coated capillary (n=10 for 
model proteins and n=8 for EPO isoforms). 
 
Protein/ 
EPO isoform glycosylation 
µa a) 
[10-8 m2V-1s-1] 
µe b) 
[10-8 m2V-1s-1] 
 
Lysozyme 4.39 ±0.01 3.52 ±0.05
β-Lactoglobulin A 4.14 ±0.02 3.27 ±0.05
Cytochrome c 4.07 ±0.02 3.20 ±0.05
RNase A 3.93 ±0.02 3.06 ±0.05
Myoglobin 3.79 ±0.02 2.92 ±0.05
RNase B 3.65 ±0.04 2.78 ±0.06
Trypsin inhibitor 3.54 ±0.04 2.67 ±0.06
Carbonic anhydrase 3.28 ±0.02 2.41 ±0.05
Hex22HexNAc19Fuc3SA10 
Hex22HexNAc19Fuc3SA11 
Hex21HexNAc18Fuc3SA12 
Hex22HexNAc19Fuc3SA12 
Hex23HexNAc20Fuc3SA12 
Hex24HexNAc21Fuc3SA12 
Hex22HexNAc19Fuc3SA13 
Hex22HexNAc19Fuc3SA14 
2.17 ±0.04 
2.12 ±0.03 
2.06 ±0.03 
2.03 ±0.03 
2.01 ±0.03 
1.99 ±0.03 
1.91 ±0.03 
1.84 ±0.03 
1.30 ±0.06 
1.25 ±0.06 
1.18 ±0.06 
1.16 ±0.05 
1.14 ±0.05 
1.12 ±0.05 
1.04 ±0.05 
0.96 ±0.05 
a)  apparent mobilities at a nebulizer gas pressure of 0.2 bar 
b) effective mobilities, determined by the subtraction of the electroosmotic mobility of an LN coated capillary and the 
observed nebulizer effect. BGE: 0.5 mol/L HAc (pH=2.5) for model proteins and 1 mol/L HAc (pH=2.4) for EPO isoforms. 
The uncertainties display combined errors. 
 
 
 
 
 
Table 2: Mean observed (pH = 2.4) and manufacturer specified (pH = 3) EOF mobilities of different coatings. Specified 
uncertainties are based on 6 (LN, fused silica) and 12 (HR) repetitive runs. 
 
 
Coating 
 
µEOF 
[10-8 m2V-1s-1] 
µEOF (theor.) 
[10-8 m2V-1s-1] 
LN  0.13 ±0.04 < 0.1c) 
PAA ca. 0.1a)  - 
Guarant™   -   0.03 
“Copolymer” - ca. -1.5c, d) 
PEI -9.2b) - 
HR -2.63 ±0.08 -3.0c)
fused silica 0.11 ±0.02 ca. 0.05c, e)
a) estimated according to the apparent electrophoretic mobilities of the model proteins 
b) only one measurement available, as no appropriate separation was observed 
c)  estimated from a graphic 
d)  according to González et al. [49] 
e) according to Lukacs and Jorgenson [58] 
Isoform glycosylation    [µg/µL] [µg/µL] [µg/µL] [cts·µL/µg] 
Hex22HexNAc19Fuc3SA10 1.8 20.9a) 1.9 18.0 0.24 0.79 0.79 – 4.0 0.93 2.5·104 
Hex22HexNAc19Fuc3SA11 1.5 9.7 1.5 10.6 0.12 0.39 0.39 – 4.0 0.99 4.9·104 
Hex21HexNAc18Fuc3SA12 1.6 8.0 1.8 7.7 0.08 0.28 0.28 – 4.0 0.99 6.7·104 
Hex22HexNAc19Fuc3SA12 1.5 11.4 1.5 11.0 0.09 0.30 0.30 – 4.0 0.99 7.9·104 
Hex23HexNAc20Fuc3SA12 1.6 7.0 1.9 12.8 0.09 0.30 0.30 – 4.0 0.98 6.3·104 
Hex24HexNAc21Fuc3SA12 1.5 8.3 1.7 10.7 0.10 0.34 0.34 – 4.0 0.99 4.6·104 
Hex22HexNAc19Fuc3SA13 1.4 15.6 1.6 16.2 0.11 0.37 0.37 – 4.0 0.98 5.3·104 
Hex22HexNAc19Fuc3SA14 1.4 6.7 1.7 8.5 0.15 0.50 0.50 – 4.0 0.99 4.2·104 
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Table 3: Results of the validation experiments on the model proteins 
 
%RSD intra-day 
(n=10) 
 
%RSD inter-day 
(n=18, 2 days) 
 
 
 
LOD 
 
 
 
LOQ 
 
 
 
linear range 
 
 
 
sensitivity 
Protein MT Area MT Area  
[µg/mL] 
 
[µg/mL] 
 
[µg/mL] 
R2 
[cts·µL/µg] 
 
Lysozyme 
 
0.3 
 
11.7 
 
1.3 23.8a) 
 
0.06 
 
0.20 
 
0.20 –  62.5 
 
0.93 24.0·106 
β-Lactoglobulin A 0.4 9.0 1.5 9.5 0.22 1.15 1.15 –  62.5 0.91 11.7·106 
Cytochrome c 0.6 10.6 1.5 10.2 0.81 2.50 2.50 – 187.5 0.99 5.5·106 
RNase A 0.4 12.3 1.6 13.8 0.27 0.85 0.85 – 125.0 0.96 9.8·106 
Myoglobin 0.5 13.5 1.5 12.3 0.72 2.60 2.60 – 187.5 0.98 7.7·106 
RNase B 1.0 13.6 2.2 16.3 0.35 0.69 0.69 – 125.0 0.96 11.6·106 
Trypsin inhibitor 1.2 12.6 2.2 15.6a) 0.75 1.62 1.62 – 375.0 0.92 2.6·106 
Carbonic anhydrase 0.7 10.9 2.4 14.7 -b) -b) 37.50 – 375.0b) 0.95 4.8·106 
 
a)  n=15 (due to degradation of lysozyme and trypsin inhibitor in a sample used on two following days) 
b) lowest measurable concentration: 37.5 µg/mL (S/N = 70), no signal was observed below (potential adsorption to vial or 
capillary) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Intra- and inter-day precisions and LODs of EPO isoforms 
 
%RSD intra-day 
(n=8) 
 
%RSD inter-day 
(n=11, 2 days) 
 
 
 
LODb) 
 
 
 
LOQb) 
 
 
 
linear range 
 
 
 
sensitivity 
MT Area MT Area R2 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) high peak area variation due to low abundance of the isoform 
b) total EPO concentration 
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Table 5: Parameters tested by PCA for their influence on the relative quantitation of EPO isoforms 
 
tested parameters 
 
HAc conc. in the BGE 
levels 
 
0.5, 1, 2 mol/L 
grouping 
yesc) 
intensity 
EOF directiona) 
< 104 and > 104 cps 
anodic and cathodic 
no 
no 
operator 
resolution 
number: 3 
poor and highb) 
no 
no 
instrument number: 2 no
a)  various coatings 
b) quality feature: mean relative height of the point of intersection of two peaks each (good resolution: rel. height < 80%, poor 
resolution: rel. height ≥ 80%) 
c)  results obtained for 0.5 mol/L HAc differed considerably from those obtained for 1 and 2 mol/L HAc 
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Figure 3 
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High resolution TOF MS coupled to CE for the analysis of isotopically 
resolved intact proteins 
 
A. Taichrib, M. Pelzing, C. Pellegrino, M. Rossi, C. Neusu¨ß 
 
Journal of Proteomics (2011), 74, 958-966. 
 
 
 
 
 
 
 
 
 
The manuscript describes the application of high resolution TOF MS for the differen- 
tiation of protein modifications leading to small changes in the protein mass and charge. 
By this means, several deamidated forms of rhGH were determined. The resolution of the 
EPO isotopes revealed overlapping isoforms. Confirmation of the overlap was carried out 
by statistical evaluation of the isotope pattern determined. 
 
 
 
 
 
 
 
 
 
Candidate’s work: 
Performance of the rhEPO analyses by CE-TOF MS, data processing and interpretation 
for both rhGH and rhEPO, partial evaluation of the overlapping isotopic distributions of 
rhEPO isoforms, manuscript preparation. 
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A  R T  I  C L E  I N F O A B  S T  R A  C  T  
 
Available online 25 January 2011  Intact protein analysis by mass spectrometry is of great interest for the characterisation of 
biotechnological products. Exact  mass measurement  in combination  with isotopic 
Keywords: 
CE/MS 
Erythropoietin 
Glycoprotein 
Growth hormone 
Isotopic resolution 
Time-of-flight mass spectrometry 
resolution  allows the detection  of  modifications  leading  to small mass changes like 
deamidation or reduction of disulfide bonds directly on the level of the intact protein. Here, a 
concept is presented based on time-of-flight mass spectrometry. A bench top TOF MS and a 
high resolution TOF MS were used to resolve the isotopes of intact recombinant human 
growth hormone and intact human erythropoietin, respectively. Thus, these 22 and around 
30 kDa large proteins can be characterised sensitively in great detail and along with capillary 
electrophoretic separation unambiguous identification of minor protein modifications like 
deamidation is possible. 
© 2011 Elsevier B.V. All rights reserved. 
 
 
 
1. Introduction 
 
Nowadays biopharmaceuticals play an increasingly important 
role in drug development. Thus, protein analysis is of high 
relevance in fields of impurity profiling and characterisation 
during quality control, stability monitoring or conformation 
studies. Within these scopes there are several approaches 
where mass spectrometric detection is  used  [1–7].  Mass 
spectrometers  exhibit high sensitivity and selectivity and 
provide the possibility for identification and characterisation 
of  proteins by exact mass measurement and/or fragmenta- 
tion. Protein identification by MS is mostly based on peptide 
analysis after enzymatic digestion. Today, due to less effort on 
sample preparation, there is a growing interest for the direct 
exact mass measurement of the intact proteins followed by 
fragmentation (top down approach) [8–13]. The characterisa- 
tion of  proteins implies,  among others, the analysis of 
posttranslational modifications (phosphorylation, glycosyla- 
tion, etc.)  or other protein modifications  (deamidation, 
oxidation, or cleavage).  These modifications, particularly 
deamidation, change the protein in a biologically important 
way  and may serve as molecular  clocks for e.g.  protein 
 
 
 
Abbreviations: BGE, background electrolyte; BPE, Base peak electropherogram; EIE, Extracted ion electropherogram; EPO, erythropoietin; 
Fuc, fucose; FWHM, full width at half maximum; Hex, hexose; HexNAc, N-acetylhexose; rhGH, recombinant human growth hormone; SA, 
sialic acid; SL, sheath liquid. 
*  Corresponding author at: Aalen University, Chemistry Department, Beethovenstr. 1, 73430 Aalen/Germany. Tel.: +49 7361 576 2399; fax: +49 
7361  576 442399. 
E-mail address: Christian.Neusuess@htw-aalen.de (C. Neusüß). 
 
1874-3919/$ – see front matter © 2011 Elsevier B.V. All rights reserved. 
doi:10.1016/j.jprot.2011.01.006 
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turnover or ageing [14–16]. Deamidation occurs frequently to 
biopharmaceuticals because it is a spontaneous, non-enzy- 
matic process under mild  conditions  and arises during 
approach and especially for the discrimination of 
overlapping protein modifications. 
production, purification or storage. The rates of deamidation    
depend on the primary sequence and 3D structure of the 
protein and on solution properties, like  pH, temperature or 
ionic strength [14–16]. The molecular mass of the deamidated 
protein differs by only 1 Da. Thus, for the detection of minor 
protein modifications like deamidation a mass spectrometer 
which provides exact mass measurement is needed. Due to a 
wide mass range, high mass accuracy, and relatively low costs 
as compared to other high resolving instruments, time-of- 
flight mass spectrometers  turned  out  to be  particularly 
suitable for intact protein analysis. 
Prior to mass spectrometric detection a separation of the 
proteins is carried out either simply to remove the matrix, which is 
critical to obtain sensitive and clear mass spectra, or to 
separate complex mixtures of different naturally occurring 
protein isoforms. Both liquid chromatography (HPLC) [1,17–19] 
and capillary electrophoresis (CE) [20–23] are suitable techniques 
for the separation of intact proteins. Generally, the advantages of 
CE over HPLC are the low sample and solvent consumption and 
especially the high separation efficiency. Hence, e.g. protein 
isoforms can be separated at least partially by CE. Another 
advantage of CE is that no stationary phase or organic modifiers 
in the mobile phase are needed; both might cause conforma- 
tional changes or even degradation of the proteins. 
Nevertheless, the separation of intact proteins by CE is 
challenging because protein characteristics may lead to their 
adsorption to the (negatively  charged)  capillary wall and 
hence to EOF alteration, irreproducible migration times, peak 
broadening and restricted separation efficiency [24]. To avoid 
protein adsorption to the capillary wall either background 
electrolytes (BGE) of high pH values [25] or capillary coatings 
[21,22,26,27] can be applied. Highly alkaline BGEs ensure the 
electrostatic repulsion of analytes from the capillary wall. 
However, they are only applicable to few small proteins; due to 
hydrophobic interactions, proteins of higher molecular weight 
often adsorb to the capillary wall anyway. In addition, a high 
pH value may lead to conformational changes or degradation 
of the protein. Furthermore a high pH value interferes with the 
preferred positive electrospray  ionisation,  where a high 
abundance of protons is required. On the contrary, by using 
capillary coatings, which often consist of soluble polymers, 
both hydrophobic interactions and high pH values are avoided 
during protein analysis. Dependent  on the charge of  the 
polymer used, these coatings produce a normal, a reversed or 
a  suppressed EOF. For the analysis of  proteins with low 
electrophoretic  mobility neutral coatings may give  better 
separation efficiencies [28,29]. 
In this contribution two proteins of high clinical relevance 
but also known due to misuse as doping agents were analysed 
by CE/TOF MS in order to show the importance of high mass 
accuracy and high resolving power for the detection of protein 
modifications changing the molecular weight of the protein by 
a few daltons. Generally, MS allows the fast and straightfor- 
ward analysis of intact proteins and in combination with high 
mass accuracy and high resolution even isotopically resolved 
spectra are obtained. Isotopic resolution is helpful for  the 
unambiguous identification of  proteins  in the top down 
2.  Materials and methods 
 
2.1.  Chemicals and standards 
 
Methanol, 2-propanol (ROTISOLV® ≥ 99.95%,  LC–MS grade), NH3     
(ROTIPURAN®  30%,  p.a., ACS),  ammonium  hydrogen 
carbonate (> 99%, p.a.), formic acid (ROTIPURAN® ≥ 98%, p.a., 
ACS) and acetic acid (ROTIPURAN® 100%, p.a.) were purchased 
from Carl Roth GmbH and Co. KG (Karlsruhe, Germany) and 
used without further purification. NaOH p.a. was 
purchased from Merck (Darmstadt, Germany). Ultrapure 
water of an 
electrical resistivity > 18 MΩcm was supplied by an ELGA- 
STAT® UHQ PS (Elga Ltd.,  High Wycombe, England) water 
purification system  and used  for  the preparation of  all 
samples, rinsing solutions and background electrolytes. 
rhGH (Merck Serono) was strongly stressed by storage at 
40 °C for 24 months. All analyses were performed using an 
initial (pre-stress) rhGH concentration of 1 μg/μL. 
EPO BRP (batch 3) was purchased from European Pharma- 
copoeia (Strasbourg, France). Each vial contained 32,280 IU 
(specified by manufacturer) which corresponds to 271 μg of EPO 
(calculated according to the value of EPO alpha (10,000 IU ≙ 84 μg 
EPO)). After dissolving in 1 mL of water the vial content was 
aliquoted and purified by ultra filtration through a cut off 10,000 
membrane (Microcon® YM-10; Millipore Corporation, USA). 
Thereafter  EPO was lyophilized by  a vacuum  centrifuge 
(SpeedVac, Thermo Scientific, Waltham, USA) and re-dissolved in 
20 μL  of  water  for  measurement  resulting  in  a final 
concentration of ≈ 3 μg/μL. 
 
2.2.  Capillary electrophoresis 
 
CE experiments were performed on a HP 3DCE (Agilent Technolo- 
gies, Waldbronn, Germany) or a P/ACE™ MDQ (Beckman Coulter 
Inc.,  CA, USA). The  separation capillaries exhibited an inner 
diameter of 50 μm and a length of ca. 60 cm. Prior to usage new 
bare fused silica capillaries (Polymicro Technologies, AZ, USA) 
were flushed with methanol (5 min), water (5 min), 1 M NaOH 
(20 min), water (5 min) and BGE (5 min). For rhGH analysis 
capillaries were used without further treatment. EPO separation 
however was performed on a soluble linear polyacrylamide made 
of N-substituted acrylamide copolymer (UltraTrol™ LN, Target 
Discovery, Palo Alto, USA) coated capillary. The coating procedure 
included the following rinsing steps: water for 3 min, air for 2 min, 
coating material for 5 min, water for 3 min and BGE for 3 min at 
1000 mbar each. 
The background electrolyte (BGE) consisted of 1 M acetic 
acid for EPO separation and of 40 mM ammonium bicarbonate 
(pH 8.5) for rhGH analysis. 
Samples were injected hydrodynamically (50 or 100 mbar 
for 12 or 6 s, respectively). Prior to injection the capillary was 
rinsed with BGE for 2 min. The analyses of both EPO and rhGH 
were carried out in positive polarity mode with a constant 
separation voltage of + 30 kV. 
When not in use, uncoated capillaries were stored dry 
whereas coated capillaries were stored in water. 
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2.3.  Electrospray mass spectrometry 
 
The CE/MS coupling was carried out by a commercial CE–MS- 
interface (Agilent Technologies, Waldbronn, Germany). This 
interface has a  triple-tube-design, thus a co-axial  sheath 
liquid (SL) is provided during analyses. In all experiments the 
SL consisted of water and 2-propanol (1:1) with an addition of 
1% acetic acid when the BGE contained acetic acid and 0.2% 
formic acid when the BGE consisted of ammonium bicarbon- 
ate. The SL was supplied by a syringe pump (Cole-Parmer®, 
Illinois, USA) at a flow rate of 4 μL/min. Prior to analyses the 
outer capillary coating at the capillary tip was burned off a few 
mm and cleaned using 2-propanol. 
The mass spectrometers used were a micrOTOFQ and a 
maXis quadrupole time-of-flight mass spectrometer (Bruker 
Daltonik, Bremen,  Germany)  for  rhGH and EPO analyses 
respectively. These two mass spectrometers differ by the 
length of their flight path which is ca. 2 m for the micrOTOFQ 
and ca. 5 m for the maXis. In both CE/MS systems the CE- 
sprayer was grounded while the transfer capillary was kept at a 
voltage of − 4500 V (positive ion polarity mode). The nebulizer 
was set to 0.2 bar, the dry temperature to 170 °C and the dry gas 
flow  rate  to 4 L/min. When isotopic resolution was  not 
intended (EPO measurement by micrOTOFQ for comparison) 
ion optics were optimised to the highest possible intensity in 
the mass range m/z 600–3000 by keeping R constant at ≈ 10,000. 
For isotopic resolution (hGH measurement by micrOTOFQ and 
EPO measurement by maXis) ion optics were optimised to the 
highest possible R (≈ 30,000 in case of hGH and ≈ 40,000 in case 
of EPO). 
The TOF MS mass calibration was carried out by direct 
infusion of a 100 fold dilution of ES Tuning Mix (Agilent 
Technologies, Waldbronn, Germany) at 4 μL/min. 
 
2.4.  Data analysis software 
 
CE ChemStation (version B.04.02 [96], Agilent Technologies, 
Waldbronn, Germany) and 32 Karat 8.0 (Beckman Coulter Inc., 
USA) were used for CE instrument control. micrOTOF control 
(Bruker Daltonik, Bremen, Germany) was used for data acqui- 
sition and Bruker Compass DataAnalysis (version 4.0 SP 2 (Build 
266), Bruker Daltonik, Bremen, Germany) for data processing 
respectively. Maximum Entropy was used for the deconvolution of 
mass spectra. Calculation of average and monoisotopic protein 
masses was performed using the Uniprot database to retrieve 
the protein sequences and the mass calculation tool in 
DataAnalysis. Protein modifications have been taken into 
account; i.e. disulfide bridges have been considered for rhGH as 
given by the database. Mass changes due to glycosylation of 
EPO have been determined previously [28]. 
The separation of rhGH, which has a pI of ca. 5.1, was 
performed on a bare fused silica capillary in combination with 
an alkaline BGE. Hence, both the protein and the capillary wall 
were  negatively charged and no  electrostatic  interactions 
occurred. This method, which was described earlier by the 
European Pharmacopoeia [30], gave good separation efficiency 
for rhGH and its deamidated products (Fig. 1). Based on this 
approach Catai et al. recently described a CE/MS method using 
coated capillaries which improves separation efficiency and 
reproducibility [25]. Both methods served as a basis for  a 
relative simple approach used here, applying a fused silica 
capillary and a BGE based on ammonium bicarbonate (40 mM) 
at pH 8.5. This method results in sufficient separation of various 
degradation products of rhGH as shown in Fig. 1. The extracted 
ion electropherogram (EIE) of the most abundant isotopes of the 
four main charge states (13-, 14-, 15-, and 16-fold protonated 
ions of intact rhGH) in a ± 0.5 m/z window (average mass 
considered here) shows three peaks almost baseline separated. 
According to the accurate masses in the mass spectra these 
three peaks most likely arise from intact, singly and doubly 
deamidated rhGH respectively. The two modifications were 
already postulated by Catai et al. [25] but at that time the 
evidence failed because their mass spectrometer (ion trap) 
didn't provide exact mass measurement or high resolution. In 
order to prove this assumption the entire mass spectrometric 
capabilities were exploited. The TOF MS was operated in focus 
mode, thus a resolving power of nearly 30,000 at FWHM was 
achieved. Using these settings it was possible to resolve the 
isotopes of rhGH, which has an average mass of 22,124.81 Da. Fig. 
2 shows the corresponding detailed deconvoluted mass spectra 
of the three major electrophoretically separated peaks of 
 
   Fig. 1 – CE separation of stressed rhGH (initial concentration 
3.  Results and discussion 
 
High mass accuracy and isotopic resolution are needed for the 
unambiguous detection of minor protein modifications like 
deamidation or oxidation. In this contribution rhGH and EPO 
were used as model proteins to show the identification of 
these modifications by high resolution TOF MS on the intact 
protein level. 
1 mg/mL) using a fused silica capillary and 40 mM ammonim 
hydrogen carbonate (pH 8.5) as BGE. For further parameters 
see text. Blue trace: EIE of the most abundant isotopes of the 
four main charge states of rhGH (m/z 1383.76; 1475.95; 
1581.30; 1702.86 ± 0.5 corresponding to Mr = 22124.81 Da). For 
discussion see text. Brown trace: EIE of m/z 1368.50; 1459.60; 
1564.00; 1684.10; 1824.40 ± 0.5 (corresponding to rhGH after 
spontaneous elimination of PhePro). 
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Fig. 2 – A. Simulated isotope pattern of intact rhGH 
(C990H1528N262O300S7, assumed resolving power of 30,000 at 
FWHM). B–D. Charge deconvoluted mass spectra of peaks 1, 2, 
3 of stressed rhGH (see Fig. 1): B. intact rhGH (peak 1), C. singly 
deamidated rhGH (peak 2), and D. doubly deamidated rhGH 
(peak 3). The blue line was inserted to clarify the shift of the 
maximum of the isotopic distribution by 1 Da at a time. 
 
stressed rhGH (numbered 1–3 in Fig. 1). The charge deconvolu- 
tion was carried out using Maximum Entropy with a data point 
spacing of  0.01 m/z and the  instrument  resolving power 
parameter set to 30,000. For comparison the mass spectrum of 
intact rhGH was simulated at R = 30,000 (at FWHM, shown in Fig. 
2A). It is clearly visible that the isotope pattern shifts by 1 Da 
between spectrum B and C, and C and D, respectively. A simple 
proof of the mass shifts was accomplished by the respective 
polynomials of best fit of the isotopic peak maxima determined 
from the 3 isotopic distributions measured. The degree of the 
polynomials was chosen to 2 and 3 in order to match the 
approximate shape of the isotopic distributions rather than to 
cover every single data point fluctuation. The difference between 
the maxima of the best polynomial fit of the first and the second 
electrophoretic peak (corresponding to intact and mono deami- 
dated rhGH)  was calculated to be 0.8 Da (1.0 Da) and the 
difference between the maxima of the best polynomial fit of 
the second and the third electrophoretic peak (corresponding to 
mono and doubly deamidated rhGH) was calculated to be 1.6 Da 
(1.2 Da) using the polynomial orders 2 and (3) respectively. The 
calculated differences don't match 1 perfectly because the data 
are prone to measurement uncertainties and the trend lines only 
approximate the real shape of the isotopic distribution. How- 
ever, these calculations show, that the determined isotopic 
distributions, namely distributions 1  and  2 and 2 and 3 
respectively differ by 1 Da. Thus, the three major peaks arise 
from intact, singly and doubly deamidated rhGH. Further 
evidence is provided by the electrophoretic separation. In 
alkaline BGE systems, as  applied here, each deamidation 
introduces an additional negative charge to the protein. Hence, 
the molecule migration against the EOF increases and it is 
detected later than the intact form (Fig. 1). The combination of 
accurate mass and migration time change proves the presence 
of deamidated forms of rhGH under stress conditions. 
Furthermore, the mass spectra corresponding to these three 
peaks each exhibited an additional charge distribution. The 
corresponding EIE shows again three peaks, each of them 
slightly shifted to higher anionic mobility (longer 
migration time), however not separated from the respective 
main peak (Fig. 1). The deconvoluted mass spectra show a 
difference of 
244 Da each (not shown). Masses and relative migration times 
lead to the  assumption that  these  peaks  correspond  to 
proteins originated from non-, mono-, di-deamidated rhGH 
and spontaneous elimination of the two N-terminal amino 
acids phenylalanine and proline due to the strong stress 
conditions (24 months at 40 °C). 
In order to study protein modifications causing only small 
mass shifts such as deamidation on intact protein level by 
isotopically resolved MS  in more  detail another complex 
protein was analysed. EPO, which is used for the treatment of 
anaemia, shows three N-glycosylations of complex type and 
one O-glycosylation. These  glycosylations introduce high 
variation to the protein structure and mass. Hence, EPO is a 
complex mixture of dozens of glycoforms. CE is a highly 
suitable technique for the analysis of EPO due to its ability to 
partially separate the different major glycoforms [28,29]. In 
Fig. 3 a separation of BRP EPO (European Pharmacopoeia, ca. 
120 ng injected) using a linear polyacrylamide coated capillary 
and an acidic BGE is shown. This neutral coating caused the 
EOF to be suppressed to near zero so that the analytes were 
separated due to their own mobility only. The capillary wall 
needed to be recoated about every 5th run. As the new coating 
layer was introduced without prior removal of the old layer 
frequently used capillaries showed better performances and 
recoating needed to be done less often. As clearly visible in the 
extracted ion electropherograms in Fig. 3 separation of the 
different EPO glycoforms is primarily based on the number of 
sialic acids (SA—different colours) but also on the number of 
HexHexNAc units. Neighbouring peaks (of same colour) differ 
by one HexHexNAc unit. As expected, the separation improves 
with an increasing number of SA and HexHexNAc units, even 
if baseline resolution is not achieved for most of the peaks. 
This separation is an excellent result not only compared to a 
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Fig. 3 – Electropherogram of an EPO BRP CE separation 
(ca. 120 ng injected) using a soluble linear polyacrylamide 
coated capillary and 1 M acetic acid as BGE. For further 
conditions see text. All traces are EIEs of the average mass of 
the most abundant charge state (mostly [M + 15 H]15+-ions). 
Traces of same colour represent EIEs of glycoforms showing 
the same number of sialic acids (SA). Within these groups 
the glycoforms are separated by the number of HexHexNAc 
units (repeats). Further considerations on EPO analysis are 
carried out based on the mass spectrum corresponding to the 
shaded area (compare Fig. 4). 
 
 
previous separation [31] but rather taking into account the fact 
that isoforms with a mass difference of slightly more than 
1%  (365 Da for a 30 kDa protein) can be separated based on 
differences in their electrophoretic mobility. Under denaturing 
conditions, as applied in the Pharmacopoeia reference method 
[32], separation is solely based on the number of sialic acids. 
A view on the mass spectrum corresponding to the shaded 
area in Fig. 3 illustrates the complexity of a glycoprotein like 
EPO (Fig. 4A). This mass spectrum shows the charge distribution 
of  the main glycoform present and,  besides, the charge 
distributions of  several other partially overlapping or  co- 
migrating glycoforms. Fig. 4B shows the corresponding decon- 
voluted mass spectrum. The charge deconvolution was carried 
out using Maximum Entropy with R = 10,000 (at FWHM) and a 
data point spacing of 1 m/z. This spectrum yields the molecular 
weights of the different co-migrating glycoforms. In addition 
modifications like acetylation can be identified. The two highest 
peaks represent two EPO glycoforms which differ by one 
HexHexNAc unit. 
A detailed view on the deconvoluted mass spectrum clearly 
shows the limitation of the resolving power of a benchtop TOF 
MS (Fig. 5). The spectrum in Fig. 5A was generated by a bench top 
instrument optimised for sensitivity at R ≈ 10,000 (at FWHM), 
whereas Fig. 5B shows the same detail of a deconvoluted spectrum 
of  a single  EPO glycoform obtained by  a high resolution TOF 
MS showing a resolving power of > 40,000 (at FWHM). While the 
bench top TOF MS was appropriate to resolve the isotopes of 
rhGH with a molecular weight around 20 kDa, a high resolution 
TOF MS is needed for the isotopic resolution of EPO glycoforms. 
These two examples illustrate that for isotopic resolution the 
value of the resolving power has to be higher than the  value of  
the molecular weight of  the  protein  being considered. The 
reason for this discrepancy lies in the definition of R in TOF MS, 
which is based on the full width at half maximum (50%) 
definition. Thus, e.g. proteins of a molecular weight of 30 kDa 
require a TOF MS with a resolving power of about 40,000 or 
higher to be resolved isotopically. 
In order to verify the obtained isotope pattern, the pattern of the 
assumed glycoform was simulated using an assumed 
instrument resolving power of 40,000 at FWHM (Fig. 6), resulting 
 
 
 
Fig. 4 – Mass spectrum of a selected time window of an EPO isoform separation (see shaded area in Fig. 3) where three or more 
different charge distributions are visible (A) and corresponding charge deconvoluted mass spectrum using Maximum Entropy 
deconvolution (B). The two highest peaks represent two EPO glycoforms which differ by one HexHexNAc unit. 
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Fig. 5 – Comparison of two deconvoluted mass spectra of a selected EPO glycoform. A. Detailed spectrum of Fig. 4B. Spectrum 
obtained by a bench top TOF MS showing R ≈ 10,000. B. Detailed charge deconvoluted spectrum obtained by a high resolution 
TOF MS (R ≈ 40,000). 
 
in equivalent resolution. It is clearly visible that these two 
isotope patterns show a good match at the first half of the 
isotopic peak pattern. However, the second half of the measured 
isotopic distribution shows higher intensity as compared to 
the simulated distribution  of the elemental composition 
C1218H1962N258O535S5 (red spectrum). This lead to the assumption that 
the measured spectrum contains the pattern of two 
overlapping EPO forms, where the second isotope pattern might 
arise from the protein after reduction of one of the two disulfide 
bridges (compare simulation blue spectrum). Hence, a 
mathematical evaluation was performed in order to explain the 
measured isotopic distribution. The theoretical isotopic dis- 
tributions of  two  overlapping  forms differing by  2 Da 
(corresponding to the intact and a reduced EPO isoform) were 
simulated and summed up to a single pattern (with factorial 
consideration of the actual background). Thereafter the squared 
residuals between the measured and the summed theoretical 
pattern were calculated and minimised by variation of the 
isoform ratio. Analogous calculations were performed for two 
isoforms differing by 1 Da (corresponding to the intact and e.g. a 
singly deamidated isoform) and for the presence of one single 
(intact) EPO isoform only. The minimal sum of squares was 4 
times lower considering two overlapping distributions than 
considering only one. The calculated ratios matching the least 
sum of squares were 82% (64%) of the intact EPO isoform 
(C1218H1962N258O535S5) and 18% (36%) of the isoform shifted by 
2 Da (1 Da).  In  addition the residuals between one single 
theoretical distribution and the measured data weren't ran- 
domly scattered but showed a tendency. Fig. 7 shows an example 
for the calculations. The black crosses represent the measured 
isotopic distribution; the dark grey bars the theoret- ical pattern 
of the supposed EPO isoform (C1218H1962N258O535S5) and the  black 
bars a theoretical  pattern  of  an  isotopic distribution shifted 
by 2 Da. The summation of these two theoretical patterns is 
represented by the light grey bars (with factorial  background  
consideration). The  residuals  of  this example (shown in the 
upper right corner of Fig. 7) are randomly scattered and thus 
represent the good  approximation. In addition, a calculation 
of the uncertainty was performed taking into account the 
specified 2% isotopic pattern accuracy of the TOF instrument  
used  [33].  Therefore, a skewed isotopic distribution induced 
by a positive maximum error (+ 2%) in the beginning of the 
distribution and a negative maximum error 
(−2%) at the end was assumed. It can be shown that even in this 
worst case the minimal sum of squared residuals is still about 4 
times lower considering two overlapping distributions than 
considering only one. 
However, the presence of two molecules could not be proved 
entirely because no separation was obtained. The presence of 
deamidated forms (which would correspond to a mass shift of 
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Fig. 6 – Detailed spectrum of Fig. 5B. The red trace represents 
the simulated isotope pattern of the EPO glycoform (using an 
assumed resolving power of 40,000 at FWHM) which the 
measured mass spectrum (black trace) is assumed to belong 
to (C1218H1962N258O535S5). The blue trace represents the 
simulated isotope pattern of the same EPO glycoform, but 
with two additional hydrogen atoms as the reduction of one 
disulfide bond would introduce to the molecule. 
beginning and at the end of the electrophoretic peak or by 
creating EIEs of masses corresponding to small and large masses of 
the isotopic distribution (results not shown). The presence of a 
reduced  form is possible, but was not  proven  (e.g. by 
alkylation) as it was not the scope of this contribution. This 
example illustrates that a high resolution MS is able to detect 
modifications but may not be sufficient for the unambiguous 
identification of small protein modifications, since isotopic 
patterns of proteins of this size can overlap. Electrophoretic or 
chromatographic separation is required additionally. 
One of the major benefits of high resolution (isotopically 
resolved) spectra over low  resolution mass spectra is the 
improved selectivity of the extracted ion traces. Fig. 8 shows 
the extracted ion electropherogram of the major isotopologues 
of the EPO isoform considered above ([C1218H1962N258O535S5]
15+). 
The summation of all major isotopologues in a very narrow 
EIE (± 0.003 m/z; red trace) represents the peak profile of 
this particular EPO isoform (21 Hex, 18 HexNAc, 3 Fuc, 11 SA). 
The same accurate masses in a ± 0.01 m/z window lead to a 
much wider peak due to the overlapping masses from 
different EPO isoforms. 
These examples illustrate that TOF MS is adequate for the 
isotopic resolution  of  intact proteins  up to about  20 kDa 
(benchtop instrument) or 30 kDa (high resolution instrument). 
However, other high resolution MS can be used for intact protein 
measurement as well. Recently, isotopic resolution of a 20 kDa 
protein was shown using an Orbitrap mass spectrometer, which 
is specified to a resolving power of up to100,000 (at low m/z) 
using appropriate parameter settings [34]. FT-ICR MS is capable 
   to resolve the isotopes of even larger proteins [35], e.g. intact BSA 
1 Da) is not very likely as at least a slight electrophoretic 
separation would be expected under these conditions. Such a 
separation was not observed by comparing mass spectra at the 
 
 
 
Fig. 7 – Theoretical approximation for the experimentally 
determined isotopic distribution. Black crosses: measured 
data. Dark grey bars: theoretic pattern of the supposed EPO 
isoform (C1218H1962N258O535S5). Black bars: isotopic pattern 
shifted by 2 Da as compared to the isoform. Light grey bars: 
summation of the two theoretic patterns with factorial 
consideration of the measured background. Upper right 
corner: residual plot of the measured data and the summed 
theoretical pattern. 
[36]. However, the resolution of all scanning FT type mass 
spectrometers (Orbitrap, ICR) is inversely proportional to the 
measurement time. Thus, they are achieving the highest 
resolution at a high acquisition time (t > 1 s), being insufficient 
when coupled to fast separation techniques like CE. On the 
contrary TOF MS is suitable for this combination as it keeps its 
resolution even at fast data acquisition. 
Furthermore a correct depiction of the isotopic pattern is a 
prerequisite for the identification protein isoforms with small 
mass differences showing an overlapped isotopic pattern. The 
distortion of  the isotopic pattern  particularly of  multiply 
charged ions (proteins) due to the limited dynamic range and 
the counting dead time of a TDC (Time to Digital Converter) 
based QqTOF  type mass spectrometer have been reported 
earlier [37]. With the introduction of ADC (Analog to Digital 
Converter) based TOF MS the dynamic range could be extended 
up to 5 orders of magnitude [38]. Using this instrumentation 
high isotopic fidelity reflecting the theoretical ratios of the 
elemental composition with high accuracy has been reported 
[39]. On the contrary Erve et al. [40] reported a loss of isotopic 
fidelity operating the Orbitrap at higher resolution which lead 
to limitations assigning the mono-isotopic mass in complex 
isotopic patterns of intact proteins. 
 
 
4. Conclusions 
 
Conventional bench top TOF mass spectrometers allow the 
isotopic resolution of intact proteins showing a molecular 
weight of up to 20 kDa. Using high resolution TOF MS larger 
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Fig. 8 – High resolution EIEs (± 0.003 m/z vs. ± 0.01 m/z) of the specific EPO isoform considered before ([C1218H1962N258O535S5]15+). 
The blue trace shows the BPE (not scaled). The EIEs were generated as summations of the major isotopologues within a 
± 0.003 m/z (red) and a ± 0.01 m/z window (green). 
 
 
proteins of about 30 kDa can be isotopically resolved as shown 
for the first time for intact EPO. High resolution extracted ion 
traces in a very narrow mass window (down to ± 0.003 m/z) are 
providing additional  selectivity in  comparison to lower 
resolved mass spectra. The high isotopic fidelity of the used 
TOF mass spectrometer allows the recognition of isotopically 
overlapping protein forms and hence the detection of protein 
modifications, like  deamidation or changes in disulfide 
bridging. Furthermore, high separation efficiency is needed for 
the unambiguous identification of these protein modifica- 
tions. As deamidation influences the charge of a protein in 
solution, electrophoretic mobility is changed, allowing the 
unequivocal identification of deamidation on the level of 
intact proteins combining capillary electrophoresis and TOF 
MS. 
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Abstract 
 
Due to the increasing number of erythropoietin biosimilars being approved, the comparison of 
different  erythropoietin  preparations  in the pharmaceutical  area gains in importance. 
Erythropoietin holds a distinct natural heterogeneity arising from its glycosylation, which 
shows strong composition variations. This heterogeneity increases the complexity with respect 
to the analysis of erythropoietin considerably, but may also be used to distinguish different 
preparations. Here, a method  is presented for the differentiation of various erythropoietin 
preparations based on the determination of intact erythropoietin glycoforms by capillary 
electrophoresis-mass spectrometry and the subsequent application of multivariate statistics. 
Relative peak areas of selected isoforms were used as variables in Principal Component Analysis 
and Hierarchical Agglomerative Clustering. Both these strategies were suited for the clear 
differentiation of all erythropoietin preparations, including marketed products and pre-
production preparations, which differ in the manufacturer, the production cell line, and the 
batch number. By this means, even closely related preparations were distinguished based on the 
combined information on the antennarity, the sialoform, and the acetylation of the observed 
isoforms. 
 
 
 
 
 
 
 
 
 
Keywords:  CE/MS,  biosimilars,  erythropoietin,  principal  component  analysis,  cluster 
analysis 
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1 Introduction 
 
The glycoprotein erythropoietin (EPO) is an erythropoiesis stimulating hormone, mainly 
produced in the adult kidney [1]. It is composed of 165 amino acids and shows 3 N- 
glycosylations of complex type and one O-glycosylation [2-6]. Glycosylations are post 
translational modifications which play a crucial role in terms of stability and biological activity 
of the protein [4,7-9]. They also induce a high heterogeneity to the molecule, leading to  
numerous  glycoforms,  which differ mainly in the number  of hexoses  (Hex), N- 
acetylhexosamines  (HexNAc),  and  sialic  acids  (SA).  In  addition,  acetylations  (Ac), 
phosphorylations (Ph), and other modifications may occur. Hence, EPO represents a complex 
mixture of various naturally occurring isoforms (> 100) rather than a single molecule. 
Due to the hormonal activity of EPO with respect to the stimulation of the red blood cell 
production, the glycoprotein is used as a biopharmaceutical for the treatment of anemia [10- 
14] ever since its first recombinant expression in 1985 [15]. EPO is also known as a performance 
enhancing substance in endurance sports [16-18] being prohibited by the World Anti-Doping 
Agency since 1990 [19]. Consequently, the analysis of EPO is of great interest regarding 
both quality control of the pharmaceutical products and abuse detection. Common methods 
applied in doping analysis are based on isoelectric focussing (IEF), as isoelectric profiles of 
endogenous and recombinant human EPOs (which are expressed in Chinese hamster ovary 
cells) were shown to be different [20,21]. Besides, other approaches were applied 
successfully in doping control and the development of the analytical strategies continues [22-26]. 
In the quality control of the EPO biopharmaceuticals the characterization of EPO is a main 
issue, as variations in the number and type of the numerous isoforms caused by the uniqueness of 
each cell used for the production are inevitable (even between batches). Apart from the 
verification of the production consistency, the characterization of the EPO glycoform 
distribution gains in importance as the patents of the innovator biopharmaceuticals have expired 
or will expire soon, giving way to follow-on biologics, i.e. biosimilars [27-31]. Hence, 
comparisons have to be carried out in order to verify the similarity of the biosimilars to  the  
innovator  biopharmaceutical,  but  also  to  differentiate  the  various  products 
(manufacturers) from each other. For this purpose, capillary electrophoresis (CE) coupled to 
time-of-flight mass spectrometry (TOF MS) was shown to be a suitable analysis technique as 
it  combines  high  separation  efficiency  and  high  selectivity  with  the  possibility  of 
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characterization and identification [32-36]. In this way, various EPO isoforms, which show 
differences in the glycosylation patterns, were separated and the overall glycan composition 
of these isoforms was determined. Furthermore, low abundant glycoforms as well as isoforms 
showing acetylations could be detected by TOF MS. 
Here, a statistical evaluation based on CE-TOF MS experiments is described for the 
discrimination of various EPO preparations showing differences in the origins and the production 
cell line but also batch-to-batch variations. EPO preparations from commercial suppliers and 
pre-production preparations were analysed and the relative peak areas of selected glycoforms 
were used to distinguish the preparations by grouping in Principal Component Analysis (PCA) 
and Cluster Analysis (CA). 
 
2 Methods and materials 
 
 
2.1 Chemicals 
 
Methanol, 2-propanol (both ROTISOLV® ≥ 99.95 %, LC-MS grade) and acetic acid 
(ROTIPURAN® 100 %, p.a.) were purchased from Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) and used without further purification. NaOH (p.a.) and HCl (37%, p.a.) were 
purchased from Merck  (Darmstadt, Germany). Ultrapure water showing  an electrical 
resistivity of > 18 MΩ cm was supplied by an ELGASTAT® UHQ PS (Elga Ltd., High 
 
Wycombe,  England)  water  purification  system  and  used  for  the  preparation  of  all 
preparations, rinsing solutions and background electrolytes. 
EPO preparations included the biological reference preparation (BRP, batch 3, European 
Directorate for the Quality of Medicines & HealthCare, EDQM, Strasbourg, France) and 
different  injection  solutions  containing  4,000  – 10,000  international  units  of  EPO 
(Recormon® and NeoRecormon® (Hoffmann-La Roche Ltd, Basel, Switzerland), ERYPO® 
and EPREX® (Janssen-Cilag GmbH, Neuss, Germany), SILAPO® (Stada Arzneimittel AG, 
Bad Vilbel, Germany)). Furthermore, various pre-production preparations (Sample A – H) 
showing differences in the manufacturer, the cell line, and the batch number were analyzed 
(further information is confidential). The syringe/vial contents were purified by ultra filtration 
through a cut off 10,000 membrane (Microcon® YM-10; Millipore Corporation, USA). 
Thereafter EPO was lyophilized by a vacuum centrifuge (SpeedVac, Thermo Scientific, 
Waltham, USA) and re-dissolved in 20 µ L of water for measurement leading to a final 
concentration of ≈ 2 – 4 µ g/µ L (10,000 IU ˆ  83 µ g EPO) each. 
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2.2 Capillary electrophoresis 
 
CE experiments were performed on an HP 3DCE (Agilent Technologies, Waldbronn, Germany) 
using capillaries with an ID of 50 µ m and a length of approximately 60 cm. Prior to usage new 
bare fused silica capillaries (Polymicro Technologies, AZ, USA) were conditioned by flushing 
(1000 mbar) with methanol (5 min), water (5 min), 1 mol/L NaOH (20 min), and water (5 
min), followed by the coating procedure (3 mol/L HCl for 5 min, water for 5 min, coating 
solution for 5 min, water for 2 min, and BGE for 2 min). Re-coating needed to be carried 
out every 5 to 10 runs. In order to avoid contamination of the ESI source and the MS the 
capillary was removed from the CE-ESI-MS interface during the re-coating procedure. 
The coating solution used was UltraTrol™ low normal (LN, Target Discovery, Palo Alto, CA, 
USA). The background electrolyte (BGE) was composed of 1 mol/L acetic acid (HAc).  
Samples were injected hydrodynamically (100 mbar for 12 or 24 s respectively). Prior to 
injection the capillary was rinsed with BGE for 2 min. A constant separation voltage of +30 
kV was applied (typical current: 16 µ A). When not in use, the coated capillaries were stored 
in water. 
 
2.3 Electrospray mass spectrometry 
 
The CE/MS coupling was carried out via electrospray ionisation (ESI) using a commercial 
CE-ESI-MS interface (Agilent Technologies, Waldbronn, Germany) which has a triple-tube- 
design. A co-axial sheath liquid (SL) flow, composed of water and 2-propanol (50:50) with an 
addition of 1% HAc, was provided during analyses. It was supplied by a syringe pump (Cole- 
Parmer®, Illinois, USA) equipped with a 5 mL syringe (5MDF-LL-GT, SGE Analytical Science 
Pty Ltd, Melbourne, Australia) at a flow rate of 3 µ L/min. Prior to conditioning the outer 
polyimide coating at the capillary tip was burned off a few mm and the tip was cleaned with 
2-propanol. 
A micrOTOFQ quadrupole time-of-flight mass spectrometer controlled by micrOTOFcontrol 
software (Bruker Daltonik GmbH, Bremen, Germany) was used. The ESI sprayer was grounded 
while the transfer capillary was kept at a constant voltage of -4500 V (positive ion polarity 
mode). The drying gas (nitrogen) flow rate was set to 4 L/min, the drying temperature to 170 
°C, and the nebulizer gas (nitrogen) pressure to 0.2 bar. The ion optics were optimized 
to the highest possible intensity in the mass range of m/z 700 – 3000 by direct infusion of a 
 
100-fold dilution of ES Tuning Mix (Agilent Technologies, Waldbronn, Germany) at 4 
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µ L/min. The same solution and flow rate were used for the mass calibration of the TOF MS, 
which was performed at least once a day. 
Data processing was carried out by the Bruker Compass DataAnalysis software (Version 4.0 
 
SP 2, Bruker Daltonik GmbH, Bremen, Germany). The theoretical masses and charge 
distributions of the EPO glycoforms used for ion trace extraction were calculated using the 
‗IsotopePattern‘ tool of the Bruker software. 
 
 
2.4 Statistical evaluation 
 
The PCA was carried out using The Unscrambler® 7.51 (CAMO Software AS, Oslo, Norway). 
The data matrix was composed of 12 variables and 93 incidents (repeat experiments on 14 
different EPO preparations). The chosen variables were EPO isoforms showing differences in the 
glycosylation. They covered the EPO SA distribution as well as the distribution  of isoforms 
differing in the number  of HexHexNAc  units: Hex22HexNAc19Fuc3SA10, 
Hex22HexNAc19Fuc3SA11, Hex21HexNAc18Fuc3SA12, Hex23HexNAc20Fuc3SA12, 
Hex24HexNAc21Fuc3SA12,  Hex22HexNAc19Fuc3SA13, Hex22HexNAc19Fuc3SA14.  Furthermore, 
the mono-, di- and tri-acetylated isoforms of Hex22HexNAc19Fuc3SA12 and two isoforms 
showing a phosphorylated high-mannose glycan structure (Hex21HexNAc15Fuc2SA9Ph, 
Hex21HexNAc15Fuc2SA10Ph) were considered. Being the reference with respect to the peak areas, 
the high abundant  isoform Hex22HexNAc19Fuc3SA12  was not considered as a variable itself. The 
CA in terms of Hierarchical Agglomerative Clustering was carried out using XLSTAT 
Version 2011.4.03 (Addinsoft, New York, USA) taking the same variables into account. 
Euclidean distances were used as the distance metric. 
 
3 Results and discussion 
 
The comparison of different EPO preparations is crucial with respect to the verification of the 
similarity of biosimilars  to  the  innovator  biopharmaceuticals but  also regarding  the 
optimization of the production, quality control, and the detection of plagiarism, which can be 
found in countries outside the European Union and the USA with less stringent regulatory 
control of licenses and patents. Therefore, the characterization of the various EPO glycoforms is 
of high importance, as the number, type, and relative abundances of the isoforms may 
provide an indication to the similarity or the dissimilarity. The characterization of the 
isoforms of innovator EPO preparations was shown in detail previously, including the 
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comparison of EPO α and EPO β  [33,35,37]. However, the strong heterogeneity of the  
 
products in combination with a large variety of biosimilars, that will continue to increase in 
the following years, leads to the need for the support of the analytical strategies by statistical 
methods for the detailed comparison of these pharmaceutical products. 
A suitable CE-MS method for the extensive characterization of EPO preparations applying a 
neutral coated capillary was described previously (Taichrib et al., submitted). The method was 
optimized by the variation of certain CE-MS parameters and validated to a large extent, taking 
the intra and inter-day precisions of the migration times and the peak areas, the LOD, the 
LOQ, the linearity, and the sensitivity into account. Applying PCA no differences with respect to 
the HAc concentration in the BGE, the coating type (cationic or neutral), the overall sample 
concentration, the resolution, the operator, and the mass spectrometer were found. Here, 
this optimized and validated method was applied for the analysis of several marketed and 
pre-production EPO preparations, showing differences in the production cell line, the 
production conditions, and the batch number. Figure 1 shows the corresponding separations, 
which are represented by the respective base peak electropherograms (BPEs, black) and the 
extracted ion electropherograms (EIEs) of selected EPO glycoforms: 
Hex21HexNAc15Fuc2SA9Ph  (m/z 1846.5,  dark  green),  Hex21HexNAc15Fuc2SA10Ph  (m/z 
1865.9, pink), Hex22HexNAc19Fuc3SA10 (m/z 1935.3, brown), Hex22HexNAc19Fuc3SA11 (m/z 
 
1954.7, orange), Hex21HexNAc18Fuc3SA12 (m/z 1949.8, blue (1)), Hex22HexNAc19Fuc3SA12 
(m/z 1974.1, blue (2)), Hex23HexNAc20Fuc3SA12 (m/z 1998.5, blue (3)), 
Hex24HexNAc21Fuc3SA12 (m/z 2022.9, blue (4)), Hex22HexNAc19Fuc3SA13 (m/z 1993.6, red), 
and Hex22HexNAc19Fuc3SA14 (m/z 2013.0, light green). These glycoforms were chosen such 
as to cover the main possible structural differences arising in EPO glycoforms (number of 
SAs, number of HexHexNAc units, occurrence of phosphorylated high-mannose structures). 
Migration time variations are due to the application of two capillaries of different lengths 
(compare shift from Sample B to Sample C) but also due to the influence by the formulation 
of the respective EPO preparation (compare Sample H). Differences in the intensities are 
induced by the additional presence of acetylated isoforms, which considerably increase the 
heterogeneity of the preparations and hence decrease the intensity of each isoform (compare 
EPREX ® and Sample H). In this case, the extracted ion traces were strongly affected by the 
background noise, which is induced by various charge states of different isoforms showing 
similar m/z. However, using mass spectra three or even more acetylations could be detected in 
these preparations. 
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By comparison of the BPEs and the EIEs of the selected isoforms in Fig. 1, differences 
regarding the number and the relative abundances of the isoforms can be observed for the 
considered EPO preparations. The separations of BRP and NeoRecormon®/Recormon® 
(EPO β ) show similar appearances, as BRP is composed of EPO α  and EPO β  in equal 
shares. All other preparations seem to differ mainly by the presence or absence of the 
uncommon isoforms showing phosphorylated high-mannose glycans 
(Hex21HexNAc15Fuc2SA9Ph and Hex21HexNAc15Fuc2SA10Ph in Fig. 1), showing a high 
abundance in some pre-production preparations particularly (Samples A, B, C, and E). In order 
to perform a reliable comparison, multivariate statistical methods were applied for the 
evaluation of the experimental results. 
A suitable method for the detection of possible hidden structures (groups) in an extensive data 
set is given by PCA. PCA was carried out using the relative peak areas of the selected EPO 
isoforms described above as variables for a set of 93 experiments. The results are given in the 
score plots in Fig. 2A and 3A and the corresponding loading plots in Fig. 2B and 3B. Regarding 
Principal Components (PCs) 1 and 2 (Fig. 2A), which explain 43% and 23% of the total 
variance, respectively, most of the different EPO preparations form narrow clusters that are 
separated from each other. And although some of the measurements on the different 
preparations  were  repeated  only  2  or  3  times  (e.g.  Sample  A,  Sample  B,  and 
EPREX®/ERYPO®), these results indicate the suitability of the PCA for the distinction of 
these preparations. The variables being responsible for the formation of these clusters are 
displayed in the loading plot in Fig. 2B. It has to be noted that the direction of the variables 
matches  the direction of the clusters. Thus,  the  acetylated isoforms 
(Hex22HexNAc19Fuc3SA12Ac,  Hex22HexNAc19Fuc3SA12Ac2,  Hex22HexNAc19Fuc3SA12Ac3) 
show a high significance with respect to EPREX®, ERYPO® and Sample H, whereas being 
trivial regarding e.g.  SILAPO®.  Likewise, the uncommon  isoform 
Hex21HexNAc15Fuc2SA10Ph shows the highest significance with respect to Sample A, whereas 
Hex21HexNAc15Fuc2SA9Ph seems to have the highest impact on Sample E, F, and G. Similar 
considerations can be performed for the remaining variables and preparations. 
Despite the good separation of the single clusters (EPO preparations), few conglomerations 
can be observed. NeoRecormon® is not separated from Recormon®, as these two EPO 
preparations are known to be equal products with different brand names (NeoRecormon® is 
the successor of Recormon®), showing only batch-to-batch variations. An equal link can be 
claimed for EPREX® and ERYPO®. In addition, the NeoRecormon® cluster shows a high 
overlap with the cluster of Sample C, and two analyses on NeoRecormon® show a higher 
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statistical similarity to BRP, obviously displaying outliers. Another conglomeration can be 
observed for BRP and Sample D, with BRP showing a higher overall distribution. 
These observations demonstrate the restrictions of a PCA considering only 2 PCs, which, in 
this case, clarify only about 66% of the total variance of the multivariate data set. Thus, a 
more detailed evaluation of the statistical comparison of the various EPO preparations is 
provided by the consideration of an additional PC (PC3, explaining 15% of the total variance). 
Figure 3A shows the corresponding score plot and Fig. 3B the respective loading plot 
regarding PC1 and PC3. The variables displayed in the loading plot are arranged differently as a 
different dimension is considered here. Nevertheless, the interpretation works likewise. 
On the whole, the distances between the clusters formed by the different EPO preparations are 
smaller. However, the clusters for which overlapping was determined in the first two dimensions 
(score plot PC1 vs. PC2, Fig. 2A), i.e. NeoRecormon® and Sample C as well as BRP and 
Sample D, show a clear separation now. Even Recormon®, which is supposed to show only 
batch-to-batch variations as compared to NeoRecormon®, seems to be separated from 
NeoRecormon®, at least partly, although the meaningfulness is low due to the lack of a 
substantial  number  of  measurements.  EPREX®  and  ERYPO®,  however,  are  not 
distinguishable considering three PCs. The two outlying measurements on NeoRecormon® 
also remain conglomerated with BRP, verifying the outlier status. In summary, all considered 
EPO preparations (despite EPREX® and ERYPO®) could be distinguished using three PCs, 
which explained about 80% of the total variance of the data set. 
Applying a second statistical evaluation of the data, i.e. hierarchical agglomerative clustering 
(Cluster Analysis, CA), similar grouping as obtained by PCA was observed. The clusters 
shown in the dendrogram (Fig. 4) are formed by the differences of the Euclidean distances. 
Thereby, the height of the U-shaped lines connecting two groups displays the magnitude of 
the dissimilarity of these two groups. The classification of the clusters based on their 
dissimilarity (magnitude of the distances) is limited by the predefined number of classes (6, 
compare colour coding). However, the number of classes is subjective and may be adapted for 
individual evaluations. In contrast to PCA, considering only parts of the total variance for 
each score plot, the dendrogram in CA is created taking all present distances into account. 
Despite slight differences, an overall similarity of the CA and PCA results was observed. The 
obtained  classification  in CA (compare colour coding in  Fig. 4) is represented by 
neighbouring groups in the score plots of PCA (Fig. 2A and Fig. 3A). The conglomeration of 
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two experiments on NeoRecormon® with BRP described above can be determined by PCA 
and CA likewise. Slight differences of the two statistical evaluations are represented by the 
separation of EPREX® and ERYPO® in CA, which can not be observed applying PCA. 
Furthermore, CA reveals a relatively high similarity of SILAPO® to Sample G and E, while 
PCA shows a clear separation of SILAPO® from all other preparations. 
In summary, based on CE-MS data on intact glycoforms multivariate statistical methods like 
PCA and CA are highly suitable strategies for the distinction of EPO preparations, which 
show differences in the manufacturer and the production cell line, and batch-to-batch variations. 
The differentiation can be performed based on few selected isoforms out of a pool of 100 or 
more various glycoforms present in each preparation. And although only some EPO 
preparations were used here for the comparison, the described strategy is expected to work 
likewise on other EPO preparations. Still, the suitability of this strategy for the differentiation 
of all known EPO preparations (about 70, [38,39]) remains unclear. However, the strategy 
may be improved by the consideration of additional variables (EPO isoforms), thus being able 
to distinguish even closest related preparations. Furthermore, the reliability of the statistical 
strategies can be increased by an appropriate number of repetitive measurements on all EPO 
preparations (compare Sample A, Sample B, EPREX®/ERYPO®, and Recormon®). 
In the context of intact proteins characterized by CE-MS statistical methods were also described 
for the differentiation of cancer patients and healthy people based on the different isoform 
distributions of g-acid glycoprotein by Ongay et al. [40]. However, to the best of our knowledge 
this is the first study differentiating EPO preparations on their molecular level, i.e. 
based on the overall composition of the intact glycoforms determined by CE-MS. 
 
 
4 Conclusions 
 
Due to the high number of isoforms inherent in each EPO preparation the combination of 
selective analytical techniques and statistical methods is inevitable for the comprehensive and 
detailed comparison of highly complex biopharmaceuticals. Here, PCA and CA (in terms of 
hierarchical agglomerative clustering) were applied to distinguish these preparations based on 
the relative peak areas of selected isoforms determined by CE-TOF MS. Differences in the 
relative abundances of these isoforms were shown to be responsible for the statistical cluster 
formations,  which  consequently  induced  the  differentiation  of  the  considered  EPO 
preparations. Using PCA, all considered preparations were distinguished based on three 
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principal components explaining about 80% of the total variance of the multivariate data set. 
A similar clustering was found by hierarchical classification in CA. 
This strategy is highly suitable for the monitoring of the structural similarity and dissimilarity. 
Hence, this strategy may be applied in quality control and for the optimization of the production 
but also for the evaluation of biosimilars as a detected structural similarity may provide  an  
indication  to  the  overall  similarity  of  a  biosimilar  to  an  innovator biopharmaceutical. 
However, the clinical equivalence has to be verified by different methods, as only both, 
structural and clinical similarity will result in equal medical efficacy of the compared 
pharmaceuticals. 
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Figure captions 
 
Figure 1: Separations of the different EPO preparations in an LN coated capillary. Other 
conditions see text. Colour coding: BPE (black), EIE of Hex21HexNAc15Fuc2SA9Ph (m/z 
1846.5, dark green), EIE  of Hex21HexNAc15Fuc2SA10Ph  (m/z 1865.9, pink),  EIE  of 
Hex22HexNAc19Fuc3SA10 (m/z 1935.3, brown), EIE of Hex22HexNAc19Fuc3SA11 (m/z 1954.7, 
orange), EIE of Hex21HexNAc18Fuc3SA12 (m/z 1949.8, blue (1)), EIE of 
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Hex22HexNAc19Fuc3SA12  (m/z 1974.1, blue (2)), EIE of Hex23HexNAc20Fuc3SA12  (m/z 
 
1998.5, blue (3)), EIE of Hex24HexNAc21Fuc3SA12  (m/z 2022.9, blue (4)), EIE of 
Hex22HexNAc19Fuc3SA13  (m/z 1993.6, red), EIE of Hex22HexNAc19Fuc3SA14  (m/z 2013.0, 
light green). EIEs were created using an extraction width of ± 0.2. 
 
 
Figure 2: Score plot (A) and loading plot (B) for PC1 and PC2 of the PCA on the different 
 
EPO preparations. 
 
 
 
Figure 3: Score plot (A) and loading plot (B) for PC1 and PC3 of the PCA on the different 
 
EPO preparations. 
 
 
 
Figure 4: Dendrogram of the CA showing the dissimilarity of the different EPO preparations. 
Clusters were determined using Euclidean distances. The different colours indicate similar 
clusters based on the number criterion (predefined number of classes: 6). 
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Chapter 3 
 
 
 
 
Discussion 
 
 
 
 
 
The detailed characterization of pharmaceutical preparations is of great importance with 
respect to the assessment of the quality, the verification of the medical efficacy of the 
respective pharmaceuticals, and the approval of new products.  In this context LC-MS [88–
91] and CE-MS [33, 92, 93] gained in importance over the past years, with CE- MS being 
particularly suited for the isoform characterization of intact proteins [44, 47, 
94], e.g. biopharmaceuticals. The presented thesis shows the application of CE-ESI- 
QTOF MS for the quality control of peptide and protein pharmaceuticals based on the 
evaluation of the respective structures. The impurities of a peptide hormone were fully 
identified and described in detail by the determination of the relative abundances and the 
evaluation of the respective migration and retention times. In terms of intact proteins, a fast 
and widely applicable CE-MS method was provided.  Therefore, different para- meters were 
optimized and the method was validated to a large extent. The structural 
characterization of protein preparations was carried out by the comprehensive profiling 
of possible isoform patterns on the one hand and the verification of protein modifications 
on the other. Furthermore, the relative abundances of selected EPO isoforms obtained by 
CE-ESI-QTOF MS were used for the successful differentiation of marketed products, 
biosimilars, and pre-production preparations applying multivariate statistical methods. 
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3.1  Application of CE-ESI-QTOF MS - separation 
 
 
3.1.1  Separation of peptides by CE-MS and comparison to LC-MS 
 
 
Capillary electrophoretic separation 
Due to their relatively low mass (MW < ca. 3000 Da) most peptides can be separated 
straightforwardly using common unmodified fused silica capillaries and a common BGE 
containing aqueous FAc. The electrophoretic separation of peptides was shown by taking 
the example of the peptide hormone tetracosactide (TCS) and its numerous structurally 
related impurities. TCS is composed of 24 amino acids (SYSMEHFRWGKPVGKKR- 
RPVKVYP) and possible impurities are represented by N- and C-terminally truncated 
peptides, peptides with additional amino acids, and peptides with residual protecting groups 
like tert -butyl (tBu) and tert -butyloxycarbonyl (tBoc) (manuscript 1). The im- purities 
commonly arise during the chemical synthesis of TCS induced by incomplete or 
inaccurate coupling reactions and purification steps. 
 
The electrophoretic separation of TCS and its impurities was carried out using an un- 
modified fused silica capillary and an acidic BGE (0.5 mol/L FAc, pH 2.0). It is illu- 
strated by the extracted ion electropherograms (EIEs) of TCS and the corresponding N- 
(A) and C-terminally truncated peptide impurities (B) in Fig. 3.1. The ion traces of TCS 
at the very top of both parts of the figure exhibit two signals stemming from TCS it- self 
and its 16 D-Lys diastereomer (marked with an asterisk), which is a well known TCS 
impurity. Due to the different Stokes’s radii almost baseline separation was achieved here. 
By contrast, the separation of TCS and the other impurities (shortened peptides) 
displayed in Fig. 3.1 is not only a result of the different sizes (due to different number of 
amino acids) but also a result of the different charges (due to the different numbers of 
charge carriers, i.e. basic amino acids). As clearly visible in Fig. 3.1 peptides with fewer 
acidic amino acids migrate faster as the respective larger relatives, whereas the migration 
times (MTs) of peptides with fewer alkaline amino acids like lysine or argi- nine are 
considerably higher compared to the MTs of the larger peptides showing higher charge-to-
size ratios.  These observations demonstrate the dependence of the MTs on structural and 
chemical properties [25, 95–100] for a set of highly related peptides, i.e. a synthetic 
peptide and its structurally derived impurities. 
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Figure 3.1 – EICs of TCS and its corresponding N- (A) and C-terminally (B) truncated peptide 
impurities. The ion traces were created by extraction of the m/z of the 3 most abundant isotopes of 
the major charge state of each peptide (listed in the figure). The signal marked with an asterisk 
represents the diastereomer of TCS, while the signals marked with an X did not come from the indicated 
peptide but rather arose from fragmentation of the main substance on the one hand and isotopes from 
different peptides or background signals showing identical m/z on the other. 
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Beside the N- and C-terminally shortened peptides,  several peptides with additional amino 
acids or residual protecting groups were identified as impurities in different TCS samples. 
These groups changed the charge density (charge-to-size-ratio) of the molecules only to a 
small extent as no charge carriers were added to the peptides.  Thus the ob- served 
efficiency was considerably lower regarding the separation of these peptides com- pared to 
the separation of peptides showing strong differences in the charge-to-size-ratio. 
Consequently, the identified (larger) peptides were only partly separated from TCS and 
from each other.  A similar migration behavior was observed for the second known im- 
purity, i.e.  the oxidized form of TCS (TCS sulphoxide).  In this case the separation 
efficiency was even lower as the single oxygen atom introduced to the peptide changed the 
peptide’s charge density only marginally. 
In summary, TCS fragments, which show differences in the charge-to-size-ratio, were bet- 
ter separated by CE compared to peptides with additional or residual functional groups 
showing differences in hydrophobicity. However, an opposed behavior was observed for 
the separation of TCS and its impurities by LC-MS. 
 
Comparison of CE and RP-HPLC 
A comparison of CE and RP-HPLC with respect to the separation of TCS and its impu- 
rities was carried out, as the standard method for routine analyses of the pharmaceutical 
product TCS is based on liquid chromatography [101]. Due to the relatively high salt 
content of the mobile phase (0.5% (NH4)2 SO4), the LC method specified by the Eu- 
ropean Pharmacopoeia had to be adapted for the coupling of LC and MS. The first 
attempt consisted in the substitution of (NH4)2SO4  by NH4Ac applying a similar sta- 
tionary phase as described in the standard method. The corresponding chromatograms 
are displayed in Fig. 3.2. 
 
The top chromatogram (Fig 3.2 A) represents a routine analysis of a TCS preparation 
described by the European Pharmacopeia [102]. The provided separation reveals a single 
unknown impurity partly separated from the active substance TCS (denoted as 1). The 
corresponding LC-MS analyses (as described above) are represented by the base peak 
chromatograms (BPCs) in Fig. 3.2 B (gradient elution) and C (isocratic elution). Ob- 
viously, no separation of the sample components similar to the separation shown by the 
European Pharmacopoeia (Fig 3.2 A) was observed. These results indicated a certain 
content of (NH4)2SO4  in the mobile phase to be crucial for an acceptable separation. In 
order to achieve a good separation by LC-MS, both the stationary and the mobile phase 
were substituted, hereafter applying the Poroshell 300SB-C18 column in combination 
with 0.1% FAc in water and methanol as the mobile phase, respectively (Fig 3.2 D). The 
evaluation of the corresponding retention times (RTs) of TCS and its shortened peptide 
impurities revealed a behavior that was comparable to the behavior found for 
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Figure 3.2 – Chromatographic separations of TCS and its impurities represented by the corre- 
sponding UV trace (A) and the BPCs (B−D). A. LC-UV analysis applying the ODS Hypersil C18 
separation column and gradient elution by 0.5% HAc + 0.5% (NH4 )2 SO4  in water and ACN, respec- 
tively. For detailed method description see [101], B. LC-MS analysis applying similar conditions as in 
A, but substitution of (NH4 )2 SO4  by NH4 Ac, C. same conditions as in B, but isocratic elution at 
80% organic solvent, D. Poroshell 300SB-C18 column, gradient elution by 0.1% FAc in water and 
methanol, respectively. 
 
 
the respective migration times (CE-MS) described above (increase/decrease in depen- 
dence on the basicity of the lacking amino acid).  However, the observation was not 
consistent within the whole set of truncated peptides.  The strongest differences of the 
RTs were observed for peptides differing by the number of highly hydrophobic, aromatic 
amino acids like phenylalanine and tryptophan (manuscript 1). In comparison to CE, this 
hydrophobicity based separation also provided a higher efficiency for the peptide 
impurities showing additional functional groups like tBu and tBoc (peaks separated at 
higher RTs than TCS in Fig 3.2 D). Due to the different separation principles, CE and 
LC also showed opposed efficiencies with respect to the separation of the two known im- 
purities 16 D-Lys TCS, which was clearly better separated by CE, and TCS sulphoxide, 
which showed co-migration with TCS in CE, but baseline separation in LC. 
In summary, with respect to the analysis of TCS and its various impurities CE was 
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found to be more suitable for the separation of truncated peptides, which showed con- 
siderable differences in the charge-to-size ratio, while LC showed a higher suitability for 
the separation of peptides showing additional functional groups and hence stronger 
hydrophobicity differences. This example demonstrates strikingly that CE and LC re- 
present complementary separation techniques, with either being highly suitable for the 
analysis of peptides using mass spectrometric detection. Hence, both CE-MS and LC- MS 
are frequently described in the literature for the analysis of peptides covering various 
application areas, e.g. quality control (characterization of synthetic peptides) [88–90], 
sports drug testing [91, 103–105], and clinical applications [106–108]. 
 
 
 
 
3.1.2  Separation of proteins by CE-MS 
 
 
In comparison to peptides, the electrophoretic separation of proteins is challenging due to 
the commonly arising protein adsorption to the capillary wall [39, 40]. This effect is 
illustrated by the separation of intact model proteins using a bare fused silica capillary 
and an acidic BGE (Fig. 3.3). Despite the addition of an organic solvent to the BGE 
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Figure 3.3 – Separation of eight intact model proteins applying an uncoated fused silica capillary 
and a BGE composition of 0.2 mol/L FAc and methanol (80/20 v/v). Pink: lysozyme, blue: ❜- 
lactoglobulin A, green: cytochrome c, red: RNase A, light blue: myoglobin, black: RNase B, yellow: 
trypsin inhibitor, purple: carbonic anhydrase I. 
 
(20% methanol) a strong adsorption of the majority of the eight model proteins in terms 
of broad and badly shaped peaks was observed.  And although few of the considered 
proteins, i.e. ❜-lactoglobulin A (blue), myoglobin (light blue), and cytochrome c (green), 
showed a quite good peak shape and intensity, the overall resolution was rather poor, 
leading to considerable quenching effects in the ESI. 
 
In order to prevent adsorption effects, two approaches were used: the application of 
extreme pH values for the separation of rhGH and its modifications on the one hand 
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[109–113] and the application of capillary coatings for the separation of EPO isoforms on 
the other [33, 42–58, 114–117]. 
 
Application of unmodified fused silica capillaries 
A highly alkaline pH value of the BGE may ensure the electrostatic repulsion of the 
protein and the unmodified capillary wall, thus providing suitable protein separation 
conditions [109, 110].  Hence, previously described methods [111, 114] were adapted for the 
analysis of intact rhGH and the detected variants (manuscript 3), which were postulated to be 
singly and doubly deamidated isoforms [114].  The confirmation of this postulation was 
accomplished here by accurate mass determination and isotopic resolution on the one hand 
(see section 3.2.2) and a successful separation of these isoforms on the other.  The 
separation insofar contributes to the unambiguous verification of deamidated isoforms as 
deamidation leads to a change of the protein’s charge density by the removal of a charge 
carrier, thus having a strong influence on the migration by reducing the protein’s 
electrophoretic mobility.  In addition  to the change of the proteins’s charge, its mass is 
increased by 1 Da. 
 
Despite the good separation of rhGH and the two deamidated isoforms (MW ≈ 22 kDa), 
the applied method showed restrictions regarding the separation of larger proteins, which 
still showed adsorption due to their potentially higher hydrophobicity.  In addition, highly 
alkaline pH values may lead to conformational changes or even degradation of the 
proteins.  Alkaline BGEs also counteract the preferable positive electrospray ioni- zation 
and extended capillary usage due to frequent breakages. Thus, acidic BGEs but in 
combination with coated capillaries were used for further experiments on intact proteins. 
 
Application of coated capillaries 
Although acidic BGEs may also affect the protein conformations, they are frequently 
described in the literature for the analysis of intact proteins by CE-MS applying coated 
capillaries [33, 42–50, 52–58, 97]. Often, these methods are specified to certain appli- 
cations, showing strong differences in the method parameters, e.g.  the BGE and SL 
compositions and in particular the coating agent. In order to specify a widely applicable 
method for the analysis of various intact proteins, several CE-MS parameters, i.e. the 
capillary coating, the composition of the BGE and the SL, the flow rate of the SL, and 
the nebulizer gas pressure, were optimized (manuscript 2). 
 
The most influencing parameter is represented by the capillary coating, as shown in 
manuscript 2 for the separation of eight model proteins (lysozyme, ❜-lactoglobulin A, 
cytochrome c, RNase A and B, myoglobin, trypsin  inhibitor,  carbonic anhydrase I) using 
three neutral (underivatized  polyacrylamide (PAA), GuarantTM , UltraTrolTM LN) and 
three cationic (N,N-dimethylacrylamide-ethylpyrrolidine metacrylate copoly- mer 
(“copolymer”), trimethoxy-silylpropyl(polyethylenimine) (PEI), UltraTrolTM HR) 
Coating µEOF (exp.) 
[10-8 m2 V-1 s-1 ]
µEOF  (Ref.) 
[10-8 m2 V-1 s-1 ]
LN 0.13 ±0.04 < 0.1c)
PAA ca. 0.1a) −
GuarantTM − 0.03
“Copolymer” − −1.5c),[118]
PEI −9.2b) −
HR − 2.63 ±0.08 −3.0c)
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coating agents. While all of the neutral coatings provided good separation efficiencies, the 
application of cationic coatings for the separation of the model proteins was re- stricted, 
revealing peak broadening and/or poor separation. A detailed evaluation of 
the observed separations was carried out based on the electroosmotic mobilities (µEOF) 
of the respective coating agents and the electrophoretic protein mobilities (µe) listed in 
Table 3.1 and 3.2. 
 
Table 3.1 – Experimental (at pH 2.4) and theoretical (as specified by the manufacturer at pH 3) 
electroosmotic mobilities of different coatings and a bare fused silica capillary. Specified uncertain- 
ties are based on 6 (LN, fused silica) and 12 (HR) repetitive runs. 
 
 
 
 
 
 
 
 
 
 
 
fused silica 0.11 ±0.02  ca. 0.05c),[119] 
 
a)  estimated according to the apparent electro- 
phoretic mobilities of the model proteins 
b) only one measurement available 
c)  estimated from a graphic 
 
 
Table 3.2 – Electrophoretic mobilities of model proteins separated on an LN coated capillary using 
a BGE composition of 0.5 mol/L HAc (pH 2.5). The uncertainties display combined errors. 
 
Protein µe 
[10-8 m2 V-1 s-1] 
 Lysozyme  3.52 ± 0.05 
β -Lactoglobulin A 3.27 ± 0.05 
Cytochrome c 3.20 ± 0.05 
RNase A 3.06 ± 0.05 
Myoglobin  2.92 ± 0.05 
RNase B 2.78 ± 0.06 
Trypsin inhibitor 2.67 ± 0.06 
Carbonic anhydrase 2.41 ± 0.05 
 
 
The effective protein mobilities were determined by the subtraction of the electroosmotic 
mobility of an LN coated capillary (0.13⋅10-8 m2V-1 s-1 ) and the observed nebulizer suc- 
tion effect (0.75⋅10-8 m2V-1 s-1 ) from the apparent protein mobilities at a nebulizer gas 
pressure of 0.2 bar (manuscript 2). The nebulizer effect needed to be taken into account 
as the nebulizer was found to have a strong suction effect. Its magnitude was determined 
based on identical experiments applying UV detection on the one hand and MS detec- tion 
on the other (manuscript 2). The uncertainties stated for the effective mobilities of the 
model proteins display combined uncertainties based on the precision of repetitive 
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protein analyses and the precision of repetitive experiments on the EOF determination and 
the determination of the suction effect, respectively (error propagation). 
 
The described suction effect of the nebulizer was discussed and evaluated in detail in 
manuscript 2. It has to be considered particularly for the separation of low mobility 
analytes (proteins) which additionally show only small mobility differences. Beside the 
disadvantage of a possible negative impact on the resolution, a present nebulizer suction 
effect may also stabilize a separation system by the introduction of a considerable bulk 
flow. In addition and even more important, a possible reversed EOF, induced by the un- 
desired permanent or transient adsorption of positively charged hydrophobic molecules to 
the capillary surface, may be compensated to some extent, thus preventing current 
breakages due to the entrance of SL at the capillary outlet.  The lack of this positive effect 
of the nebulizer suction in systems using sheathless ESI-MS interfaces may lead to a lower 
overall stability with respect to the application of neutral coated capillaries and/or acidic 
BGEs, which are mostly preferable for intact protein analysis. Considering the 
electroosmotic and electrophoretic mobilities mentioned above, the re- striction of the 
cationic coatings with respect to the separation of the model proteins (described in 
manuscript 2) becomes clear. Only PEI coated capillaries showed a reason- able EOF, 
enabling the separation of the relatively small and fast standard proteins against their 
migration direction (negative polarity mode), although the resolution was low (shown in 
manuscript 2). Yet, both other cationic coatings, which induce a consider- ably lower 
electroosmotic mobility, are suitable for the acceptable counter-electroosmotic separation 
of slower (glyco-)proteins, e.g. the various isoforms of EPO, which all show 
electrophoretic mobilities lower than 1.3⋅10−8  m2V-1 s-1  (manuscript 2).  Nevertheless, as 
in the case of the standard proteins the neutral coating agent (LN) provides better 
separation conditions for the EPO isoforms also. 
 
Optimization of the BGE, the SL, and the nebulizer 
Apart from the capillary coating, the other CE-MS parameters, i.e. the composition of the 
BGE and the SL, the SL flow rate, and the nebulizer gas pressure, were optimized by 
monitoring both the resolution and the signal intensity. Best results were obtained using the 
commercial LN coating agent, a BGE composition of 0.5 and 1 mol/L HAc, a SL 
composition of 2-propanol/water 1/1 (v/v) with an addition of 1% HAc, a SL flow rate of 
2−4 ➭L/min, and a nebulizer gas pressure of 0.2 bar. Fig. 3.4 shows the corresponding best 
separation of the 8 model proteins using the optimal conditions.  Despite the fast 
separation (analysis time < 7 min) a good resolution was obtained for all proteins (mean 
resolution: 1.7). 
 
The optimized method was validated to a large extent, determining the intra and inter- 
day precisions of the MTs and the peak areas, the LODs and LOQs as well as the 
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Figure 3.4 – Separation of model proteins using an LN coated capillary, 0.5 mol/L HAc as BGE, 
a SL composition of 2-propanol/water 1/1 (v/v) with an addition of 1% HAc, a SL flow rate of 3 
µL/min, and a nebulizer gas pressure of 0.2 bar.  Pink:  lysozyme, blue: ❜-lactoglobulin A, green: 
cytochrome c, red:  RNase A, light blue:  myoglobin, black:  RNase B, yellow: trypsin inhibitor, purple: 
carbonic anhydrase I. 
 
 
linearity and the sensitivity with respect to the 8 model proteins and EPO (manuscript 
2). The results were in good agreement with the results described in the literature for the 
analysis of intact proteins [52, 55, 57, 115] and small molecules [120] by CE-MS (e.g. mean 
MT RSD = 1.4%, mean peak area RSD = 12.3%). Applying a PCA based on selected 
EPO isoforms, the method was also shown not to be prone to changes of the HAc 
concentration in the BGE, the reversal of the EOF direction (by application of a cationic 
coating), the overall sample concentration, the resolution, the operator, or the mass 
spectrometer. Still, a more detailed investigation with respect to e.g. trueness and matrix 
effects has to be carried out when real matrix samples are analyzed. Nevertheless, due to 
the optimization and validation of the method based on the analysis of various intact 
proteins covering a wide range of pI values (4.4−11.3), hydrophobicities, and 
heterogeneities, this method is provided as a standard method for the characterization of 
most small and medium sized biopharmaceuticals (MW up to at least 30 kDa). 
 
Separation of EPO 
Applying the optimized method,  improved separations of the various EPO isoforms present 
in different EPO samples were achieved (manuscript 2, 3 and 4). The separa- tions were 
based on the differences in the number of sialic acids (SA) but also on the differences in 
the number of hexose N-acetyl-hexosamine (HexHexNAc) units, which is a great advance 
with respect to the separations that can be achieved using denaturing conditions as 
specified for the reference method by the European Pharmacopoeia [121]. By this means, 
even isoforms showing a mass difference of slightly more than 1% (cor- responding to the 
mass of a single HexHexNAc unit) were separated satisfactorily. The observed 
separations also display an improvement with respect to a previously described 
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separation applying similar separation conditions [44]. The results demonstrate the high 
separation efficiency of CE based on marginal differences in the structure, which induce 
a sufficient change of the electrophoretic mobility. A similar separation of highly related 
isoforms will not be achievable by RP-HPLC, as the mass difference of the isoforms is due 
to differences in the hydrophilic glycan structures. Hence, the various EPO isoforms may 
show different solvation properties but do not exhibit different hydrophobicities, which 
are crucial for an appropriate separation by RP-HPLC. 
Based on the appropriate separation and the satisfying intra and inter-day precisions of 
the peak areas (mean RSD 11.4%, manuscript 2), the described method may be provided 
not only for the identification but also the relative quantitation of different isoforms. 
 
 
 
 
 
3.2  Application of CE-ESI-QTOF MS - detection and 
identification 
 
  
3.2.1  Identification of peptide impurities 
 
 
Incomplete or false coupling reactions may lead to the formation of different impurities 
during the solid phase synthesis of a peptide [1, 2]. Here, accurate mass determination 
and fragmentation experiments were used to identify such impurities in different TCS 
samples. TCS is composed of 24 amino acids (SYSMEHFRWGKPVGKKRRPVKVYP) 
and the first approach for the identification of the detected impurities was based on the 
verification of the presence of TCS fragments.  Therefore, the exact masses of all N- and C-
terminally shortened peptides (compared to TCS) lying within the chosen mass range of 
the QTOF MS (m/z > 400) were calculated. The presence of these peptides was verified by 
the extraction of the corresponding m/z within a narrow extraction window (mostly 
±0.01). A high mass accuracy is required here as background and isotope signals showing 
an identical nominal mass may lead to false positive results. By this means, all the 
truncated peptides down to a size of 7 (shortened from the N-terminus) or 8 amino acids 
(shortened from the C-terminus) were found to be part of the TCS impurities in the 
considered samples (manuscript 1). 
Besides, other peptide impurities were identified.  Therefore, the accurate  masses in terms of 
the mass differences of the unknown substances and TCS were used in combi- nation with 
fragmentation experiments. If possible, the observed mass differences were matched with 
short amino acid sequences already present in the amino acid sequence of TCS. The 
sequence of the corresponding extended peptide was then verified by the evaluation of the 
respective fragment ion spectra. Furthermore, mass conformities with protecting groups 
used during the solid phase synthesis of TCS, i.e. tBu and tBoc, were 
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found. The structures of the protected peptides were confirmed by MS/MS experiments, 
although no site specifity was determined. Still, as the protecting groups are used for the 
side chain protection of several different amino acids, up to 4 stereoisomers could be 
separated by CE and by HPLC in particular. The latter showed a higher suitability for 
the separation of these peptide impurities, which exhibited a stronger hydrophobicity 
than TCS. 
The example strikingly demonstrates that the accurate mass of the intact molecule alone 
might not be sufficient for the unambiguous identification of unknown substances. This is 
especially true for larger molecules like peptides as the composition possibilities in- crease 
considerably with an increasing accurate mass and several different amino acid 
combinations show mass conformity (i.e. peptides containing identical number and type of 
amino acids but showing different sequences). However, in combination with MS/MS 
spectra the accurate mass may be applied efficiently for the in-depth impurity profiling of 
pharmaceutical products, as the masses of the MS/MS fragments (amino acids) are 
determined accurately as well, enabling the identification of these fragments and hence 
the identification of the unknown peptide based on its amino acid sequence [122, 123]. 
 
 
 
 
3.2.2  Isotopic resolution and mass accuracy regarding intact proteins 
 
 
Isotopic resolution may be crucial with respect to the detection of peptide and protein 
modifications leading to minor mass and charge changes of the biomolecule. It is espe- 
cially useful for the detection of such modifications on the intact protein level, shown for 
rhGH and rhEPO (manuscript 3). 
Singly and doubly deamidated isoforms of rhGH were identified by the evaluation of the 
corresponding isotope patterns, which showed a mass shift by 1 Da each, and the 
comparison of the experimental isotope patterns to the theoretical isotope patterns. The 
verification of the deamidated isoforms was facilitated by the clear electrophoretic sepa- 
ration of the isoforms, which show small differences in the size but strong differences in 
the charge and hence the electrophoretic mobility. 
In difference to rhGH, the verification of protein modifications leading to minor changes of 
the protein mass and charge becomes more difficult regarding proteins showing a higher 
mass, thus a broader natural isotopic pattern, e.g. rhEPO. By the comparison of the 
experimental isotope patterns of different EPO glycoforms with the corresponding 
theoretical isotope patterns overlapping isoforms differing by 1 or 2 Da were detected. 
In order to exclude technical artifacts a detailed mathematical evaluation was carried out. 
The results confirmed the observed overlapping of two different isoforms. However, the 
presence of a deamidated isoform similar to rhGH was discarded here as the EPO 
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glycoform and the unknown overlapping isoform did not show any electrophoretic sepa- 
ration. A possible explanation for the observed overlay may be given by the presence of 
reduced isoforms (dissociation of the disulfide bond between Cys-Cys), which in prin- cipal 
would have similar electrophoretic mobilities in comparison to their non-reduced relatives 
as the size of the protein is changed to a minor extent only and the charge of the protein is 
not affected at all.  In order to verify the presence of reduced isoforms, further experiments, 
e.g. methylation, are needed. 
 
The mass accuracy of the QTOF instruments used here for the identification of protein 
modifications is specified to be better  than 5 ppm using external calibration (small 
molecules).  As isotopic resolution was achieved here, a similar mass accuracy should apply.  
In fact, regarding the 5 most abundant isotopes of the 5 most abundant EPO isoforms 
mass accuracies of 5 (external calibration) and 2 ppm (internal calibration) were found. 
The calibrations, both external and internal, were carried out using ES Tuning Mix 
(Agilent Technologies), with the internal calibration meaning the calibration of the whole 
data set based on one average mass spectrum rather than the internal correction of each 
single spectrum. When isotopic resolution was not achieved the mean mass accuracy (daily 
calibration with ES Tuning Mix) amounted to 25.6 ppm, which corresponded to a mass 
deviation of < 1 Da (MW ca. 30 kDa). Applying internal calibration (based on the 5 most 
abundant charge states of a single isoform) a mass accuracy of 9.6 ppm was achieved 
(mass accuracies were calculated for a total of 292 isoforms present in 6 EPO samples). 
These results are still reasonable regarding the fact that only average masses were 
considered. And, as shown in the following section, the observed mass accuracies are also 
sufficient for the identification of EPO isoforms when the identification is based on the 
well known EPO glycan structures [8, 9, 124–126]. 
 
The examples described above show the suitability and usefulness of high resolution TOF 
MS for the isotopically resolved analysis of intact proteins and their modifications. 
However they also demonstrate that, beside the accurate masses gained by mass spec- 
trometry, the identification of protein modifications leading to minor mass differences (± 1 
or 2 Da) may not be straightforward due to the broad natural isotopic patterns of large 
and complex intact proteins. Furthermore, the reliability of the mathematical algorithm 
and the mass spectrometer regarding the correct determination of isotopes has to be 
proven. In summary, a clear electrophoretic (chromatographic) separation is still crucial 
for the unambiguous identification of protein modifications leading to only minor changes 
of the protein structure, questioning the need for isotopic resolution. 
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3.2.3  Isoform distribution of EPO in various preparations 
 
 
In the following, the sufficiency and suitability of average masses determined by a non- 
high resolving TOF MS for the identification of protein isoforms on the intact protein level 
is demonstrated. Isoforms arise during the post-translational process of the biotech- 
nological production of intact proteins. In the case of e.g. EPO, the numerous isoforms 
show differences in the glycosylation with strong variations in the number of SAs and 
HexHexNAc units. With respect to the comprehensive characterization and comparison 
of EPO preparations, the compositions of all the various isoforms present in different 
EPO samples were determined. 
The characterization of the various isoforms was accomplished by the detailed evalua- tion 
of the deconvoluted mass spectra obtained by QTOF MS. Due to the size of EPO (MW ≈ 
26 − 33 kDa) and the medium resolving power of the mass spectrometer used 
(R ≈ 10, 000), isotopic resolution was not achieved and average rather than accurate masses 
were considered here.  The deconvoluted mass spectra revealed several dozens of EPO 
isoforms, being only partly separated by CE. The determination of the compo- sition of 
the isoforms corresponding to the average masses detected was based on the well known 
amino acid sequence and the structure of the complex type glycans of EPO [42, 44, 45]. 
It should be noted here that only the overall composition of the respec- tive glycoforms can 
be specified. Thus, the spread of the single sugars on the glycans present in each EPO 
molecule, i.e. the structure of the glycans and the respective site, remains unspecified. In 
order to simplify things, the most likely glycoform is given for a certain mass in the 
following. For the detailed evaluation of the single glycans, both the glycopeptides and the 
released glycans themselves have to be examined additionally [42, 45]. 
As much as 100 glycoforms could be detected in each EPO sample. These isoforms co- 
vered the SA distribution (8 − 15 SAs) as well as the distributions induced by the differ- 
ences in the number of HexHexNAc units. With respect to the considered EPO samples, 
i.e. the commercial biological reference preparation (BRP), which is composed of EPO 
α and EPO β in equal shares, ERYPO® and EPREX® (EPO α), NeoRecormon® and 
Recormon® (EPO β), SILAPO® (EPO ζ), as well as 8 pre-production preparations, 
which are not specified in more detail here (confidential), different abundances of the 
numerous isoforms were observed. 
 
For BRP, ERYPO®, NeoRecormon®, and SILAPO® these differences are displayed in 
Fig.  3.5.  Recormon®  and EPREX® were not evaluated  in particular, as these 
preparations are supposed to be equal to NeoRecormon® and ERYPO®, respectively. 
The numbers represent the calculated average masses of the detected isoforms, while the 
color-coding represents the abundances in the various preparations. The rows display 
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Figure 3.5 – Calculated masses of EPO glycoforms detected in different commercial EPO samples. 
Black: detected in all samples, red: detected in SILAPO® and BRP only, green: detected in 
BRP only, blue: detected in BRP, SILAPO® and NeoRecormon®, purple: detected in BRP and 
NeoRecormon®, orange: detected in SILAPO® only, grey: detected in SILAPO®, ERYPO® and 
NeoRecormon®, light green: detected in BRP, SILAPO® and ERYPO®, light blue: detected in 
ERYPO® only
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isoforms showing an identical number of SAs, while the columns display isoforms showing 
an identical number of HexHexNAc units.  Average masses placed next to each other 
represent isoforms differing by exactly one HexHexNAc unit or SA, respectively.  For 
guidance purposes, the composition of the smallest isoform is given in the figure. 
Obviously, BRP and NeoRecormon® alone showed isoforms exhibiting 15 SAs, whereas 
low sialylated isoforms (8 SAs) were detected in BRP and SILAPO® only. In addition, 
SILAPO® exhibited isoforms showing a high number of HexHexNAc units more often 
than all other preparations. 
 
Besides, glycoforms containing a phosphorylated high mannose glycan (Tab. 3.3) were 
identified in some of the analyzed EPO samples, showing a high abundance in pre- 
production  preparations particularly.  These uncommon isoforms are known to arise 
during the biotechnological expression of the protein. 
 
Table 3.3 – EPO glycoforms showing one hosphorylated high mannose glycan detected in different 
EPO samples (bold: detected in several samples, normal: detected in one sample) 
 
Composition Theor. mass [Da] m/z  (15+)
Hex19 HexNAc13 Fuc2 SA8 Ph 26660.2 1778.4
Hex20 HexNAc14 Fuc2 SA8 Ph 27025.5 1802.7
Hex21 HexNAc15 Fuc2 SA8 Ph 27390.9 1827.1
Hex22 HexNAc16 Fuc2 SA8 Ph 27756.2 1851.4
Hex23 HexNAc17 Fuc2 SA8 Ph 28121.5 1875.8
Hex20 HexNAc14 Fuc2 SA9 Ph 27316.8 1822.1
Hex21 HexNAc15 Fuc2 SA9 Ph 27682.1 1846.5 
Hex22 HexNAc16 Fuc2 SA9 Ph 28047.4 1870.8
Hex20 HexNAc14 Fuc2 SA10 Ph 27608.0 1841.5
Hex21 HexNAc15 Fuc2 SA10 Ph 27973.4 1865.9 
Hex22 HexNAc16 Fuc2 SA10 Ph 28338.7 1890.3 
 
 
Fig. 3.6 shows the differences of selected EPO preparations with respect to the abun- 
dances of these special isoforms. For the sake of clarity, only the most abundant iso- forms 
were displayed.  The top electropherogram represents EPO BRP, showing only isoforms 
with complex type glycans (displayed in grayscale).  The middle and bottom 
electropherograms represent two pre-production preparations, which show considerable 
amounts of glycoforms showing one phosphorylated high mannose glycan structure (co- 
lored). 
 
Apart from the main isoforms, the deconvoluted mass spectra also revealed up to 5 
acetylations in the different EPO samples, with EPO ❛ showing most acetylations (not 
shown). The differences in the abundances of the various glycoforms were used to dis- 
tinguish different marketed and pre-production EPO preparations (see following section 
and manuscript 4). 
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Figure 3.6 – Capillary electrophoretic separations of selected EPO preparations showing strong 
differences regarding the presence of isoforms with a phosphorylated high mannose glycan. The EIEs of 
the isoforms containing only complex type glycans are displayed in grayscale, whereas colored traces 
were used to display the isoforms containing phosphorylated high mannose glycans.  Blue: Hex20 
HexNAc14 Fuc2 SA9 Ph and Hex21 HexNAc15 Fuc2 SA9 Ph, yellow: Hex21 HexNAc15 Fuc2 SA10 Ph and 
Hex22 HexNAc16 Fuc2 SA10 Ph. 
 
 
3.3  Multivariate statistics based on CE-ESI-TOF MS data 
 
 
The verification of the similarity  of biosimilars and original biopharmaceuticals re- 
presents an increasingly important task of the comprehensive characterization of phar- 
maceutical products. Hence, the information on pharmaceutical preparations gained by 
CE-TOF MS, in particular the various isoforms of EPO determined separately, were 
used for the detailed comparison of several EPO preparations, both marketed and pre- 
production preparations (manuscript 4). The compared samples showed differences in the 
manufacturer, the cell lines used for production, and the batch number.  Differ- ences in 
the abundances of the various isoforms detected in the monitored preparations were 
already observed during the characterization of these isoforms (described for the 
commercial preparations in section 3.2.3). However, in order to perform a reliable and 
comprehensive comparison, statistical methods were applied.  Therefore, the relative peak 
areas of selected EPO isoforms were used as variables in PCA and CA. These isoforms 
covered the SA distribution as well as the distribution induced by the number of 
HexHexNAc units and acetylations. By this means all EPO preparations were distin- 
guished based on only 12 isoforms out of a pool of approximately 100 naturally occurring 
isoforms present in each sample. And although the applied statistical methods exhibited 
different mathematical approaches, both methods showed entire conformity regarding the 
results of the comparison of 14 EPO preparations from 14 different sources. 
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Despite the high efficiency of the used approach for the comparison of biopharmaceuti- 
cal preparations combining the analysis of the respective samples by CE-TOF MS with 
statistical evaluation methods, the therapeutic similarity is not implicated by the veri- 
fication of the similarity of the glycoform distribution based on the overall composition. 
The number of SAs and HexHexNAc units are known to influence the stability of the 
biopharmaceutical and the in vitro and in vivo bioactivity [19, 127–131]. Thus, further 
studies with respect to the medical efficacy but also the immunogenicity have to be carried 
out [16–18, 132, 133], leaving the approval of biosimilars considerably more time and cost 
consuming than the approval of small molecule generics [20, 21]. 
  
 
 
 
 
 
 
 
Chapter 4 
 
 
 
 
Summary 
 
 
 
 
 
The aim of this work was the enhanced and extensive characterization of peptide and 
protein pharmaceuticals applying powerful and efficient analytical and statistical me- 
thods.  In detail, the individual parts of the work are represented by the development of 
highly selective CE-TOF MS methods for the appropriate separation of structurally 
related peptides and proteins on the one hand and the comprehensive identification and 
verification of various impurities, glycoforms, and protein modifications on the other. The 
work is completed by the use of the CE-TOF MS information on EPO for statistical 
methods as supportive strategies in method validation and for the comparison of different 
EPO preparations with respect to similarity monitoring. 
 
Application of CE-QTOF MS - separation 
The electrophoretic separation of peptides was shown for TCS and its structurally re- 
lated impurities, applying an unmodified fused silica capillary and an acidic BGE. A 
detailed evaluation of the migration times of the truncated peptides (as compared to TCS) 
illustrated exemplarily the dependence of the respective MTs on the peptide’s number of 
basic amino acids (charge carriers).  Furthermore, the effect of the different separation 
mechanisms of CE and LC on the separation of truncated peptides and pep- tides 
showing additional amino acids or residual protecting groups was demonstrated. An 
unmodified fused silica capillary was also used for the separation and identification of 
rhGH and its deamidated isoforms, applying an alkaline BGE. Despite the good results, 
the method bore difficulties arising from the complexity of intact proteins. Hence, a dif- 
ferent and widely applicable method for the analysis of intact proteins was developed by 
the optimization of several CE-MS parameters for the analysis of 8 model proteins and 
EPO. Thereby, the influence of the capillary coating and the nebulizer was investigated in 
detail. The validation of the optimized method revealed highly suitable and reliable 
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CE-MS conditions for the analysis of various intact proteins in the pharmaceutical area. 
Using the optimized method numerous different EPO glycoforms were separated. 
 
Application of CE-QTOF MS - detection and identification 
The selective and beneficial properties of ESI-QTOF MS in combination with CE sepa- 
ration were used for the identification and verification of peptide impurities as well as 
protein isoforms and modifications.  Based on accurate mass and MS/MS spectra N- and C-
terminally shortened peptides (down to 7 amino acids) and peptides showing additional 
amino acids as well as residual protecting groups were identified as impurities in different 
TCS samples (beside the known impurities 16 D-Lys TCS and TCS sulfoxide). The relative 
abundances of these impurities ranged from < 0.01% to > 20%, with the non-deprotected 
peptides and the TCS sulfoxide being the major impurities. 
The presence of singly and doubly deamidated isoforms in a stressed rhGH sample was 
verified based on the corresponding isotopically resolved mass spectra.  The resolution of 
the isotopes of intact  rhEPO revealed an overlapping of two isoforms showing a mass 
difference of 1 or 2 Da. The presence of an artifact was ruled out by a detailed 
mathematical evaluation of the possible underlying isotopic distributions. Due to the lack 
of an electrophoretic separation deamidation was not considered as an explanation for 
the presence of two isoforms. The identification of the overlapping isoform may be 
accomplished by further experiments. 
With respect to EPO, a highly heterogeneous glycoprotein, numerous isoforms (> 100) were 
identified in different preparations based on their mass and the well known protein 
structure.  The isoforms covered the distributions caused by the number of SAs and the 
number of HexHexNAc units.  Additionally,  glycoforms showing phosphorylated high-
mannose glycans and acetylations were identified. 
 
Capability of multivariate statistics 
Based on the CE-QTOF MS data multivariate statistical methods, i.e. PCA and CA, were 
developed i) as a supporting strategy in method validation and ii) for the compari- son of 
different EPO preparations. By this means, the optimized CE-MS method for the analysis 
of intact proteins was shown to be insensitive to parameter changes with respect to e.g. 
relative quantitation. The tested parameters covered the HAc concentration in the BGE, 
the direction of the EOF, the overall sample concentration, the resolution, the operator, and 
the MS itself.  PCA and CA were also applied successfully for the comparison of several 
marketed and pre-production EPO preparations showing differ- ences in the 
manufacturer, the production cell line, and the batch number. All evaluated samples were 
differentiated clearly based on the relative peak areas of only few selected glycoforms 
out of a pool of more than 100 naturally occurring isoforms present in each sample. 
  
 
 
 
 
 
 
 
Chapter 5 
 
 
 
 
Zusammenfassung 
 
 
 
 
 
Das Ziel dieser Arbeit bestand in der verbesserten und umfangreichen Charakterisierung 
von Peptid- und Protein-Pharmazeutika mittels leistungsfa¨higen und effizienten analy- 
tischen und statistischen Methoden.  Im Einzelnen setzt sich die Arbeit aus der Ent- 
wicklung von selektiven CE-TOF MS Methoden fu¨r die geeignete Trennung von struk- 
turell verwandten Peptiden und Proteinen und die umfassende Identifizierung und Veri- 
fizierung von Verunreinigungen, Isoformen und Modifikationen zusammen. Abschließend 
finden die mittels CE-TOF MS ermittelten Daten Anwendung in der multivariaten 
Statistik zur Unterstu¨tzung der Methodenvalidierung und dem Vergleich von verschiede- 
nen EPO-Praparaten im Hinblick auf die Untersuchung der A¨ hnlichkeit. 
 
Anwendung von CE-QTOF MS - Trennung 
Unter Verwendung einer unbeschichteten Kapillare und eines sauren BGE wurde die 
elektrophoretische Trennung  von Peptiden am Beispiel von TCS und dessen struk- turell 
verwandten Verunreinigungen gezeigt.  Die detaillierte Auswertung  der Migra- 
tionszeiten der TCS-Fragmente belegte beispielhaft die Abhangigkeit der jeweiligen Mi- 
grationszeit von der Anzahl basischer Aminosa¨uren (Ladungstra¨ger). Des Weiteren 
wurde die Auswirkung der unterschiedlichen Trennmechanismen von CE und LC auf die 
Trennung von Peptidfragmenten und Peptiden mit zusa¨tzlichen Aminosa¨uren oder 
angebundenen Schutzgruppen diskutiert. 
In Kombination mit einem alkalischen BGE kam eine unbeschichtete Quarzkapillare auch 
fu¨r die Trennung und Identifizierung von rhGH und dessen deamidierten Isofor- men zum 
Einsatz. Trotz der guten Ergebnisse, wies diese Methode Grenzen im Hinblick auf die 
Analyse von komplexen intakten Proteinen auf.  Daher wurde eine breit an- wendbare 
Methode fu¨r die Analyse von intakten Proteinen entwickelt. Dazu wurden verschiedene 
CE-MS-Parameter optimiert, wobei der Einfluss der Kapillarbeschichtung und des 
Zerstaubers  detailliert untersucht wurden.  Die Validierung der optimierten 
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Methode zeigte, dass die gewahlten CE-MS-Parameter besonders fu¨r die Analyse ver- 
schiedener intakter Proteine im pharmazeutischen Bereich geeignet sind. Die optimierte 
Methode kam u.a. fu¨r die Trennung zahlreicher EPO-Isoformen zum Einsatz. 
 
Anwendung von CE-QTOF MS - Detektion und Identifizierung 
In Kombination mit der electrophoretischen Trennung wurden die herausragenden Eigen- 
schaften von ESI-QTOF MS dazu genutzt, Peptidverunreinigungen sowie Proteinisofor- 
men und -modifikationen zu identifizieren bzw. zu verifizieren. Mit Hilfe von genauer 
Masse und MS/MS-Spektren wurden N- und C-terminal geku¨rzte Peptide und Peptide 
mit zusatzlichen Aminosauren oder Schutzgruppen neben den bekannten Verunreinigung- en 
16 D-Lys TCS und TCS-Sulfoxid als Verunreinigungen in verschiedenen TCS-Proben 
identifiziert.  Die relativen Haufigkeiten dieser Verunreinigungen reichten von < 0,01% bis 
> 20%, wobei die geschu¨tzten Peptide und das TCS-Sulfoxid die wichtigsten Verun- 
reinigungen darstellten. 
Isotopenaufgeloste Massenspektren wurden dazu genutzt, einfach und doppelt deami- 
dierte Isoformen von rhGH in einer gestressten rhGH-Probe zu verifizieren.  Das iso- 
topenaufgeloste Massenspektrum von rhEPO wies eine U¨ berlappung zweier Isoformen 
mit einem Massenunterschied von 1 oder 2 Da auf. Durch eine detaillierte mathemati- 
sche Auswertung der moglichen zugrundeliegenden Isotopenmuster konnte ein Artefakt 
ausgeschlossen werden. Da jedoch keine elektrophoretische Trennung beobachtet wurde, 
wurde die Deamidierung als Erkla¨rung fu¨r die u¨berlappenden Isoformen nicht in Betracht 
gezogen. Fu¨r die Identifizierung dieser beiden Isoformen sind weitere Experimente er- 
forderlich. 
Zahlreiche EPO-Isoformen (> 100) wurden mit Hilfe der Moleku¨lmassen und der be- 
kannten Proteinstruktur in verschiedenen EPO-Praparaten identifiziert.  Die Isoformen 
umfassten  die durch die Anzahl der Sialinsa¨uren und HexHexNAc-Einheiten verur- sachten 
Verteilungen. Des Weiteren  wurden Isoformen, die phosphorylierte “High- 
Mannose”-Glykane und Acetylierungen aufwiesen, identifiziert. 
 
Leistungsfa¨higkeit der Multivariaten Statistik 
Unter Verwendung der CE-QTOF MS-Daten wurden multivariate statistische Metho- den, 
d.h.  PCA und CA, i) zur Unterstu¨tzung der Methodenvalidierung und ii) fu¨r den Vergleich 
verschiedener EPO-Praparate entwickelt. Auf diese Weise konnte gezeigt werden, dass die 
optimierte CE-MS-Methode fu¨r die Analyse von intakten Proteinen unempfindlich ist 
gegenu¨ber Parameteranderungen (z.B. HAc-Konzentration im BGE, Richtung des EOF, 
Auflosung) in Bezug auf bspw.  die Quantifizierung. Im Hinblick auf den Vergleich 
mehrerer EPO-Praparate konnten alle untersuchten Proben mit Hilfe von PCA und CA 
unterschieden werden.  Die Unterscheidung beruhte auf den rela- tiven Signalflächen 8 
ausgewahlter Isoformen von mehr als 100 natu¨rlich vorkommenden Isoformen. 
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